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Background State-of-the art therapy for recurrent ovarian cancer (ROC) suitable for 
platinum-based re-treatment includes bevacizumab-containing combinations (eg, 
carboplatin/paclitaxel, carboplatin/gemcitabine) or the most active non-bevacizumab 
regimen: carboplatin/pegylated liposomal doxorubicin (PLD). This head-to-head trial 
compared a standard bevacizumab-containing regimen versus carboplatin/PLD combined 
with bevacizumab. 
Methods In this multicentre, open-label, randomised, phase 3 trial, eligible patients had  
histologically confirmed epithelial ovarian, primary peritoneal, or fallopian tube carcinoma 
with first disease recurrence >6 months after first-line platinum-based chemotherapy, and 
were aged ≥18 years with Eastern Cooperative Oncology Group performance status 0–2. 
Patients were stratified by platinum-free interval, residual tumour, prior anti-angiogenic 
therapy, and study group language, and centrally randomised 1:1 using randomly permuted 
blocks of size two, four, or six to six intravenous cycles of carboplatin (AUC 4, day 1) plus 
gemcitabine (1000 mg/m2, days 1 and 8) every 3 weeks or six cycles of carboplatin (AUC 5, 
day 1) plus PLD (30 mg/m2, day 1) every 4 weeks, both given with bevacizumab (15 mg/kg 
every 3 weeks or 10 mg/kg every 2 weeks) until disease progression or toxicity. The primary 
endpoint was investigator-assessed progression-free survival (PFS). Efficacy data were 
analysed in the intention-to-treat population (all randomised patients). Safety was analysed 
in all patients who received at least one dose of study drug. This completed study is 
registered with ClinicalTrials.gov number NCT01837251. 
Findings Between August 1, 2013, and July 31, 2015, 682 patients were randomised. 
Median follow-up for PFS at the data cut-off was 12·4 (IQR 8·3–21·7) months in the 
carboplatin/PLD/bevacizumab group and 11·3 (IQR 8·0–18·4) months in the 
carboplatin/gemcitabine/bevacizumab group. PFS was significantly longer with 
carboplatin/PLD/bevacizumab (experimental arm) than 
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carboplatin/gemcitabine/bevacizumab (hazard ratio 0·81, 95% confidence interval [CI] 0·68–
0·96; p=0·012). Median PFS was 13·3 (95% CI 11·7–14·2) months versus 11·6 (95% CI 
11·0–12·7) months, respectively. The most common grade 3/4 adverse events were 
hypertension (88 [27%] of 332 patients receiving carboplatin/PLD/bevacizumab vs 67 [20%] 
of 329 patients receiving carboplatin/gemcitabine/bevacizumab) and neutropenia (40/332 
[12%] vs 73/329 [22%], respectively). Serious adverse events occurred in 33/332 patients 
(9·9%) receiving carboplatin/PLD/bevacizumab and 28/329 patients (8·5%) receiving 
carboplatin/gemcitabine/bevacizumab. Treatment-related deaths occurred in 1/332 patients 
receiving carboplatin/PLD/bevacizumab (0·3%; large intestine perforation) and 2/329 
receiving carboplatin/gemcitabine/bevacizumab (0·6%; one case each of osmotic 
demyelination syndrome and intracranial haemorrhage). 
Interpretation Carboplatin/PLD/bevacizumab is a new standard treatment option for 
platinum-eligible ROC. 





Ovarian cancer is the eighth most common cancer in women globally, and the eighth most 
common cause of cancer death.1 Almost 300,000 new cases were diagnosed worldwide in 
2018, representing 3·4% of new cancers in women. In Europe, there were an estimated 
65,500 cases of ovarian cancer in 2012 and 42,700 deaths.2  
Management of newly diagnosed ovarian cancer typically involves cytoreductive surgery and 
platinum/taxane doublet chemotherapy. At relapse, patients may be candidates for platinum 
re-treatment, depending on several factors, including previous response and the interval 
since completing platinum-containing therapy. The ICON4/AGO-OVAR2·2 trial demonstrated 
superior efficacy with a platinum/paclitaxel doublet versus platinum alone,3 establishing 
combination chemotherapy in this setting. Similarly, the AGO-OVAR2·5 trial demonstrated 
significantly superior progression-free survival (PFS) with a carboplatin/gemcitabine doublet 
versus carboplatin alone.4 A meta-analysis of individual patient data from four randomised 
trials confirmed the role of platinum doublets in this setting, showing improved PFS and 
overall survival (OS) versus single-agent platinum across all subgroups.5 
Subsequent randomised phase 3 trials have compared different chemotherapy doublets, 
including the CALYPSO/AGO-OVAR2·9 trial, which demonstrated significantly superior PFS 
with a carboplatin/pegylated liposomal doxorubicin (PLD) doublet versus 
carboplatin/paclitaxel,6 without impairing quality of life.7 This regimen has become widely 
used in recurrent ovarian cancer because of its more favourable therapeutic index 
(particularly the lower incidences of alopecia, hypersensitivity reactions, and sensory 
neuropathy) and schedule. 
Anti-angiogenic strategies combined with chemotherapy represent an important 
development in systemic therapy for ovarian cancer. Several anti-angiogenic agents have 
demonstrated efficacy in platinum-sensitive recurrent ovarian cancer8–13 but the only 
approved agent in ovarian cancer is bevacizumab, which is indicated in both newly 
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diagnosed and recurrent settings. In platinum-sensitive recurrent disease, the randomised 
phase 3 OCEANS trial demonstrated significantly superior PFS, objective response rate, and 
duration of response by adding bevacizumab to the ‘AGO-OVAR2·5’ 
gemcitabine/carboplatin chemotherapy backbone.8 The subsequent GOG-0213 trial 
demonstrated significantly improved efficacy by adding bevacizumab to a 
carboplatin/paclitaxel doublet.13 Until the present trial, the most active and widely used 
platinum combination – the ‘CALYPSO’ PLD/carboplatin regimen – had been evaluated in 
combination with bevacizumab only in a single-arm phase 2 study, indicating that 
bevacizumab/carboplatin/PLD was an active and well-tolerated regimen for platinum-
sensitive ovarian cancer.14 Therefore, we designed a trial to define the most appropriate 
platinum-based regimen to combine with bevacizumab by determining whether 
carboplatin/PLD was superior to carboplatin/gemcitabine with bevacizumab.  
Methods 
Study design and participants 
This was a European Network for Gynaecological Oncological Trial groups 
(ENGOT)/Gynecologic Cancer InterGroup (GCIG) multicentre, open-label, randomised, 
phase 3 superiority trial, led by the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) 
Study Group and conducted in academic centres in Germany, France, Australia, Austria, 
and UK (Supplementary Appendix, page 1). The trial was conducted in accordance with the 
present version of the Declaration of Helsinki, the international Good Clinical Practice 
standards, and all local laws and regulations concerning clinical trials. The trial protocol, 
amendments, and other relevant study documentation were approved by each participating 
site’s Independent Ethics Committee. There were four protocol amendments during the 
course of the study: 3 March, 2015; 3 May, 2016; 20 July, 2018; and 10 September, 2019. 
Those with a potential impact on study conduct are mentioned below. The final protocol is 
available in the Supplementary Appendix, page 12. 
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Eligible patients had histologically confirmed epithelial ovarian, primary peritoneal, or 
fallopian tube carcinoma (independent of International Federation of Gynecology and 
Obstetrics stage or histological grade or type) with first disease recurrence >6 months after 
first-line platinum-based chemotherapy. Patients were to have measurable or non-
measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) 
version 1·1, or CA-125-assessable disease according to GCIG criteria, or a histologically 
proven diagnosis of relapse. Additional inclusion criteria included age ≥18 years, Eastern 
Cooperative Oncology Group performance status 0–2, life expectancy >3 months, and 
adequate coagulation parameters and bone marrow, liver, and renal function. Cytoreductive 
surgery for recurrence and/or prior front-line anti-angiogenic therapy were allowed. Key 
exclusion criteria were: prior chemotherapy for recurrent disease; ovarian tumours of low 
malignant potential (borderline tumours); surgery within 4 weeks before the first 
bevacizumab dose; planned surgery during or within 4 weeks of study treatment; history of 
abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess related to prior 
anti-vascular endothelial growth factor therapy; or a history of hypertensive crisis or 
hypertensive encephalopathy. All patients provided written informed consent before any trial-
specific procedures or treatment.  
Randomisation and masking 
Eligible patients were enrolled by investigators and randomised using randomly permuted 
blocks of size two, four, or six stratified by: platinum-free interval (6–12 vs >12 months); 
residual tumour (yes [or no debulking surgery for recurrence] vs no); prior anti-angiogenic 
therapy (yes vs no); and study group language (initially participating study group, changed in 
the first protocol amendment in March 2015). Patients were randomised centrally by 
authorised personnel from KKS, Philipps-University of Marburg, Germany, in a 1:1 ratio. The 
assigned patient number of each patient was documented by using an enrolment log and 
subject ID list. There was no masking in this open-label trial.  
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Procedures 
Eligible patients were randomised to receive either carboplatin/gemcitabine/bevacizumab 
(standard arm) or carboplatin/PLD/bevacizumab (experimental arm). Standard arm 
treatment comprised bevacizumab 15 mg/kg on day 1, gemcitabine 1000 mg/m2 on days 1 
and 8, and carboplatin area under the concentration curve (AUC) 4 on day 1, all 
administered intravenously and repeated every 3 weeks for six cycles (maximum), followed 
by intravenous single-agent maintenance bevacizumab at the same dose until disease 
progression or unacceptable toxicity. Treatment in the experimental arm comprised 
bevacizumab 10 mg/kg on days 1 and 15, carboplatin AUC 5 on day 1, and PLD 30 mg/m2 
on day 1, administered intravenously and repeated every 4 weeks for six cycles and followed 
by intravenous single-agent maintenance bevacizumab 15 mg/kg every 3 weeks until 
disease progression or unacceptable toxicity. The first dose of bevacizumab could be 
omitted if chemotherapy was started within 4 weeks after debulking surgery for recurrent 
disease. No bevacizumab dose reductions for toxicity were permitted and the dose was to 
be modified only in the event of >10% weight change. Bevacizumab treatment was either 
temporarily or permanently interrupted in the event of hypertension, proteinuria, 
thrombosis/embolism, haemorrhage, congestive heart failure, wound-healing complications, 
or any other grade 3 or 4 bevacizumab-related toxicity. Bevacizumab was temporarily 
interrupted in the event of grade 4 febrile neutropenia and/or grade 4 thrombocytopenia 
(regardless of the relationship to treatment). In addition, bevacizumab was to be 
permanently discontinued in any patient developing any of the following events: posterior 
reversible encephalopathy syndrome (PRES); grade 3/4 haemorrhagic/bleeding events; 
grade 3/4 left ventricular dysfunction (congestive heart failure); grade 4 venous 
thromboembolism including pulmonary embolism; grade 4 hypertension (hypertensive crisis) 
or hypertensive encephalopathy; grade 4 non-gastrointestinal fistula; grade 4 proteinuria 
(nephrotic syndrome); or any grade of CNS bleeding, arterial thromboembolism, 
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gastrointestinal perforation, tracheo-oesophageal fistula, or hypersensitivity/allergic reactions 
related to bevacizumab. 
In the event of haematological toxicity, chemotherapy was to be delayed until haematological 
recovery. If neutrophil and/or platelet counts had not recovered within 7 days, the day 8 
gemcitabine dose was to be reduced to 50% of the starting dose in case of absolute 
neutrophil count (ANC) 1·0–1·4 x 109/L and/or platelet count 75–99 x 109/L. Day 8 
gemcitabine was to be omitted if the neutrophil count was <1·0 x 109/L and/or the platelet 
count was <75 x 109/L. Subsequent gemcitabine dose adjustment was based on toxicity 
observed during the preceding cycle. The day 1 and 8 gemcitabine dose was to be 
permanently reduced in the event of any of the following: ANC <0·5 x 109/L for more than 5 
days; ANC <0·3 x 109/L for more than 3 days; febrile neutropenia; platelets <25 x 109/L; 
cycle delay of more than 1 week due to toxicity. If any of the above toxicities recurred after 
the initial dose reduction, gemcitabine was to be reduced to 800 mg/m2 (no dose on day 8) 
and carboplatin to AUC 3. Granulocyte-colony stimulating factor (G-CSF) was required in 
case of delayed neutrophil recovery, administered according to American Society of Clinical 
Oncology guidelines or local practice guidelines. Hypersensitivity to carboplatin was to be 
managed according to local practice guidelines, with the option of substitution with cisplatin 
at the investigator’s discretion. In the experimental arm, PLD was to be reduced to 25 mg/m2 
in the event of ANC <1·5 x 109/L and/or platelet count <100 x 109/L.  
Any patient enrolled into the trial remained on study unless she withdrew consent (which 
was allowed at any time).  
Tumours were assessed by the investigators at screening and then every 12 weeks for at 
least 30 months (or until disease progression if earlier). The method used at screening was 
used for each subsequent tumour assessment. CA-125 was assessed locally every 3 or 4 
weeks during study treatment, and every 3 months thereafter until disease progression, 
unacceptable toxicity, or 30 months’ follow-up. QoL was assessed using the European 
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Organisation for Research and Treatment of Cancer Quality of Life Questionnaire core 
module (QLQ-C30) and ovarian cancer-specific module (QLQ-OV28) at baseline, then every 
12 weeks until disease progression, and at every visit thereafter for the 5-year follow-up.  
Adverse events were graded according to National Cancer Institute Common Terminology 
Criteria for Adverse Events (version 4·03). Laboratory parameters and adverse events were 
assessed at each visit during treatment, at the safety follow-up visit, and at every 6-monthly 
visit thereafter. Left ventricular ejection fraction was assessed by echocardiogram or 
multigated acquisition scan in patients receiving PLD during the treatment period (and at the 
treating investigator’s discretion at all other times).  
Outcomes  
The primary outcome measure was investigator-assessed PFS according to RECIST version 
1·1, defined as the interval between randomisation and first documented disease 
progression or death, whichever occurred first. Secondary outcome measures included OS 
(defined as the interval between randomisation and death from any cause), biological PFS 
(assessed based on locally determined serum CA-125 levels according to GCIG criteria), 
quality of life (QoL), safety, and tolerability. Exploratory subgroup analyses of PFS according 
to randomisation stratification factors were prespecified.  
Statistical analysis 
The assumed median PFS with carboplatin/gemcitabine/bevacizumab was 12·4 months 
(based on the OCEANS trial8). Assuming randomisation of 654 patients recruited over 30 
months with a further 30 months’ follow-up, the trial would provide 80% power with a two-
sided log-rank test at 5% significance to detect a 27% improvement in median PFS from 
12·4 to 15·7 months (hazard ratio [HR] 0·79). Based on these assumptions, a total of 564 
PFS events was anticipated at the time of the primary PFS analysis. Statistical results 
reported for OS and further secondary endpoints are exploratory (not corrected for multiple 
testing). 
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Efficacy data were analysed in the intention-to-treat population, defined as all randomised 
patients irrespective of whether they received treatment. PFS was compared between the 
two treatment arms using a stratified log-rank test at a two-sided 5% significance level, 
stratified by the factors used for randomisation. OS was analysed similarly. Median PFS and 
OS were estimated using Kaplan-Meier estimates with corresponding 95% confidence 
intervals (CIs). HRs were assessed using a stratified Cox regression analysis with 
corresponding 95% CIs for the HR ratio point estimate. Exploratory univariable subgroup 
analyses according to prognostically relevant predefined randomisation strata were analysed 
by Cox regression models. Exploratory multivariable Cox regression analyses were 
calculated to assess potential interactions between treatment arms and predefined 
randomisation strata. The assumption of proportional hazards for the Cox models was 
assessed according to the method described by Lin et al.15 A post hoc exploratory sensitivity 
analysis excluding patients who received bevacizumab after progression (date of tumour 
assessment) was done to investigate potential impact on the outcome of the primary PFS 
analysis. Health-related quality of life was assessed using the QLQ-C30 and according to 
the scoring manual.16 The summary score of the QLQ-C30 was calculated using the r-
package QoLR.17 The prespecified statistical analysis used a linear mixed-model analysis 
including study centre as a random effect, main effects for group and time, a group-by-group 
interaction term, and a generalised covariance matrix to account for serial dependency 
among observations to assess mean change over time from baseline every 3 months 
descriptively. Safety analyses were based on the safety population, comprising all patients 
who received at least one dose of study drug. There were no planned interim analyses. 
Statistical analyses were done using SAS version 9.4. 
This trial is registered with ClinicalTrials.gov number NCT01837251. 
Role of the funding source 
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The trial was performed according to ENGOT model A.18 The sponsor (AGO Study Group, 
represented by the first author) was responsible for writing the report with the support of a 
medical writer. The funder of the study had no role in study design, data collection, data 
analysis, data interpretation, or writing of the report. JP and JR had access to the raw data. 
The corresponding author had full access to all of the data and the final responsibility to 
submit for publication. 
Results 
Between August 1, 2013, and July 31, 2015, 682 patients were enrolled from 161 sites in 
Europe, Australia, and New Zealand; 682 were randomised (337 to standard therapy and 
345 to the experimental arm), representing the intention-to-treat population, and 661 
received study treatment, representing the safety population (figure 1). No patients were 
deemed ineligible. After completion of chemotherapy, 256 (78%) of 329 patients and 225 
(68%) of 332 patients, respectively, continued bevacizumab as maintenance therapy. 
Baseline characteristics were generally well balanced with no relevant differences between 
treatment arms (table 1). Almost half of the patients (161 of 337 [48%] in the standard arm, 
163 of 345 [48%] in the experimental arm had previously been treated with anti-angiogenic 
therapy, typically bevacizumab.  
At the data cutoff for the final analysis (July 10, 2018), all but 20 patients (3%; 5 of 337 [1%] 
in the standard arm vs 15 of 345 [4%] in the experimental arm) had stopped all study 
treatments per protocol. Details of treatment exposure are presented in table 2.  
In total, 84 of 661 treated patients (13%; 46 of 329 [14%] in the standard arm and 38 of 332 
[11%] in the experimental arm) received bevacizumab after disease progression. The 
median duration of post-progression bevacizumab exposure was 20·5 days in both arms 
(IQR 7–424 with carboplatin/gemcitabine/bevacizumab and 5–385 with 
carboplatin/PLD/bevacizumab). A sensitivity analysis excluding these 84 patients did not 
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alter the conclusion for PFS (hazard ratio 0·81, 95% CI 0·67–0·97) or OS (hazard ratio 0·81; 
95% CI, 0·66–0·99). 
Median follow-up for PFS was 12·4 (IQR 8·3–21·7) months in the 
carboplatin/PLD/bevacizumab group and 11·3 (IQR 8·0–18·4) months in the 
carboplatin/gemcitabine/bevacizumab group. At the data cutoff, PFS events had been 
recorded in 571 patients (84%) (294 of 337 [87%] receiving 
carboplatin/gemcitabine/bevacizumab, 277 of 345 [80%] receiving 
carboplatin/PLD/bevacizumab). There was no indication that the proportional hazard 
assumption of the Cox regression models for PFS or OS had been violated (Supplementary 
Appendix, page 7). The HR for PFS was 0·81 (95% CI 0·68–0·96; stratified log-rank 
p=0·012) (figure 2A). Median PFS was 11·6 (95% CI 11·0–12·7) months with 
carboplatin/gemcitabine/bevacizumab and 13·3 (95% CI 11·7–14·2) months with 
carboplatin/PLD/bevacizumab.  
Median follow-up for OS was 27·8 (IQR 15·6–36·8) months in the 
carboplatin/PLD/bevacizumab group and 25·5 (IQR 14·5–35·5) months in the 
carboplatin/gemcitabine/bevacizumab group. After 439 deaths (64%; 232 [69%] of 337 in the 
standard arm, 207 [60%] of 345 in the experimental arm), the OS HR was 0·81 (95% CI 
0·67–0·98). Median OS was 27·8 (95% CI 25·5–30·2) months with standard therapy versus 
31·9 (95% CI 28·5–34·8) months with experimental therapy (figure 2B). A similar effect to 
that observed for PFS was seen for biological PFS. After events in 583 patients (300 of 337 
[89%] vs 283 of 345 [82%] in the standard vs experimental arms, respectively), median 
biological PFS was 10·0 (95% CI 9·0–10·7) months with standard therapy versus 11·5 (95% 
CI 10·6–12·5) months with experimental therapy (Supplementary Appendix, page 9). The 
HR was 0·76 (95% CI 0·64–0·90).  
Univariable subgroup analyses of PFS favoured the experimental arm with respect to the HR 
point estimate in prognostically relevant predefined exploratory subgroups (figure 3A). In 470 
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patients with a platinum-free interval of >12 months, the HR was 0·81 (95% CI 0·66–0·99; 
median 14·0 [95% CI 11·8–15·9] months in the standard arm versus 14·9 [95% CI 13·6–
17·1] months in the experimental arm). In 309 patients previously treated with anti-
angiogenic therapy, the HR was 0·73 (95% CI 0·57–0·94); median 10·1 [95% CI 8·5–11·2] 
months with experimental therapy versus 11·3 [95% CI 10·1–13·8] months with standard 
therapy). Univariable subgroup analyses of the secondary endpoint OS are shown in figure 
3B.  
Compliance with QoL assessment was high at baseline (91% in the standard arm vs 86% in 
the experimental arm) and showed similar attrition over time in the two treatment arms. 
Mean global health status peaked at month 3 in the standard group and month 6 in the 
experimental group, showing a minor difference (not clinically relevant) favouring 
experimental therapy at month 6. Thereafter, mean score  declined to below baseline levels 
in both treatment groups (Supplementary Appendix, page 10). 
Almost all of the 661 treated patients experienced at least one adverse event during the 
study (319 of 329 [97·0%] of patients in the standard arm vs 327 of 332 [98·5%] in the 
experimental arm). Grade ≥3 adverse events were slightly more common with standard (267 
of 329; 81·2%) than experimental (250 of 332; 75·3%) therapy. Ten patients had fatal 
adverse events: six (1·8%) in the standard arm (two cases of acute kidney injury, one case 
each of osmotic demyelination syndrome, intracranial haemorrhage, general physical health 
deterioration, and suicide) and four (1·2%) in the experimental arm (subileus, large intestine 
perforation, cardiac/renal failure, and disease-related general physical health deterioration), 
but of these, only three were considered treatment related (two [0·6%] of 329 patients 
receiving carboplatin/gemcitabine/bevacizumab [one case each of osmotic demyelination 
syndrome and intracranial haemorrhage] and one [0·3%] of 332 patients receiving 
carboplatin/PLD/bevacizumab [large intestine perforation]). Details of grade 3/4 adverse 
events and grade 1/2 adverse events in >10% of patients are provided in the Supplementary 
Appendix, page 4. Serious adverse events were reported in 28 (8·5%) of 329 patients in the 
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standard arm and 33 (9·9%) of 332 in the experimental arm. These serious adverse events 
were considered drug related in 24 (7·3%) of 329 and 32 (9·6%) of 332 patients, 
respectively. The most common treatment-related serious adverse events were pulmonary 
embolism (5/329 [2%] in the standard group vs 5/332 [2%] in the experimental group) and 
hypertensive crisis (3/329 [1%] vs 5/332 [2%], respectively). Adverse events led to treatment 
discontinuation in 78 (24%) of 329 patients in the standard group and 104 (31%) of 332 
patients in the experimental group. Of these, adverse events were considered to be related 
to bevacizumab in 56 (17%) of 329 and 73 (22%) of 332 patients, respectively, most 
commonly hypertension (11/329 [3%] vs 22/332 [7%]), proteinuria (11/329 [3%] vs 18/332 
[5%], and pulmonary embolism (2/329 [1%] vs 4/332 [1%], respectively). Incidences of grade 
≥3 adverse events of special interest were similar in the two arms (149 of 329 [45·3%] vs 
146 of 332 [44·0%] in the standard and experimental arms, respectively). Grade ≥3 
thrombocytopenia was reported in more patients in the 
carboplatin/gemcitabine/bevacizumab group than the carboplatin/PLD/bevacizumab group. 
Blood transfusions were required in 52 of 329 (15·8%) and 38 of 332 (11·4%) of patients in 
the two groups, respectively. Only five patients (two [0·6%] in the control arm, three [0·9%] in 
the experimental arm) received G-CSF. Overall, 22 patients reported 47 episodes of 
hypersensitivity to carboplatin: 39 cases in 20 of 329 patients (6·1%) in the standard arm 
and 8 cases in 2 of 332 patients (<0·1%) in the experimental arm. Two isolated cases of 
hypersensitivity to gemcitabine were reported in two patients in the standard arm. There 
were no reports of hypersensitivity to PLD in the control arm.  
Grade ≥3 neutropenia was more common with standard than experimental therapy but there 
was no difference in the incidence of febrile neutropenia (table 3). Grade ≥3 hypertension 
was less common in the standard arm. The incidences of grade ≥3 proteinuria and other 
typical bevacizumab adverse events were similar in the two treatment arms. Gastrointestinal 
perforation was rare.  
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Discussion 
The trial met its primary objective, demonstrating significantly superior PFS with 
carboplatin/PLD/bevacizumab versus the carboplatin/gemcitabine/bevacizumab regimen 
established in the OCEANS trial.8 To our knowledge, this is the first phase 3 trial comparing 
two bevacizumab-containing regimens in recurrent ovarian cancer. Furthermore, OS was 
significantly improved with PLD-containing therapy, with an increase in median OS of more 
than 4 months; while some may question the clinical meaningfulness of a 3-month median 
PFS advantage, improvement in OS represents the ultimate goal of treatment and a 4-month 
improvement in the recurrent setting is clinically meaningful. There was no clinically relevant 
difference in global health status between treatment arms.  
Overall, the safety profile in both treatment arms was consistent with the known side effects 
of bevacizumab and the chemotherapy backbones. As expected, the gemcitabine-containing 
standard arm was associated with more grade ≥3 adverse events (81% vs 75% with PLD-
containing therapy). However, grade 5 adverse events were infrequent in both arms 
(standard arm 1·8% vs experimental arm 1·2%). Qualitative differences included more 
frequent grade ≥3 neutropenia with carboplatin/gemcitabine/bevacizumab (22% vs 12% with 
carboplatin/PLD/bevacizumab) and more grade ≥3 thrombocytopenia (19% vs 10%) but less 
frequent grade ≥3 hypertension (21% vs 28%, respectively). Gastrointestinal perforations 
were rare in both arms and no new safety signals were observed.  
Relative dose intensity and median treatment duration with bevacizumab for the standard 
arm are similar to those reported in the OCEANS8 and AGO-OVAR2.5 trials.4 The proportion 
of patients starting maintenance bevacizumab was higher in the standard arm (256 of 332 
patients; 77%) than in the experimental arm (225 of 337 patients; 67%). A plausible 
explanation is the imbalance in cycle length, resulting in planned chemotherapy durations of 
24 weeks for PLD/carboplatin versus 18 weeks for gemcitabine/carboplatin. Whether the 
duration of (perhaps more tolerable) induction chemotherapy contributes to the efficacy 
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benefit cannot be answered here; however, there was a clear PFS and OS benefit with the 
PLD-containing regimen. While we acknowledge the limitations of cross-trial comparisons, 
median PFS of 11·6 months in the standard arm is very similar to the assumptions used 
when designing the trial based on bevacizumab-containing therapy in OCEANS (12·4 
months).8  
Since AGO-OVAR2.21 was designed in 2012, polyADP ribose polymerase (PARP) inhibitors 
have become a standard of care in patients with recurrent ovarian cancer suitable for 
retreatment with platinum-based therapy. The PARP inhibitors olaparib, niraparib, and 
rucaparib are approved as maintenance therapy in patients with recurrent ovarian cancer 
after successful retreatment with platinum, and show the greatest effect in patients with 
BRCA1/2-mutated tumours.19 Therefore the absence of a PARP inhibitor in either treatment 
arm in our trial is a limitation. In addition, the lack of information on BRCA mutation status in 
this trial is a weakness. Although BRCA1/2 testing and PARP inhibition were not routinely 
available when this trial was designed, BRCA1/2 testing is now recommended for all patients 
with non-mucinous ovarian cancer.19 As well as guiding treatment decisions, knowledge of 
BRCA mutation status provides important prognostic information and may correlate with 
sensitivity to platinum and other chemotherapy agents.20 Therefore any potential imbalance 
in BRCA mutation status between treatment arms in our trial could introduce unrecognised 
bias.  
As the treatment landscape continues to evolve at a rapid pace and PARP inhibitors are 
used earlier in the treatment algorithm, the patient population enrolled in AGO-OVAR2.21 
may become less representative of patients presenting in clinical practice in the future. 
Olaparib is already approved as monotherapy in the front-line maintenance setting based on 
results from the SOLO-1 trial,21 and following positive results from the PAOLA-122 and 
PRIMA23 trials, the use of PARP inhibitors in the front-line setting, alone or in combination 
with bevacizumab, is expected to increase further. Consequently, in the future, patients 
presenting with recurrent ovarian cancer, particularly those considered candidates for re-
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exposure to platinum-based treatment, are likely to have received prior PARP inhibitor 
therapy.  
The trial demonstrated a significant improvement in overall survival with the experimental 
regimen. However, the trial was not designed to estimate the impact of subsequent therapy 
after disease progression, and therefore potential imbalances in post-progression treatment, 
which may bias overall survival results, cannot be excluded. Moreover, although the trial has 
completed, a small number of patients (15 in the experimental arm, 5 in the control arm) 
remain on bevacizumab treatment and therefore the long-term effect of each regimen may 
not be fully captured in this final analysis.        
AGO-OVAR 2.21 results support the design of the ongoing phase 3 ATALANTE/AGO-
OVAR2.30 trial (NCT02891824) evaluating atezolizumab combined with bevacizumab-
containing therapy in platinum-sensitive disease. The ‘CALYPSO-bevacizumab’ regimen 
evaluated here is one of the permitted backbone regimens in ATALANTE, alongside the 
OCEANS and GOG-0213 bevacizumab-containing regimens.  
Overall, these results suggest that carboplatin/PLD/bevacizumab is a new standard regimen 
for patients with recurrent ovarian cancer suitable for platinum-based and anti-angiogenic 
treatment. This benefit is observed irrespective of prior anti-angiogenic therapy, expanding 
on findings from the randomised phase 3 MITO16b trial, which demonstrated significantly 
superior PFS with chemotherapy/bevacizumab re-treatment versus chemotherapy alone for 
platinum-sensitive recurrent ovarian cancer after front-line bevacizumab-containing 
therapy.24 
Panel: Research in context 
Evidence before this study 
We searched PubMed for journal articles describing positive phase III trials in platinum-
sensitive recurrent ovarian cancer published between 2001 and 2013 using the search terms 
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‘platinum-sensitive recurrent ovarian cancer’ and ‘phase III trial’. In addition to the 
ICON4/AGO-OVAR2.2 and AGO-OVAR2.5 phase III trials, which demonstrated superiority 
of a paclitaxel–platinum doublet and a gemcitabine–carboplatin doublet versus single-agent 
carboplatin, we identified two positive randomised phase III trials: the OCEANS placebo-
controlled randomised phase III trial of bevacizumab in platinum-sensitive recurrent ovarian 
cancer, which demonstrated superior progression-free survival and objective response rate 
with the addition of bevacizumab to a gemcitabine/carboplatin chemotherapy doublet; and 
the CALYPSO randomised phase III trial, which demonstrated superior efficacy with a 
pegylated liposomal doxorubicin/carboplatin doublet compared with paclitaxel/carboplatin in 
platinum-sensitive recurrent ovarian cancer. We identified no additional positive phase III 
trials published when the AGO-OVAR2.21 trial was designed.  
Added value of this study 
In patients with recurrent ovarian cancer suitable for platinum-based retreatment, the 
approved chemotherapy regimens for use in combination with bevacizumab are 
gemcitabine/carboplatin (based on the OCEANS trial) and paclitaxel/carboplatin (based on 
the GOG-0213 trial). The present trial evaluates bevacizumab in combination with a more 
widely used, more active chemotherapy regimen, demonstrating superior efficacy and thus 
defining a new standard-of-care bevacizumab-containing regimen.  
Implications of all the available evidence 
These results suggest that carboplatin/PLD/bevacizumab is the new standard regimen for 
patients with recurrent ovarian cancer suitable for platinum-based and anti-angiogenic 
treatment. This regimen is a reasonable backbone for future immunotherapy-containing 
regimens in recurrent ovarian cancer.  
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 90 (27%) 92 (27%) 
Residual tumour  Yes (no surgery for 
recurrence or surgery with 
residuals) 
257 (76%) 260 (75%) 
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 No (surgery for recurrence 
with macroscopic complete 
resection) 
80 (24%) 85 (25%) 














































Table 2: Summary of treatment exposure 
Exposure Carboplatin/gemcitabine/bevacizumab (n=332) Carboplatin/PLD/bevacizumab (n=337) 
Bevacizumab mean relative dose intensity (n=329) (n=332) 
Entire treatment period 93·8% 89·3% 
Chemotherapy phase 92·2% 85·9% 
Maintenance period 96·3% 96·6% 
Bevacizumab treatment interruptions   
Entire treatment period 116 (35·3%) 230 (69·3%) 
Chemotherapy phase 40 (12·2%) 195 (58·7%) 
Maintenance phase 89 (27·1%) 86 (25·9%) 





Bevacizumab administration for ≥12 months 101 (31%) 100 (30%) 
Chemotherapy mean relative dose intensity (n=332) (n=337) 
Carboplatin 91·1% 92·2% 
Gemcitabine  77·5% – 
PLD _ 93·9% 
Chemotherapy dose reductions   
Carboplatin 99 (30%) 73 (22%) 
Gemcitabine 157 (48%) – 
PLD – 61 (18%) 
PLD=pegylated liposomal doxorubicin. 
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Table 3: Summary of adverse events of special interest 
Adverse event of special interest Carboplatin/gemcitabine/bevacizumab (n=329) Carboplatin/PLD/bevacizumab (n=332) 
Grade ≥3 neutropenia 73 (22%) 40 (12%) 
Grade ≥3 febrile neutropenia 4 (1%) 3 (1%) 
Grade ≥3 hypertension 68 (21%) 92 (28%) 
Grade ≥3 proteinuria 22 (7%) 18 (5%) 
Grade ≥3 venous thromboembolic event 9 (3%) 6 (2%) 
Grade ≥3 congestive heart failure 5 (2%) 2 (1%) 
Any-grade CNS bleeding 3 (1%) 4 (1%) 
Any-grade fistula 3 (1%) 3 (1%) 
Any-grade GI perforation 1 (<1%) 2 (1%) 
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Any-grade PRES 2 (1%) 1 (<1%) 






Figure 1: Patient disposition 
 
 
Figure 2: Kaplan-Meier estimates of (A) PFS and (B) OS in the intention-to-treat 
population 
CD-BEV=carboplatin/pegylated liposomal doxorubicin/bevacizumab, CG-
BEV=carboplatin/gemcitabine/bevacizumab, CI=confidence interval, HR=hazard ratio, 
OS=overall survival, PFS=progression-free survival. 
 
Figure 3: Subgroup analyses of progression-free survival (intention-to-treat 
population) 
CD-BEV=carboplatin/pegylated liposomal doxorubicin/bevacizumab, CG-
BEV=carboplatin/gemcitabine/bevacizumab, CI=confidence interval, HR=hazard ratio, 
PFI=platinum-free interval, PFS=progression-free survival. 
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Evang. Kliniken Essen-Mitte, Essen Germany Philipp Harter 34 
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University Women’s Hospital, Ulm Germany Wolfgang Janni 8 
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Centre Jean Perrin, Clermont-Ferrand France Marie-Ange Mouret-
Reynier 
7 
University Women’s Hospital Tübingen, Tübingen Germany Eva-Maria Grischke 7 
Medical University Hannover, Hannover Germany Tjoung-Won Park-Simon 7 
Klinikum Mutterhaus, Trier Germany Rolf Mahlberg 7 
Evangelisches Krankenhaus Düsseldorf, Düsseldorf Germany Werner Meier 7 
Women’s Health, Royal North Shore Hospital, Sydney Australia Sally Baron-Hay 6 
Innsbruck Medical University, Innsbruck Austria Christian Marth 6 
Department of Oncology, Hôpital Michallon, Grenoble France Cristina Costan 6 
Centre Hospitalier Départemental les Oudairies, La Roche-sur-Yon France Tifenn L’Haridon 6 
Marienhospital Stuttgart, Stuttgart Germany Manfred Hofmann 6 
University Hospital Schleswig-Holstein, Campus Kiel, Kiel Germany Felix Hilpert 6 
Gynäkologische Praxis Drs Uleer/Pourfard, Hildesheim Germany Christoph Uleer 6 
Gynäkologisch-Onkologische Praxis Hannover, Hannover Germany Hans-Joachim Lück 6 
Andrew Love Cancer Centre, Geelong Australia Inger Olesen 5 
University Hospital for Gynaecology, Medical University Vienna, 
Vienna 
Austria Alexander Reinthaller 5 
Centre Eugène Marquis, Rennes France Claudia Lafeuvre-Plesse 5 
Hôpital Privé du Confluent, Nantes France Alain Lortholary 5 
Medical Cancer, Hôpital Privé Villeneuve d’Ascq, Institut de 
Cancérologie, Villeneuve d’Ascq 
France Olivier Romano 5 
ViDia Christliche Kliniken Karlsruhe, Karlsruhe) Germany Oliver Tomé 5 
Ortenau-Klinikum Offenburg-Gengenbach, Offenburg Germany Matthias Frank 5 
University Women’s Hospital, Klinikum Südstadt, Rostock Germany Bernd Gerber 5 
Agaplesion Markus Krankenhaus, Frankfurt Germany Marc Thill 5 
DIAKO Ev. Diakonie-Krankenhaus, Bremen Germany Susanne Feidicker 5 
Agaplesion Evangelisches Klinikum Schaumburg, Obernkirchen Germany Sabine Lemster 5 
Klinikum Kulmbach, Kulmbach Germany Benno Lex 5 
Praxis Dr Grafe, MVZ Nordhausen, Nordhausen Germany Andrea Grafe 5 
University Hospital Essen, Essen Germany Martin Heubner 5 
Gynäkologisch-Onkologische Gemeinschaftspraxis, Braunschweig Germany Ralf Lorenz 5 
Gynaecology Department, Klinikum Darmstadt, Darmstadt Germany Sven Ackermann 5 
Onkologie Ravensburg, Ravensburg Germany Martina Gropp-Meier 5 
Beatson West of Scotland Cancer Centre, Glasgow UK Rosalind Glasspool 5 
Ordensklinikum Linz, Barmherzige Schwester, Linz Austria Judith Lafleur 4 
ICO Centre René Gauducheau, Saint Herblain France Dominique Berton-Rigaud 4 
ORACLE – Centre d’Oncologie de Gentilly, Nancy France Célia Becuwe-Roemer 4 
Centre Hospitalier Régional d’Orléans, Orleans France Jérôme Meunier 4 
Centre Oscar Lambret, Lille France Anne Lesoin 4 
University Hospital, Ludwig-Maximilian-University, Munich Germany Alexander Burges 4 
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Site Country Principal investigator 
No. of patients 
randomised 
Kreiskrankenhaus “Johann Kentmann”, Torgau Germany Simon Eike 4 
Sana Klinikum Offenbach, Offenbach Germany Christian Jackisch 4 
University Women’s Hospital, Medical University Graz, Graz Austria Edgar Petru 4 
HELIOS Klinikum Berlin-Buch, Berlin Germany Antje Sperfeld 4 
Klinikum Worms, Worms Germany Thomas Hitschold 4 
Schwarzwald-Baar Klinikum Villingen-Schwenningen, Villingen Germany Wolfgang Bauer 4 
University Hospital Mainz, Mainz Germany Marcus Schmidt 4 
Florence-Nightingale-Krankenhaus, Kaiserswerther Diakonie, 
Düsseldorf 
Germany Björn Lampe 4 
GYNAEKOLOGICUM Bremen, Bremen Germany Willibald Schröder 4 
Klinikum Starnberg, Starnberg Germany Christoph Anthuber 4 
Chris O’Brien Lifehouse, Camperdown Australia Philip Beale 3 
St. George Hospital, Kogarah Australia Chee Lee 3 
ICON Cancer Care Centre, Milton Australia Paul Vasey 3 
North Coast Cancer Institute Port Macquarie, Port Macquarie Australia Stephen Begbie 3 
Bankstown-Lidcombe Hospital, Bankstown Australia Sandra Harvey 3 
CHRU de Strasbourg Hôpital Civil, Strasbourg France Jean-Emmanuel Kurtz 3 
Hôpitaux Universitaires de Strasbourg, Strasbourg France Sophie Abadie-
Lacourtoisie 
3 
Centre Hospitalier la Dracénie, Draguignan France Emmanuel Guardiola 3 
Institute Daniel Holland, Groupe Hospitalier Mutualiste de Grenoble, 
Grenoble 
France C Garnier-Tixidré 3 
Klinikum am Steinenberg, Reutlingen Germany Peter Krieger 3 
Klinikum Hanau, Hanau Germany Thomas Müller 3 
St. Elisabeth Krankenhaus Köln-Hohenlind, Cologne Germany Daniel Rein 3 
Klinikum Frankfurt-Höchst, Frankfurt Germany Volker Möbus 3 
Klinikum Chemnitz, Chemnitz Germany Petra Krabisch 3 
Klinikum Kassel, Kassel Germany Gabriele Feisel-
Schwickardi 
3 
Asklepios Klinik Lich, Lich Germany Alexandra Bender 3 
Klinikum Bremen-Mitte, Bremen Germany Mustafa Aydogdu 3 
Diakonie-Klinikum Schwäbisch Hall, Schwäbisch Hall Germany Andreas Rempen 3 
Leopoldina-Krankenhaus, Schweinfurt Germany Michael Weigel 3 
Städtisches Klinikum Dessau, Dessau Germany HermannVoß 3 
Marienkrankenhaus, Hamburg Germany Gerhard Gebauer 3 
Thüringen-Kliniken, Saalfeld Germany Dietrich Hager 3 
Klinikum Konstanz, Konstanz Germany Andreas Zorr 3 
Die Frauenarztpraxis in Grafin, Grafing Germany Isolde Gröll 3 
Nambour General Hospital, Nambour Australia Mary Azer 2 
Institut Paoli-Calmettes, Marseille France Maria Cappiello-Bataller 2 
Clinique Armoricaine de Radiologie, St Brieuc France Anne-Claire Hardy-
Bessard 
2 
Centre Hospitalier de Thonon-les-Bains, Thonon-les-Bains France Francesco Del Piano 2 
Hôpital Antoine Béclère, Carmart France Sophie Barthier 2 
Groupe Hospitalier Saint-Joseph, Paris France  Gaël Deplanque 2 
Polyclinique Bordeaux-Nord, Bordeaux France Nadine Dohollou 2 
Hôpital de la Milétrie – Centre Hospitalier Universitaire de Poitiers – 
Pôle Régional de Cancérologie, Poitiers 
France Nadia Raban 2 
Insitut d’Oncologie Hartmann, Levallois-Perret France Jean-Michel Vannetzel 2 
CHR Metz-Thionville/Hôpital de Mercy, Metz France Raffaele Longo 2 
Clinique Francheville, Périgueux France  Charles-Briac Levache  2 
Centre Catalan d’Oncologie, Perpignan France Stéphanie Catala 2 
University Women’s Hospital Freiburg, Freiburg Germany Beate Rautenberg 2 
Klinikum St. Marien, Amberg Germany Tanja Hauzenberger 2 
Klinikum Esslingen, Esslingen Germany Thorsten Kühn 2 
University Hospital Düsseldorf, Düsseldorf Germany Tanja Fehm 2 
University Women’s Hospital Magdeburg, Magdeburg Germany Kerstin Wollschlaeger 2 
Caritasklinikum St. Theresia, Saarbrücken Germany Mustafa Deryal 2 
g.Sund Gynäkologisches Kompetenzzentrum, Stralsund Germany Carsten Hielscher 2 
St. Vincenz-Krankenhaus, Limburg Germany Angelika Ober 2 
University Hospital Mannheim, Mannheim Germany Axel Gerhardt 2 
DIAKO Flensburg, Flensburg Germany Horst Ostertag† 2 
University Hospital Jena, Jena Germany Ingo Runnebaum 2 
Albertinen-Krankenhaus, Hamburg Germany Uwe Herwig 2 
Lahn-Dill-Kliniken Wetzlar, Wetzlar Germany Ulrich Winkler 2 
Praxisklinik Krebsheilkunde für Frauen, Berlin Germany Gülten Oskay-Özcelik 2 
University Hospital Augsburg, Augsburg Germany Arthur Wischnik 2 
Klinikum Kempten-Oberallgäu, Kempten) Germany Ricardo Felberbaum 2 
University Hospital Greifswald, Greifswald Germany Antje Belau 2 
Lukaskrankenhaus, Neuss Germany Hans-Joachim Koch 2 
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Site Country Principal investigator 
No. of patients 
randomised 
Klinikum Deggendorf, Donau-Isar-Kliniken, Deggendorf  Germany Ronaldo Stuth 2 
Heinrich-Braun-Klinikum Zwickau, Zwickau Germany Sabine Schnohr 2 
Onkozentrum Dresden, Dresden Germany Steffen Dörfel 2 
Auguste-Kranken-Anstalten, Bochum Germany Dirk Behringer 2 
Klinikum Nürnberg, Nürnberg Germany Cosima Brucker 2 
Praxis Dr med. WW Reiter, Viersen Germany Wilhelm Reiter 2 
Schwerpunktpraxis Onkologie/Hämatologie, Bottrop Germany Carla Hannig 2 
Hochtaunus-Kliniken, Bad Homburg Germany Dominik Denschlag 2 
Kreisklinik Altötting-Burghausen, Altötting Germany Peer Hantschmann 2 
Städtisches Klinikum Brandenburg, Brandenburg Germany Peter Ledwon 2 
Onkologische Schwerpunktpraxis Lüneburg Germany Juliane Ebert 2 
Velindre Cancer Centre, Cardiff UK Rachel Jones and Emma 
Hudson  
2 
NCCI – Coffs Harbour Health Campus, Coffs Harbour Australia Karen Briscoe 1 
Gold Coast University Hospital, Southport Australia Marco Matos 1 
Royal Hobart Hospital, Hobart Australia Allison Black 1 
Peninsula Health – Frankston Hospital, Frankston Australia  Yoland Antill 1 
Centre Henri Becquerel, Rouen France Marianne Le Heurteur 1 
Clinique Pasteur – ONCOSUD, Toulouse France Raymond Despax 1 
Centre Hospitalier de Blois, Blois France Olivier Arsene 1 
Centre Hospitalier de Cholet, Cholet France Alain Zannetti 1 
Cancer Clinic, Institute Sainte-Catherine, Avignon France Julien Grenier 1 
University Hospital Münster, Münster Germany Ludwig Kiesel 1 
Marienhospital, Osnabrück Germany Götz Menke 1 
Franziskus-Hospital Harderberg, Georgsmarienhütte Germany Trygve Daabach 1 
Kliniken Südostbayern, Traunstein Germany Thomas Kubin 1 
Rotkreuzklinikum Munich, Munich Germany Martin Pölcher 1 
University Hospital Halle/Saale, Halle Germany Hans-Georg Strauß 1 
HELIOS Kliniken Schwerin, Schwerin Germany Susanne Vogel 1 
Klinikum Aschaffenburg-Alzenau, Aschaffenburg Germany Angelika Baldauf 1 
Diakonie-Klinikum Jung-Stilling, Siegen Germany Volker Müller 1 
Robert-Bosch-Krankenhaus, Stuttgart Germany Annette Steckkönig 1 
Paracelsus-Klinik, Henstedt-Ulzburg Germany Tobias Zeiser 1 
Johanniter-Krankenhaus, Evangelische Kliniken Bonn, Bonn Germany Yon-Dschun Ko 1 
Kliniken des Landkreises Neumarkt, Neumarkt Germany Heinz Scholz 1 
Klinikum Fürth, Fürth Germany Volker Hanf 1 




Supplementary Table S1: Adverse events (grade 1–2 in >10% of patients, any grade ≥3). 
Grade 
Carboplatin/gemcitabine/bevacizumab (n=329) Carboplatin/PLD/bevacizumab (n=332) 
1–2 3 4 1–2 3 4 
Nausea 169 (51%) 8 (2%) 0 161 (48%) 12 (4%) 0 
Fatigue 137 (42%) 11 (3%) 0 155 (47%) 10 (3%) 0 
Hypertension 54 (16%) 66 (20%) 1 (<1%) 56 (17%) 88 (27%) 0 
Anaemia 102 (31%) 32 (10%) 0 90 (27%) 32 (10%) 0 
Constipation 110 (33%) 3 (1%) 0 111 (33%) 2 (1%) 0 
Vomiting 73 (22%) 6 (2%) 0 84 (25%) 9 (3%) 0 
Diarrhoea 64 (19%) 5 (2%) 0 78 (23%) 5 (2%) 0 
Headache 70 (21%) 2 (1%) 0 79 (24%) 4 (1%) 0 
Epistaxis 81 (25%) 2 (1%) 0 80 (24%) 2 (1%) 0 
Proteinuria 48 (15%) 20 (6%) 2 (1%) 57 (17%) 18 (5%) 0 
Dyspnoea 55 (17%) 8 (2%) 0 64 (19%) 10 (3%) 0 
Palmar-plantar erythrodysaesthesia syndrome 5 (2%) 0 0 58 (17%) 7 (2%) 0 
Thrombocytopenia 35 (11%) 30 (9%) 32 (10%) 29 (9%) 20 (6%) 13 (4%) 
Neutropenia 30 (9%) 51 (16%) 22 (7%) 19 (6%) 33 (10%) 7 (2%) 
Mucosal inflammation 38 (12%) 0 0 56 (17%) 3 (1%) 0 
Alopecia 81 (25%) 0 1 (<1%) 59 (18%) 0 0 
Stomatitis 41 (12%) 1 (<1%) 0 56 (17%) 0 0 
Platelet count decreased 21 (6%) 15 (5%) 18 (5%) 27 (8%) 13 (4%) 13 (4%) 
Abdominal pain  55 (17%) 7 (2%) 0 41 (12%) 10 (3%) 0 
Urinary tract infection  50 (15%) 4 (1%) 0 43 (13%) 5 (2%) 0 
Arthralgia 34 (10%) 3 (1%) 0 42 (13%) 0 0 
Peripheral sensory neuropathy 32 (10%) 2 (1%) 0 34 (10%) 5 (2%) 0 
Decreased appetite 24 (7%) 1 (<1%) 0 38 (11%) 1 (<1%) 0 
Nasopharyngitis 30 (9%) 0 0 35 (11%) 0 0 
Neutrophil count decreased 13 (4%) 26 (8%) 11 (3%) 12 (4%) 16 (5%) 6 (2%) 
Leucopenia 23 (7%) 21 (6%) 1 (<1%) 21 (6%) 8 (2%) 0 
Dizziness 19 (6%) 2 (1%) 0 27 (8%) 0 0 
Pyrexia 25 (8%) 2 (1%) 0 24 (7%) 2 (1%) 0 
Back pain 42 (13%) 1 (<1%) 0 24 (7%) 0 0 
Asthenia 31 (9%) 1 (<1%) 0 20 (6%) 4 (1%) 0 
Pain 12 (4%) 2 (1%) 0 19 (6%) 3 (1%) 0 
White blood cell count decreased 22 (7%) 11 (3%) 1 (<1%) 14 (4%) 5 (2%) 0 
Oedema 8 (2%) 3 (1%) 0 17 (5%) 1 (<1%) 0 
General physical health deterioration 10 (3%) 6 (2%) 2 (1%)* 12 (4%) 4 (1%) 1 (<1%)* 
Alanine aminotransferase increased 11 (3%) 5 (2%) 0 11 (3%) 2 (1%) 0 
Aspartate aminotransferase increased 11 (3%) 1 (<1%) 0 9 (3%) 3 (1%) 0 
Unevaluable event 8 (2%) 2 (1%) 0 12 (4%) 0 0 
Pleural effusion 7 (2%) 2 (1%) 0 4 (1%) 7 (2%) 0 
Ileus 2 (1%) 2 (1%) 0 6 (2%) 2 (1%) 2 (1%) 
Subileus 6 (2%) 4 (1%) 0 5 (2%) 4 (1%) 1 (<1%) 
Device-related infection 2 (1%) 4 (1%) 0 4 (1%) 6 (2%) 0 




Carboplatin/gemcitabine/bevacizumab (n=329) Carboplatin/PLD/bevacizumab (n=332) 
1–2 3 4 1–2 3 4 
Hyperkalaemia 4 (1%) 1 (<1%) 0 6 (2%) 1 (<1%) 1 (<1%) 
Hypertonia 1 (<1%) 1 (<1%) 0 3 (1%) 5 (2%) 0 
Gamma glutamyltransferase increased 3 (1%) 2 (1%) 1 (<1%) 5 (2%) 3 (1%) 0 
Pulmonary embolism 3 (1%) 6 (2%) 0 3 (1%) 3 (1%) 1 (<1%) 
Infection 4 (1%) 0 0 5 (2%) 2 (1%) 0 
Pneumonia 1 (<1%) 3 (1%) 0 3 (1%) 3 (1%) 0 
Ascites 1 (<1%) 2 (1%) 0 3 (1%) 3 (1%) 0 
Lymphopenia 1 (<1%) 2 (1%) 0 6 (2%) 0 0 
Renal impairment 0 1 (<1%) 0 0 3 (1%) 2 (1%)* 
Hypertensive crisis 2 (1%) 1 (<1%) 0 1 (<1%) 2 (1%) 2 (1%) 
Blood creatinine increased 0 1 (<1%) 0 1 (<1%) 4 (1%) 0 
Embolism 2 (1%) 2 (1%) 1 (<1%) 2 (1%) 1 (<1%) 1 (<1%) 
Intestinal obstruction 0 0 0 1 (<1%) 3 (1%) 0 
Hypoacusis 3 (1%) 0 0 2 (1%) 2 (1%) 0 
Haematuria 3 (1%) 0 0 2 (1%) 2 (1%) 0 
Chronic kidney disease 3 (1%) 0 0 2 (1%) 2 (1%) 0 
Drug hypersensitivity 14 (4%) 5 (2%) 1 (<1%) 3 (1%) 1 (<1%) 0 
Pelvic pain 3 (1%) 2 (1%) 0 4 (1%) 0 0 
Acute kidney injury 1 (<1%) 0 2 (1%)† 4 (1%) 0 0 
Nephrotic syndrome 0 0 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 
Febrile neutropenia 0 3 (1%) 1 (<1%) 0 3 (1%) 0 
Hyperglycaemia 2 (1%) 1 (<1%) 0 0 3 (1%) 0 
Large intestinal obstruction 0 0 0 1 (<1%) 2 (1%) 0 
Haemoglobin decreased 6 (2%) 0 0 1 (<1%) 2 (1%) 0 
Impaired healing 4 (1%) 2 (1%) 0 2 (1%) 1 (<1%) 0 
Urinary tract obstruction 1 (<1%) 3 (1%) 0 3 (1%) 0 0 
Large intestine perforation 0 0 0 0 0 2 (1%)* 
Pancytopenia 3 (1%) 5 (2%) 0 0 0 2 (1%) 
Device-related sepsis 0 0 0 0 0 2 (1%) 
Cardiac failure 0 1 (<1%) 0 0 1 (<1%) 1 (<1%)* 
Hyponatraemia 1 (<1%) 4 (1%) 1 (<1%) 0 1 (<1%) 1 (<1%) 
Anal abscess 0 0 0 0 2 (1%) 0 
Infusion-related reaction 4 (1%) 2 (1%) 0 2 (1%) 0 0 
Syncope 2 (1%) 2 (1%) 0 0 1 (<1%) 0 
Sepsis 0 0 2 (1%) 0 1 (<1%) 0 
Posterior reversible encephalopathy syndrome 0 1 (<1%) 1 (<1%) 0 1 (<1%) 0 
Confusional state 1 (<1%) 3 (1%) 0 1 (<1%) 0 0 
Lymphocyte count decreased 2 (1%) 2 (1%) 0 1 (<1%) 0 0 
Intervertebral disc protrusion 1 (<1%) 2 (1%) 0 1 (<1%) 0 0 
Hepatic enzyme increased 1 (<1%) 2 (1%) 0 1 (<1%) 0 0 
Neutrophil count 2 (1%) 2 (1%) 0 0 0 0 
Dental caries 1 (<1%) 2 (1%) 0 0 0 0 
Myocardial infarction 0 0 2 (1%) 0 0 0 
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PLD=pegylated liposomal doxorubicin. 
*Includes one case at grade 5. †Includes two cases at grade 5. 
In addition, in the carboplatin/gemcitabine/bevacizumab arm there was: one grade 5 case each of suicide, osmotic demyelination syndrome neoplasm progression, and 
haemorrhage intracranial; one grade 4 case each of parainfluenzae virus infection, lung disorder, jaundice, haematotoxicity, brain oedema, and acute coronary syndrome; and 
one grade 3 case each of transaminases increased, tooth infection, spinal fracture, pyelonephritis, osteonecrosis of the jaw, malnutrition, hypoalbuminaemia, hypersensitivity, 
hydronephrosis, flank pain, cerebrovascular accident, vision blurred, urostomy complication, urinary fistula, tooth extraction, thyroid cancer, thrombophlebitis, tendon 
rupture, tachycardia, strangulated hernia, splenic infarction, small intestinal obstruction, skin ulcer, sinus node dysfunction, renal colic, presyncope, pain in extremity, 
neuropathy peripheral, migraine, lumbar vertebral fracture, kidney infection, intestinal perforation, infectious pleural effusion, incisional hernia, hypomagnesaemia, 
hyperbilirubinaemia, herpes zoster infection, hernia, hepatotoxicity, hepatic pain, haemorrhage, haematoma, gastrointestinal pain, gastrointestinal obstruction, gastrointestinal 
haemorrhage, gallbladder cancer, flushing, female genital tract fistula, fall, endocarditis, dysphonia, disease progression, diabetic ketoacidosis, depression, cystitis, 
computerised tomogram, coagulopathy, cellulitis, cell death, bone pain, blood disorder, bile duct stone, atrioventricular block, arterial occlusive disease, anxiety, angina 
unstable, allergic transfusion reaction, agitation, acute myocardial infarction, abdominal pain lower, and abdominal abscess. 
In the carboplatin/PLD/bevacizumab arm there was: one grade 4 case each of cerebrovascular accident, staphylococcal bacteraemia, myelodysplastic syndrome, 
haemorrhagic stroke, gait disturbance, and fistula; and one grade 3 case each of transaminases increased, tooth infection, spinal fracture, pyelonephritis, osteonecrosis of the 
jaw, malnutrition, hypoalbuminaemia, hypersensitivity, hydronephrosis, flank pain, wound infection, vertigo, venous thrombosis, urinary tract stoma complication, urinary 
tract disorder, toothache, tooth development disorder, thrombotic microangiopathy, thoracic vertebral fracture, tension, surgery, subcutaneous abscess, small intestinal 
haemorrhage, seizure, retinal detachment, retinal artery embolism, renal artery stenosis, rectal haemorrhage, polyneuropathy, plantar fasciitis, pain in jaw, overdose, 
osteoarthritis, oesophagitis, myocardial strain, muscular weakness, mouth haemorrhage, metastases to meninges, libido decreased, lethargy, knee operation, insomnia, 
influenza-like illness, hypotension, hepatitis toxic, hemiparesis, hemianopia, haematochezia, groin abscess, granulocyte count decreased, gastrointestinal disorder, 
extravasation, enteritis infectious, embolism venous, dysphagia, dry skin, diaphragmatic hernia, diabetes mellitus, depressed mood, dehydration, cough, colostomy, 
circulatory collapse, cholelithiasis, chest pain, cerebral haemorrhage, central venous catheterisation, central venous catheter removal, campylobacter gastroenteritis, cachexia, 
C-reactive protein increased, bronchitis, breast abscess, brain stem haemorrhage, blood pressure increased, blood alkaline phosphatase increased, atrial fibrillation, anal 
fistula, acute abdomen, acidosis, abscess, abdominal wound dehiscence, and abdominal pain upper. 
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Supplementary Figure S1: Proportional hazards  
Plots of the standardised score process against time for (A) the primary endpoint of PFS and (B) the secondary 
endpoint of OS for each of the observed and the first 100 simulated paths. Comparison of the observed and 
simulated paths of the martingale residual process did not indicate violations of the proportional hazard 
assumption of the stratified cox regression models according to the methods of Lin, Wei, and Ying.1 The 
supremum tests for proportional hazard assumption were non-significant for both PFS (p=0.79, giving 0.6 for 
the maximum absolute value of the residuals) and OS (p=0.18, giving 1.05 for the maximum absolute value of 
the residuals). Overall, the observed processes of PFS/OS did not seem to be unusual compared with the 







































Supplementary Figure S2: Biological PFS in the intention-to-treat population 
CD-BEV=carboplatin/pegylated liposomal doxorubicin/bevacizumab. 
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CG-BEV (n=337) CD-BEV (n=345)
PFS events, n (%) 300 (89) 283 (82)
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Supplementary Figure S3: Quality of life (QLQ-C30 global health status) 
CD-BEV=carboplatin/pegylated liposomal doxorubicin/bevacizumab. 
CG-BEV=carboplatin/gemcitabine/bevacizumab. CI=confidence interval. QLQ-C30=European Organisation for 


























































6 2412 15 18
219
Time (months)
No. at risk, n (%)
CG-BEV 306 237 200 140 105 70 45 32 21
(91) (70) (59) (42) (31) (21) (13) (10) (6)
CD-BEV 298 252 200 152 113 75 59 36 32




1. Lin DY, Wei LJ, Ying Z. Checking the Cox model with cumulative sums of martingale-based residuals. 
Biometrika 1993; 80: 557–72. 
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GLOSSARY OF ABBREVIATIONS 
  
ADL Activities of Daily Living 
ADR Adverse Drug Reaction 





ALT (SGPT) Alanine Aminotransferase 
A()PTT Activated ProThrombin Time 
ANC Absolute Neutrophil Count 
ASCO American Society of Clinical Oncology 
AST (SGOT) Aspartate Aminotransferase 
ATE Arterial Thromboembolic Event 
AUC Area Under the plasma Concentration-time curve 
BC Breast Cancer 
BP Blood Pressure 
BR Bilirubin 
BSA Body Surface Area 
CA 125 Cancer Antigen 125 
CHF Congestive Heart Failure 
CI Confidence Interval 
Cmax maximum plasma Concentration 
CNS Central Nervous System 
CR Complete Response 
CrCl Creatinine Clearance 
CT Computed Tomography 
CTC Common Toxicity Criteria 
CTCAE Common Toxicity Criteria: Adverse Events 
CVA Cerebrovascular Accident 
CVAD Central Venous Access Device 
d Day 
dL Decilitre 
EC European Commission 
ECG Electrocardiogram 
ECHO Echocardiography 
ECOG Eastern Cooperative Oncology Group 
eCRF Electronic Case Report Form(s) 
EDC Electronic Data Capture 
EMA European Medicines Agency 
ENGOT European Network of Gynaecological Oncological trial groups 
EOC Epithelial Ovarian Cancer 
EORTC European Organisation for Research and Treatment of Cancer 
EPO Erythropoetin 
EU European Union 
EudraCT European Union Drug Regulatory Agency Clinical Trial 
FBC Full Blood Count 
FDA U.S. Food and Drug Administration 
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GLOSSARY OF ABBREVIATIONS 
FIGO International Federation of Gynaecology and Obstetrics 
FPI First Patient In 
FTC Fallopian Tube Cancer 
g Gram 
GCIG Gynecologic Cancer InterGroup 
GCP Good Clinical Practice 
G-CSF Granulocyte-Colony Stimulating Factor 
GFR Glomerular Filtration Rate 
GOG Gynecologic Oncology Group 
h/hrs Hours 
Hb Hemoglobin 
HR Hazard Ratio 
IB Investigator’s Brochure 
ICH International Conference on Harmonization 
ICON International Collaborative Ovarian Neoplasm 
ID Identification 
IDMC Independent Data Monitoring Committee 
IgG Immunglobuline G 
IMP Investigational Medicinal Product 
INR International Normalized Ratio 
ITT Intent to Treat 
i.v. Intravenous 
kg Kilogram 
KKS  Koordinierungszentrum für Klinische Studien 
L Liter 
LD Longest Diameter (RECIST) 
LVEF Left Ventricular Ejection Fraction 
m² Square Metre 
mBC Metastatic Breast Cancer 




mmHg Millimeter of Mercury 
mRCC Metastatic Renal Cell Carcinoma 
MRI Magnetic Resonance Imaging 
MUGA Multi Gated Acquisition Scan 
muMAb Murine Monoclonal Antibody 
NCCN National Comprehensive Cancer Network 
NCI National Cancer Institute 
NE Inevaluable 
NSCLC Non Small Cell Lung Cancer 
NYHA New York Heart Association 
OC Ovarian Cancer 
ORR / RR Overall Response Rate 
OS Overall Survival 
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GLOSSARY OF ABBREVIATIONS 
PET Positron Emission Tomography 
PD Progressive Disease 
PLD Pegylated Liposomal Doxorubicin 
PLT Platelet 
PFI Platinum-free Interval 
PFS Progression-free Survival 
PP Per protocol 
PPC Primary Peritoneal Cancer 
PPE Palmar-plantar Erythrodysestesia Syndrome 
PR Partial Response 
PRES Posterior Reversible Encephalopathy Syndrome 
PS Performance Status 
PSC Peritoneal Serous Cancer 
QLQ / QoL Quality of Life Questionnaire / Quality of Life 
q4w every 4 weeks 
q3w Three-weekly 
q2w Bi-weekly 
RECIST Response Evaluation Criteria in Solid Tumors 
SAE Serious Adverse Event 
SAH Sub-arachnoid Hemorrhage 
SAP Statistical Analysis Plan 
SCr Serum Creatinine 
SD Stable Disease 
SPC Summary of Product Characteristics 
SSL Secure Sockets Layer 
SUSAR Suspected Unexpected Serious Adverse Reaction 
SWFI Sterile Water for Injection 
TIA Transient Ischemic Attack 
TTP Time To Disease Progression 
ULN Upper Limit of Normal 
VEGF Vascular Endothelial Growth Factor 
WNL Within Normal Limits 
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SYNOPSIS  
TITLE A prospective randomized Phase III trial of car-
boplatin/gemcitabine/bevacizumab vs. carboplatin/ 
pegylated liposomal doxorubicin/bevacizumab in patients 
with platinum-sensitive recurrent ovarian cancer. An 
ENGOT/GCIG Trial. 
SPONSOR AGO Study Group 
AGO Research GmbH 
INTERNATIONAL CHAIR Prof. Dr. med. Jacobus Pfisterer, Wiesbaden, Germany 
CLINICAL PHASE III 
INDICATION Patients with first recurrence of epithelial ovarian cancer 
(EOC), fallopian tube carcinoma (FTC) or primary perito-
neal carcinoma (PPC) and sensitive to platinum-based 
treatment regardless of FIGO stage, histological grades 
and types.  
RATIONALE Best standard of care treatment in patients with platinum-
sensitive recurrence in ovarian cancer (OC) based on lev-
el I evidence are platinum-based combinations such as 
paclitaxel/carboplatin, gemcitabine/carboplatin and 
pegylated liposomal doxorubicin (PLD)/carboplatin and 
gemcitabine/carboplatin/bevacizumab. 
Bevacizumab has been shown single-agent activity in re-
current OC (single-arm studies), in upfront treatment in 
combination with carboplatin/paclitaxel and in platinum-
sensitive recurrence. 
Today, more than 2600 patients with ovarian cancer were 
treated with bevacizumab in phase III trials [GOG 218, 
AGO-OVAR11/ICON7, AGO-OVAR2.15/AURELIA and 
OCEANS]. The treatment was well tolerated with a safety 
profile in line with that in other tumor types included in the 
Summary of Product Characteristics. It could be shown 
that chemotherapy in combination with bevacizumab was 
well tolerated. Especially, gastrointestinal perforations 
were not seen in the OCEANS trial. Chemotherapy with 
carboplatin/gemcitabine in combination with bevacizumab 
has a significant impact on PFS with a HR of 0.48. Addi-
tionally, there are phase II data of the combination of car-
boplatin/pegylated liposomal doxorubicin, showing that the 
combination is feasible. 
So far, carboplatin/pegylated liposomal doxorubicin was 
one of the options with the best therapeutic index for pa-
tients with platinum-sensitive recurrence and car-
boplatin/gemcitabine/bevacizumab has shown a dramatic 
improvement in PFS, the rationale of this clinical trial is to 
evaluate the best platinum-based regimen in combination 
with bevacizumab in platinum-sensitive recurrence. The 
question would be answered whether the addition of 
bevacizumab to pegylated liposomal doxorubi-
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cin/carboplatin is superior to bevacizumab combined with 
gemcitabine/carboplatin.  
TRIAL DESIGN Prospective, open-label, multinational, randomized, two-
arm, superiority Phase III trial. 
RANDOMIZATION Random assignment in 1:1 ratio to the treatment arms. 
The stratification factors will be: 
 platinum sensitive interval 
(6 -12 months vs. >12 months) 
 in case of debulking surgery for recurrence: residual 
tumor (yes vs. no);  
(In case of no debulking surgery for recurrence all 
patients will be categorized as having residual tu-
mor.) 
 prior antiangiogenetic treatment (e.g. anti-VEGF; 
yes vs. no) 
 group language 
NUMBER OF PATIENTS 654 patients will be enrolled (327 per arm). 
TARGET POPULATION Adult female patients with epithelial ovarian cancer (EOC), 
fallopian tube carcinoma (FTC) or primary peritoneal car-
cinomas (PPC) with first platinum-sensitive recurrence, re-
gardless of FIGO stage, histological grades and types.  
OBJECTIVES  Primary objective: 
The primary efficacy outcome measure for this clinical trial 
is investigator-determined progression-free survival (PFS).  
 
Secondary objectives: 
 Overall Survival (OS) 
 Biological progression-free survival (PFSBIO) by serum 
CA 125 assessed according to the GCIG criteria 
 Quality of Life (QoL) assessed by EORTC QLQ-C30 
and QLQ-OV28 
 Safety and Tolerability 
INCLUSION CRITERIA 1. Signed written informed consent obtained prior to initi-
ation of any trial-specific procedures and treatment as 
confirmation of the patients awareness and willingness 
to comply with the trial requirements. 
2. Females aged  18 years. 
3. Histologically confirmed diagnosis of 
 epithelial ovarian carcinoma (including 
mixed Mullerian tumors) or 
 fallopian tube carcinoma or 
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 primary peritoneal carcinoma. 
All FIGO stages, histological grades and types are al-
lowed. 
4. First disease recurrence > 6 months after first-line plat-
inum-based chemotherapy, no prior chemotherapy in 
the recurrent setting is allowed. Patients must have 
stopped any 1st line maintenance treatment with any 
type of anticancer treatment including bevacizumab at 
least 30 days prior randomization. 
5. Patients with measurable or non-measurable disease 
(according to RECIST v1.1) or CA 125 assessable 
disease (according to GCIG criteria) or histological 
proven diagnosis of relapse.  
6. In case of cytoreductive surgery for recurrence, pa-
tients must be able to commence cytotoxic chemo-
therapy within 8 weeks after cytoreductive surgery. 
The first dose of bevacizumab can be omitted in both 
arms if the investigator decides to start chemotherapy 
within 4 weeks after debulking surgery for recurrent 
disease. 
7. ECOG performance status (PS) 0-2. 
8. Life expectancy > 3 months. 
9. Adequate bone marrow function (within 28 days prior 
to randomization)  
 Absolute Neutrophil Count (ANC)  1.5 x 
109/L 
 Platelets (PLT)  100 x 109/L  
 Hemoglobin (Hb)  9.5 g/dL 
(Hemoglobin may be supported by transfu-
sion or erythropoietin or other approved 
hematopoietic growth factors.) 
10. Adequate coagulation parameters (within 28 days prior 
to randomization) 
 Patients not receiving anticoagulant medi-
cation who have an International Normal-
ized Ratio (INR)  1.5 and an Activated 
ProThrombin Time (aPTT)  
 1.5 x ULN 
(The use of full-dose oral or parenteral anti-
coagulants is permitted as long as the INR 
or aPTT is within therapeutic limits (accord-
ing to institution medical standard) and the 
patient has been on a stable dose of anti-
coagulants for at least two weeks at the 
time of randomization.) 
11. Adequate liver function (within 28 days prior to ran-
domization) 
 Serum bilirubin (BR)  2 x ULN 
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 Serum transaminases  2.5 x ULN ( 5 x 
ULN in the presence of liver metastasis) 
12. Adequate renal function (within 28 days prior to ran-
domization) 
 Serum creatinine < 1.6 mg/dL or creatinine 
clearance ≥ 40 mL/min 
 Glomerular filtration rate (GFR) > 40 
ml/min (estimates based on the Cockroft-
Gault or Jelliffe formula are sufficient) 
 Urine dipstick for proteinuria < 2+. If urine 
dipstick is  2+, 24 hour urine collection 
must demonstrate < 1 g of protein in 24 
hours.  
13. Normal blood pressure or adequately treated and con-
trolled hypertension (neither systolic BP ≤ 140 mmHg 
and/nor diastolic BP ≤ 90 mmHg). 
EXCLUSION CRITERIA Disease-related 
1. Non-epithelial origin of the ovary, the fallopian tube or 
the peritoneum (i.e. germ cell tumors). 
2. Ovarian tumors of low malignant potential (i.e. border-
line tumors)  
3. Malignancies other than ovarian cancer within 5 years 
prior to randomization, except for adequately treated  
 carcinoma in situ of the cervix  
 and/or basal cell skin cancer  
 and/or non-melanomatous skin cancer 
 and/or carcinoma in situ of the breast 
 and/or endometrial carcinoma (FIGO stage 
≤ IA). 
Patients may have received previous adjuvant chemo-
therapy for other malignancies e.g. breast or colorectal 
carcinoma if diagnosed over 5 years ago before ran-
domization with no evidence of subsequent recur-
rence. 
 
Prior, current or planned treatment 
4. Administration of other simultaneous chemotherapy 
drugs, any other anticancer therapy or anti-neoplastic 
hormonal therapy, or simultaneous radiotherapy during 
the trial treatment period (hormonal replacement ther-
apy is permitted as are steroidal antiemetics). 
5. Any previous radiotherapy to the abdomen or pelvis. 
6. Treatment with any other investigational agent, or par-
ticipation in another clinical trial testing a drug within 
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the past 30 days before randomization. 
7. Known hypersensitivity to used chemotherapeutic 
agents in this trial and bevacizumab and its excipients, 
chinese hamster ovary cell products or other recombi-
nant human or humanised antibodies. 
8. Current or recent (within 10 days prior to randomiza-
tion) chronic use of aspirin 
> 325 mg/day. 
9. Surgery (including open biopsy) within 4 weeks prior to 
anticipated first dose of bevacizumab (allowing for the 
fact that bevacizumab can be omitted for the first cycle 
of chemotherapy). It is strongly recommended that an 
interval of 7 days is left between the insertion of any 
central venous access devices (CVADs) and the onset 
of bevacizumab treatment. 
10. Any planned surgery during the treatment period plus 
4 additional weeks to allow for bevacizumab clear-
ance. 
 
Prior or concomitant conditions or procedures 
11. History of VEGF therapy related abdominal fistula or 
gastrointestinal perforation. 
12. Current, clinically relevant bowel obstruction, including 
sub-occlusive disease, related to underlying disease. 
13. Patients with evidence of abdominal free air not ex-
plained by paracentesis or recent surgical procedure. 
14. Previous Cerebro-Vascular Accident (CVA), Transient 
Ischaemic Attack (TIA) or Sub-Arachnoid Haemor-
rhage (SAH) within 6 months prior to randomization. 
15. Prior history of hypertensive crisis or hypertensive en-
cephalopathy. Uncontrolled hypertension (sustained 
elevation of neither systolic blood pressure > 140 
mmHg and / nor diastolic >90 mmHg despite antihy-
pertensive therapy).  
16. Clinically significant (i.e. active) cardiovascular dis-
ease, including:  
 myocardial infarction or unstable angina within 
≤ 6 months of randomization 
 New York Heart Association (NYHA)  grade 2 
Congestive Heart Failure (CHF) 
 poorly controlled cardiac arrhythmia despite 
medication (patients with rate-controlled atrial 
fibrillation are eligible) 
 peripheral vascular disease grade ≥ 3 (i.e. 
symptomatic and interfering with activities of 
daily living [ADL] requiring repair or revision). 
17. Left ventricular ejection fraction (LVEF) defined by 
ECHO/MUGA below the institutional lower limit of 
normal. 
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18. Significant traumatic injury during 4 weeks prior to ran-
domization. 
19. Current brain metastases or spinal cord compression. 
CT/MRI of the brain is mandatory (within 4 weeks prior 
to randomization) in case of suspected brain metasta-
ses. Spinal MRI is mandatory (within 4 weeks prior to 
randomization) in case of suspected spinal cord com-
pression. 
20. History or evidence upon neurological examination of 
central nervous system (CNS) disease, unless ade-
quately treated with standard medical therapy, e.g. un-
controlled seizures. 
21. Non-healing wound, active ulcer or bone fracture. Pa-
tients with granulating incisions healing by secondary 
intention with no evidence of facial dehiscence or in-
fection are eligible but require 3 weekly wound exami-
nations. 
22. History or evidence of thrombotic or hemorrhagic dis-
orders within 6 months prior to randomization. 
23. Evidence of bleeding diathesis or significant coag-
ulopathy (in the absence of therapeutic coagulation). 
24. Fertile woman of childbearing potential not willing to 
use adequate contraception (oral contraceptives, in-
trauterine device or barrier method of contraception in 
conjunction with spermicidal jelly or surgically sterile) 
for the duration of the trial and at least 6 months after-
wards. 
25. Pregnant or lactating women. 
26. Evidence of any other disease, metabolic dysfunction, 
physical examination finding or laboratory finding giv-
ing reasonable suspicion of a disease or condition that 
contra-indicates the use of an investigational drug or 
puts the patient at high risk for treatment-related com-
plications. 
27. Requirement of therapeutic anticoagulation using mar-





This trial consists of 2 treatment arms with chemotherapy 
plus bevacizumab until protocol defined disease progres-
sion or further reason for treatment discontinuation (i.e. in-
tolerable toxicity, withdrawal consent and others). Patients 
will be randomly assigned (1:1) to either arm. 
 
Arm 1 (standard arm, q3w): 
 Bevacizumab 15 mg/kg - d1  
(until disease progression or unacceptable toxicity) 
 Gemcitabine 1000 mg/m2 d1 + d8 for 6 cycles 
 Carboplatin   AUC4 d1 for 6 cycles 
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Arm 2 (experimental arm, q4w  q3w): 
 Bevacizumab  10 mg/kg. d1 +d15 q4w for 6 cy-
cles 
 PLD  30 mg/m2 d1 for 6 cycles 
 Carboplatin  AUC5 d1 for 6 cycles 
In arm 2 bevacizumab (15mg/kg q3w) will be given as 
maintenance therapy until disease progression or unac-
ceptable toxicity if chemotherapy treatment is finished. 
For arm 1 (standard arm (carboplatin/gemcitabine)) 
bevacizumab will be ‘non-investigational drug’ for those 
patients where it is standard of care in combination with 
gemcitabine and carboplatin and registered and reim-
bursed. Thus, bevacizumab will not be provided. 
For those patients in arm 1 where bevacizumab is not 
standard of care (e.g. prior anti-angiogenetic treatment) 
bevacizumab will be ‘investigational drug’. Bevacizumab 
will be provided.  
Carboplatin in combination with gemcitabine is standard of 
care and will not be an 'investigational study drug' and will 
not be provided. 
For arm 2 (experimental arm (carboplatin/pegylated lipo-
somal doxorubicin)) bevacizumab will be provided as ‘in-
vestigational study drug'. 
Pegylated liposomal doxorubicin in combination with car-
boplatin is standard of care and will not be an ‘investiga-
tional study drug’ and will not be provided. 
DURATION OF TRIAL Recruitment: N=654 patients will be recruited into this clin-
ical trial over a period of 30 months. 
Primary analysis will be done after 564 PFS events 
achieved. 
The analysis with respect to OS will be done after the last 
patient randomized has completed the 30 month follow-up. 
ASSESSMENTS Efficacy 
Analysis of PFS:  
 Tumor assessments will include gynecological ex-
amination, including ultrasound scanning. Cross 
sectional imaging (by CT, or MRI in case of con-
trast allergy) of the pelvis and abdomen and (by X-
ray or preferable by CT scan, evaluation based on 
RECIST v1.1) of the chest will be performed if clin-
ically indicated. All subsequent follow-up scans 
should be the same modality. 
 Tumor assessments will be performed at screening 
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and then every 12 weeks (starting before day 1 of 
cycle 1) until progressive disease or a minimum of 
30 months, whatever occurs first. Patients will be 
classified as having measurable or non-
measurable disease at screening and at each im-
aging visit (according to the local standard of care) 
conducted thereafter. Measurable tumors are to be 
assessed by RECIST v1.1 criteria. The same 
method should be used at screening and for all 
scans during conduct of this clinical trial if clinically 
indicated. Patients without any tumor residuals do 
not need CT scan or MRI, only in case of suspicion 
of disease progression. 
Overall survival (OS) is defined as the time period from the 
date of randomization to the date of death. 
Progressive serial elevation of serum CA 125 will be used 
to determine CA 125 response and PFSbio. CA 125 will be 
analyzed locally and assessed according to GCIG criteria. 
Safety 
Clinical safety examinations are performed before ad-
ministration of each treatment. All assessments will be 
scheduled as indicated in Table 1A. Additional assess-
ments may be performed as clinically indicated. 
General physical examination, measurement of vital signs, 
laboratory safety assessments and recording of AEs 
(grades 1–5) will be completed at each visit. Clinical safety 
assessments will include prior and interval medical history, 
prior treatments for cancer and ECOG. 
Left ventricular ejection function (LVEF) by ECHO/MUGA 
need only to be performed on those patients receiving 
pegylated liposomal doxorubicin in the treatment period. 
Investigator discretion can be used at all other times.  
Treatment emergent AEs/SAEs will be reported and grad-
ed according to NCI-CTCAE version 4.03. 
Quality of Life 
Quality of Life questionnaires EORTC QLQ-C30 and QLQ-
OV28 will be used in this trial. Questionnaires should be 
completed at baseline and then every 12 weeks until in-
vestigator determined progression-free survival and there-
after at every visit for the 5-year-follow-up or death, which-
ever occurs first.  
SAMPLE SIZE 
CALCULATION /  
STATISTICAL ANALYSIS 
The primary outcome measure of the trial is progression 
free survival (PFS). With 654 patients randomized at a 
steady rate over a period of 30 months with an additional 
30 months follow-up after the last patient randomized, the 
trial will have 80% power (two-sided log-rank test, signifi-
cance level of 5%, 15% exponential distributed drop-out 
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times) to show a 26.6% change in PFS from a median val-
ue of 12.4 months in the control arm to 15.7 months in the 
experimental arm, i.e. a Hazard Ratio (HR) of 0.79. It is 
expected that 564 PFS events will have occurred at the 
time point of primary analysis in the ITT population. 
The primary hypotheses are: H0: HR=1 versus H1: 
HR≤0.79. 
 
Primary efficacy Analysis 
The primary endpoint is progression-free survival defined 
as the time from the date of randomization to the first doc-
umented disease progression or death, whichever occurs 
first. 
The primary analysis will be done by a stratified log-rank 
test (stratifying for the factors used for randomization) for 
the difference in the distribution of progression-free surviv-
al (PFS) between the groups (two-sided at an alpha-level 
of 5%). Kaplan-Meier estimates for median PFS with the 
corresponding 95% confidence intervals will be presented. 
To assess the hazard ratio a stratified cox regression 
analysis will be performed, the point estimate for the haz-
ard ratio and corresponding 95%CI will be presented. 
 
Secondary Analyses 
Overall survival (OS) is defined as time from randomiza-
tion to death from any cause. For OS the same analyses 
as for PFS will be performed. 
To assess the secondary outcome biological progression-
free survival PFSbio according to GCIG criteria (see ap-
pendix) stratified log-rank test and a cox regression anal-
yses will be performed, the point estimate for the hazard 
ratio and corresponding 95%CI will be presented. Kaplan-
Meier estimates for median PFSbio with the corresponding 
95%CI will also be presented. 
Further Cox regression models will be performed to ana-
lyze the impact of significant baseline covariates regarding 
PFS and OS; different subgroups (such as status of prior 
anti-angiogenetic treatment) will also be explored descrip-
tively. 
Quality of Life (QoL) with the scores EORTC QLQ-C30 
and QLQ-OV28 will analysed descriptively. 
 
Safety Summaries 
The safety analyses will be based on the safety popula-
tion. All safety parameters will be summarized and also 
listed by patient. Summary tables will be presented for in-
cidence rates of all (serious) adverse events. 
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Analysis population 
The Intent-to-treat (ITT) population will be defined as all 
patients randomized in the clinical trial, regardless of 
whether they actually received treatment. The Per Protocol 
(PP) population will be a subgroup of the ITT population 
containing all patients who will have a sufficient treatment 
exposition and will not have any major protocol violation. 
Safety population will include all patients who received at 
least one dose of study drug.  
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Table 1A: FLOWCHART: Schedule of Assessments 
  






days prior to randomization1 
(visits depending on randomization arm ± 3 days) visits 
every 21 






(± 14 days) 
Cycle 12 Cycle 2 Cycle 3 Cycle 4 Cycle 5 Cycle 6 
-28 - -8 -7 - 0 1 1 1 1 1 1 
Bevacizumab3,4     X5 X X X X X X     
Gemcitabine/Carboplatin4     X X X X X X       
PLD/Carboplatin4     X X X X X X       
Randomization   X1                   
Informed Consent X X                    
Demographics X                     
Medical History X                     
Physical Examination   X X6 X X X X X X X   
Vital Signs/Blood Pressure   X X X X X X X X X   
ECOG   X X6 X X X X X X X   
Laboratory Assessments7 X   X6 X X X X X X X   
Coagulation7 X                     
Urinanalysis8 X   X6 X X X X X X     
Pregnancy Test9 X                     
CA 12510 X   X X X X X X X X X 
Tumor Assessment X11   every 12 weeks (± 7 days) until disease progression
12   X 
Chest X-ray X13                     
ECG X   if clinically indicated     
LVEF14 X   every 12 weeks X    
Concomitant Medication     X X X X X X X     
Adverse Events X X X X X X X X X X X 
QoL15   X every 12 weeks  X X 
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1. Randomization is on day 0. 
2. Day 1 of cycle 1 should be within 14 days after randomization. 
3. Following completion of chemotherapy: Patients in both arms will have further administration of bevacizumab, scheduled every 3 weeks. 
4. Standard Arm (Arm 1): Bevacizumab 15 mg/kg d1, q3w, Gemcitabine 1000 mg/m
2
 d1+8, q3w 6 cycles; Carboplatin AUC4 d1, 30 min, q3w, 6 cycles  
Experimental Arm (Arm 2): Bevacizumab 10 mg/kg d1+15, q4w, in combination with PLD 30 mg/m
2
 d1, q4w, 6 cycles; Carboplatin AUC5 d1, q4w 30 
min, 6 cycles; in bevacizumab maintenance phase the schedule will switch to bevacizumab 15 mg/kg d1, q3w. 
Both arms: until protocol defined disease progression, and/or unacceptable toxicity (whichever occurs first) 
5. Bevacizumab can be omitted for the first treatment cycle if treatment commences within 4 weeks of surgery, but cytotoxic chemotherapy must be 
started within 8 weeks of surgery. 
6. Repeat assessments not required if already performed during previous 7 days for baseline purposes. 
7. Laboratory assessments will be performed according to local standards (within 3 days prior to every treatment visit). 
8. Dipstick result (and/or 24-h urine collection result) must be available before every bevacizumab administration. 
9. A pregnancy test is only required for women of childbearing potential (within 28 days prior to randomization). 
10. At baseline, every 3 or 4 weeks during study treatment; after that every 3 months until a minimum of 30 months. 
11. The first tumor assessment for this clinical trial should be performed no more than 28 days prior to randomization. 
12. Tumor assessments via gynecological examination including ultrasound scanning will be performed every 12 weeks starting before day 1 of cycle 1 
until disease progression or up to 30 months (whatever comes first). Results of tumor assessments must be available before next scheduled cycle in 
order to exclude disease progression. CT scanning (or MRI in case of contrast allergy; evaluation based on RECIST v1.1) of the pelvis and abdomen 
and response assessment via RECIST v1.1 will be performed only if clinically indicated. All subsequent follow-up scans should be the same modality. 
Patients without any tumor residuals do not need CT scan or MRI, only in case of suspicion of disease progression. 
13. If screening chest X-ray shows any suspicion of metastatic thoracic lesions then a chest CT scan should be performed and disease measured accord-
ing to RECIST v1.1 criteria. 
14. LVEF should be assessed via ECHO/MUGA within 28 days before randomization and afterwards every 12 weeks for patients randomized in PLD arm 
and for safety follow-up visit.  
15. The QoL questionnaires (EORTC QLQ-C30 and QLQ-OV28) should be completed at baseline and then every 12 weeks until investigator-determined 
progression-free survival and thereafter at every visit for the 5-year-follow-up or death, whichever occurs first. 
16. Regardless of reason of end of treatment, patients should have a safety follow-up visit prior to start of new anticancer-treatment, or if applicable 4 
weeks (± 7 days) after last dose of bevacizumab, whichever occurs first.  
17. Follow-up visits regardless of disease status should be performed every 6 months during 5 years after study treatment start to document survival and 
any ovarian cancer therapy. 
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STUDY DESIGN AND CONDUCT 
1 BACKGROUND AND RATIONALE 
1.1 Background 
1.1.1 Epidemiology of ovarian cancer 
Epithelial ovarian cancer and related malignancies (primary peritoneal carcinoma, fallopian 
tube carcinoma) represent the fifth most common cause of cancer-related death among 
women in Europe and the United States.1,2 Ovarian cancer (OC) alone is the fourth most 
common cause of cancer-related death in women with an estimated 200,000 cases and 
125,000 deaths annually worldwide. It is also the gynecological malignancy with the highest 
mortality rate.3
 
According to statistics from the Robert-Koch-Institute, in Germany 2008, 7,790 
patients were newly diagnosed and 5,529 died from this neoplasm.3 
1.1.2 Natural history of ovarian cancer  
Despite improvements in the treatment of ovarian cancer, increases in overall survival (OS) 
have been modest
 
and as such, mortality remains high.4,5 Ovarian cancer is often asympto-
matic in early stages; consequently, patients typically have late stage disease at diagnosis, 
contributing to the high mortality rate.6 The vast majority of patients diagnosed with OC re-
spond to primary cytoreductive surgery followed by systemic chemotherapy.7 However, dis-
ease recurs in most patients within five years of diagnosis and more than half of all patients 
die within 5 years of diagnosis.8,9 Major trials published over the past 15 years reported that 
the median progression-free survival (PFS) for patients with advanced disease ranges be-
tween 16 and 23 months while the median OS is within 31 and 65 months.10-16 
Since the introduction of platinum-based chemotherapy and the addition of paclitaxel further 
advances in treatment have been modest. Survival rates of patients with advanced, recurrent 
or relapsed ovarian cancer remain poor and there continues to be a significant unmet medi-
cal need for improved treatment regimens. In this regard, molecular targeted therapeutic 
agents herald a new era for cancer treatment. In the setting of epithelial ovarian cancer, a 
growing body of evidence supports the use of anti-angiogenic agents in combination with 
chemotherapies.17 In particular, bevacizumab, a monoclonal antibody targeted against the 
pro-angiogenic vascular endothelial growth factor (VEGF), holds significant therapeutic po-
tential. In combination with the chemotherapeutic agents paclitaxel and carboplatin bevaci-
zumab is approved in the European Union (EU) and in some other countries outside Europe 
for the first-line treatment of advanced ovarian cancer (FIGO IIIB – IV). 
1.1.3 Current treatment of recurrent ovarian cancer  
Primary treatment for advanced-stage ovarian cancer usually consists of maximal cytoreduc-
tive surgery followed by chemotherapy using platinum- and taxane-based regimens, most of-
ten carboplatin and paclitaxel.18,19 Addition of a third chemotherapeutic agent has failed to 
improve efficacy in numerous trials and this strategy has been largely abandoned. However, 
incorporation of bevacizumab into platinum- and taxane-containing front-line therapy, with 
continuation of single-agent bevacizumab, was considered acceptable by the Fourth Interna-
tional Gynecologic Cancer Intergroup (GCIG) Ovarian Cancer Consensus, based on the sig-
nificantly improved progression-free survival (PFS) demonstrated in two randomized phase 
III trials.20-22 
Patients with platinum-sensitive recurrent ovarian cancer (defined as recurrence of disease 
more than 6 months from the completion of a platinum-based chemotherapy regimen) have 
higher initial response rates to chemotherapy. Recently, the U.S. Food and Drug Administra-
tion (FDA) approved gemcitabine chemotherapy in combination with carboplatin for relapsed 
platinum-sensitive disease. Carboplatin and gemcitabine resulted in a statistically significant 
progression-free survival (PFS) compared with carboplatin alone in patients with platinum-
sensitive disease.8 
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According to the NCCN and the German S3-guidelines the treatment options for patients with 
platinum sensitive recurrent ovarian cancer are the combinations car-
boplatin/gemcitabine/bevacizumab, carboplatin/pegylated liposomal doxorubicin, car-
boplatin/paclitaxel and carboplatin/gemcitabine. 
 
Carboplatin / Gemcitabine 
The combination of platinum and gemcitabine was established following the results of the 
randomized phase III AGO-OVAR 2.5 trial, which demonstrated significantly superior PFS 
with gemcitabine/carboplatin compared with carboplatin alone in this setting.8 Overall re-
sponse rate (RR) was also significantly improved with the addition of gemcitabine but there 
was no significant different in OS, since this trial was not powered for OS. 
Recently, results of the OCEANS trial demonstrated significantly improved PFS and RR 
when bevacizumab was combined with gemcitabine/carboplatin chemotherapy for platinum-
sensitive recurrent ovarian cancer and continued as a single agent until disease progres-
sion.23 Details of the trial design and results are provided in section 1.1.4. This regimen is 
approved by the EMA in the EU and by other authorities in non-EU countries. According to 
the German S3 guidelines bevacizumab in combination with carboplatin and gemcitabine is a 
preferred treatment option for patients with recurrent platinum sensitive ovarian cancer. 
 
Carboplatin / Pegylated Liposomal Doxorubicin 
Based on the results of the CALYPSO trial, the combination of carboplatin and pegylated lip-
osomal doxorubicin has become one of the options with the best therapeutic index in plati-
num sensitive recurrent ovarian cancer. The median PFS in this study was significantly better 
for patients receiving carboplatin/pegylated liposomal doxorubicin compared to those receiv-
ing carboplatin/paclitaxel. In addition, the safety profile showed a favorable toxicity profile for 




Bevacizumab is a recombinant humanized monoclonal antibody to vascular endothelial 
growth factor (VEGF) composed of human IgG1 framework regions and antigen-binding 
complementary determining regions from a murine monoclonal antibody (muMAb VEGF 
A.4.6.1) that blocks the binding of human VEGF to all VEGF-A receptors.26 
Bevacizumab recognizes and neutralizes isoforms of VEGF with a Kd
 
of around 8 x 10-10 M. It 
does not recognize other peptide growth factors tested (fibroblast growth factor, epidermal 
growth factor, hepatocyte growth factor, platelet-derived growth factor and nerve growth fac-
tor). It may exert a direct anti-angiogenic effect by binding to and clearing VEGF from the tu-
mor environment. Additional antitumor activity may be obtained via the effects of bevaci-
zumab on tumor vasculature, interstitial pressure and blood vessel permeability, providing for 
enhanced chemotherapy delivery to tumor cells.27
 
Furthermore, bevacizumab showed syner-
gistic anti-angiogenic activity with docetaxel, as assessed by endothelial cell proliferation and 
tubule formation in vitro.28  
Anti-VEGF antibodies have shown benefit when combined with chemotherapy in preclinical 
models of different tumor types. Bevacizumab can block the growth of a number of human 
cancer cell lines grown in nude mice, including metastatic colorectal cancer (mCRC), non-
squamous non-small cell lung cancer (NSCLC), metastatic or locally recurrent breast cancer 
(BC), prostate cancer, head and neck cancer, metastatic renal cell carcinoma (mRCC) and 
ovarian cancer (OC).29-32 
Bevacizumab has been evaluated in numerous phase I to IV trials in a variety of solid tumors 
as monotherapy and in combination with chemotherapy. The combination of bevacizumab 
with chemotherapy improves PFS and/or OS in mCRC33-36,
 
non-squamous NSCLC37, meta-
static BC (mBC)38,39, mRCC40,41 and OC42,43.
 
As of mid 2009, bevacizumab has been ap-
proved in more than 100 countries worldwide (including the member states of the European 
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Union and the United States of America) for the treatment of some forms of colorectal, 
breast, renal, lung and brain cancer (MBC not in the United States of America). Over 
800,000 patients have been exposed to bevacizumab in different indications.  
The placebo-controlled, phase III OCEANS trial showed a clinically meaningful and statisti-
cally significant increase in PFS (the primary endpoint) with the use of 15mg/kg q3w bevaci-
zumab in addition to carboplatin and gemcitabine in patients with platinum-sensitive recurrent 
ovarian, primary peritoneal or fallopian tube carcinoma (for more details please see section 
1.1.4.).23 The safety profile was consistent to earlier reports. 
Bevacizumab, in combination with carboplatin and gemcitabine, is indicated for treatment of 
adult patients with first recurrence of platinum-sensitive epithelian ovarian, fallopian tube or 
primary peritoneal cancer who have not received prior therapy with bevacizumab or other 
VEGF inhibitors or VEGF receptor-targeted agents. 
1.1.2.1 Safety of Bevacizumab  
The most common serious adverse events (SAEs) identified in clinical trials with bevaci-
zumab were:  
 Hypertension 
 Proteinuria 
 gastrointestinal perforation  
 hemorrhage 
 arterial thromboembolic events (ATE) 
 fistula 
 wound-healing complications  
 venous thromboembolism 
 congestive heart failure 
 thrombocytopenia 
 
The most frequently observed AEs across clinical trials in patients receiving bevacizumab 
were hypertension, fatigue or asthenia, diarrhea and abdominal pain. 
Increased rates of severe neutropenia, febrile neutropenia or infection with severe neutro-
penia have been observed in patients treated with some myelotoxic chemotherapy regimens 
plus bevacizumab in comparison to chemotherapy alone. 
There have been rare reports of bevacizumab-treated patients developing signs and symp-
toms that are consistent with posterior reversible encephalopathy syndrome (PRES). 
Gastrointestinal perforation – Bevacizumab has been associated with serious cases of 
gastrointestinal perforation or fistulae in 2.4% of patients (versus 0.3% in controls), with 
about one-third of cases being fatal (0.2%-1% of all bevacizumab treated patients). The typi-
cal presentation may include abdominal pain, nausea, emesis, constipation and fever. Perfo-
ration can be complicated by intra-abdominal abscess and fistula formation. The majority of 
cases occurred within the first 50 days of therapy. In some cases underlying intra-abdominal 
inflammation was present (either from gastric ulcer disease, tumor necrosis, diverticulitis or 
chemotherapy-associated colitis). Caution should be exercised when treating such patients 
with bevacizumab.  
In phase II trials in ovarian cancer, gastrointestinal perforation was most associated with re-
fractory or resistant ovarian cancer and greater cumulative use of chemotherapy.42,44,45  
In the phase III GOG 218 trial, gastrointestinal perforation, fistula, necrosis or leak (≥ grade 
2) occurred in 2.6% of those assigned to receive maintenance therapy (up to 22 cycles) of 
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bevacizumab following induction with 6 cycles of paclitaxel, carboplatin and bevacizumab 
and in 1.2% of those who received paclitaxel and carboplatin without bevacizumab.42 In the 
phase III AGO-OVAR 11/ICON7 trial the incidence of gastrointestinal perforations (all 
grades) was even lower occurring in 1.3% of patients assigned to the treatment arm (6 cy-
cles of paclitaxel, carboplatin and bevacizumab for 18 cycles) and in 0.4% of those in control 
arm (6 cycles of paclitaxel, carboplatin).22  
Furthermore, no unexpected safety concerns or gastrointestinal perforations were noted from 
the Phase III trial of bevacizumab plus gemcitabine/carboplatin in platinum-sensitive patients 
(OCEANS)23 but in resistant ovarian cancer patients (including AURELIA46) a few gastroin-
testinal perforations were observed.  
Bevacizumab should be permanently discontinued in patients who develop gastrointestinal 
perforation.  
For information regarding other side effects associated with the use of bevacizumab (either 
alone or in combination with chemotherapy), please refer to the current version of the IB.  
1.1.2.1 Phase II trials of bevacizumab in platinum sensitive recurrent ovarian 
cancer in combination with carboplatin and pegylated liposomal doxo-
rubicin  
A single-arm phase II trial of bevacizumab plus PLD/carboplatin in 54 patients with platinum-
sensitive recurrent ovarian, fallopian tube or primary peritoneal cancer, ORR was 72.2% and 
median TTP was 13.9 months.47 Four patients had have a grade 3 PPE, two patients  had 
have a deep vein thrombosis, and one patient had a small intestinal perforation. Otherwise, 
the safety profile of this combination was similar to the known toxicities of the three agents. 
1.1.2.1 Phase III trials of bevacizumab in ovarian cancer  
Based on two phase III trials in the front-line setting for patients with ovarian cancer (GOG-
0218, AGO-OVAR11/ICON7)21,22 bevacizumab was approved in the EU and other countries. 
The third most recently reported randomized phase III trial was OCEANS.23 Unlike GOG-
0218 and AGO-OVAR11/ICON7, patients in the OCEANS trial had platinum-sensitive recur-
rent epithelial ovarian, primary peritoneal or fallopian tube cancer. A total of 484 patients re-
ceived carboplatin AUC 4 plus gemcitabine 1000 mg/m², days 1 and 8, both given q3w for 6-
10 cycles, plus either placebo or bevacizumab 15 mg/kg q3w given until disease progres-
sion. The stratification variables were platinum-free interval (6-12 vs. > 12 months) and cy-
toreductive surgery for recurrent disease (yes vs. no). The primary endpoint was PFS as-
sessed by the investigator according to RECIST. Secondary endpoints included overall RR, 
duration of response, OS and safety. 
Almost 60% of patients hat a PFI > 12 months. The median number of chemotherapy cycles 
delivered was 6 in both arms. Patients in the control arm received a median of 10 cycles of 
placebo (range 1-36); those on the investigational arm received a median of 12 cycles of 
bevacizumab (range 1-43). 
The pre-specified primary analysis was performed after 317 PFS events. Results showed 
that the risk of progressive disease or death was halved (HR 0.484 [95% CI 0.388-0.605], 
p<0.0001). Median PFS was 12.4 months with bevacizumab/gemcitabine/carboplatin versus 
8.4 months with placebo/gemcitabine/carboplatin. These findings were supported by the re-
sults of the PFS analysis according to Independent Review Committee assessment (HR 
0.451 [95% CI 0.351-0.580], p<0.0001). The PFS benefit was seen consistently across all 
clinically relevant subgroups. Overall RR, a secondary endpoint, was also significantly supe-
rior in the bevacizumab-containing arm compared with chemotherapy alone (79% vs 58%, 
respectively, p<0.0001). The median duration of response was 10.4 months vs 7.4 months. 
At the time of primary analysis, 71% of patients were still alive and therefore the OS results 
were immature. Nevertheless, a trend favoring the bevacizumab-containing arm was seen. 
Bevacizumab or placebo was discontinued because of disease progression in more patients 
in the control arm than in bevacizumab arm; whereas discontinuation because of adverse 
events were more common in the bevacizumab arm than in the placebo arm. The safety pro-
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file of bevacizumab-containing regimen was consistent with observations from clinical trials in 
other tumor types and the two front-line trials of bevacizumab-containing therapy for ovarian 
cancer. Based on these findings the combination of bevacizumab/carboplatin and gemcita-
bine has received the European Union (EU) marketing authorization in September 2012 for 
the treatment of patients with first recurrence of platinum-sensitive recurrent ovarian cancer 
and no prior anti-angiogenic treatment. 
The randomized phase III CALYPSO trial compared pegylated liposomal doxorubi-
cin/carboplatin with paclitaxel/carboplatin in patients with relapsed, platinum-sensitive ovari-
an cancer. PLD/carboplatin was not only non-inferior to paclitaxel/carboplatin, but was signif-
icantly superior: median PFS was 11.3 months with pegylated liposomal doxorubi-
cin/carboplatin vs. 9.4 months with paclitaxel/carboplatin, with a more manageable adverse 
event profile.24 
1.2 Rationale for Study Design 
Despite standard treatment of initial debulking surgery followed by paclitaxel/carboplatin 
chemotherapy for patients with newly diagnosed ovarian cancer, most patients eventually re-
lapse even after achieving a clinical response.48 Patients who relapse after 6 months of initial 
platinum-based chemotherapy treatment have a better prognosis and are considered plati-
num-sensitive.8,24,49 Retreatment with paclitaxel/carboplatin has been associated with im-
proved PFS and OS,50-54 but with significant cumulative toxicities such as peripheral neuropa-
thy. 
Bevacizumab in addition to chemotherapy followed by bevacizumab maintenance therapy 
has demonstrated an improvement for progression-free survival (PFS) in the most essential 
phase III trials in primary or recurrent ovarian cancer (OC). In the first-line setting both trials 
GOG-0218 and AGO-OVAR 11/ICON 7 the addition of bevacizumab to chemotherapy has 
shown a significant impact on PFS compared with chemotherapy alone.  The clinical benefit 
was 3.8 and 1.7 months respectively in median PFS.21,22 
This is important for the first-line therapy because in the last 12 years no clinical trial has 
shown an improvement of therapy by addition of further chemotherapeutical or immunother-
apeutic agents to standard chemotherapy carboplatin/paclitaxel. 
Therapeutic effects of bevacizumab in platinum-resistant recurrent ovarian cancer are also 
remarkable: median PFS was 5.6 months with bevacizumab and single-agent chemotherapy 
versus 2.5 months with single-agent chemotherapy alone. This effect could be demonstrated 
for several combinations and also for pegylated liposomal doxorubicin. 
Gemcitabine/carboplatin combination in patients with platinum-sensitive recurrent ovarian 
cancer has demonstrated improved PFS compared with carboplatin alone in a phase III trial 
(median PFS 8.6 months; HR 0.72 [95% CI 0.58-0.90], p=0.0031).8 Pegylated liposomal 
doxorubicin demonstrated a statistically significant benefit over topotecan in PFS in platinum-
sensitive patients as well.55 In addition, the combination of PLD and carboplatin has been 
shown to be safe and effective, with ORR of 63% and median PFS of 9.4 months.24 
Bevacizumab has shown encouraging results in patients with recurrent ovarian cancer when 
administered in combination with standard chemotherapy. So, there is a positive effect in ad-
dition of bevacizumab to standard chemotherapy regarding median PFS as primary study 
endpoint in different therapeutic settings for ovarian cancer. 
The phase III OCEANS trial evealed that the addition of bevacizumab to standard gemcita-
bine/carboplatin significantly improved PFS (8.4 months versus 12.4 months).23,24  
Patients with platinum-sensitive recurrent ovarian cancer were evaluated in the phase III 
CALYPSO trial. In this trial carboplatin/pegylated liposomal doxorubicin was compared with 
standard chemotherapy carboplatin/paclitaxel. 12% of enrolled patients were pre-treated with 
another therapy for recurrent setting. The median PFS was 11.3 months for car-
boplatin/pegylated liposomal doxorubicin. So, the new combination of carboplatin/pegylated 
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liposomal doxorubicin could be established as a new standard of care therapy in this set-
ting.24 
Phase II data showed that the combination of carboplatin/PLD plus bevacizumab is safe and 
shows clinical activity (PFS 13.9 months).47 
Because of expected favorable safety profile of PLD in the experimental treatment arm this 
trial is designed as a prospective, open-label, randomized, two-arm superiority Phase III trial 
of bevacizumab plus gemcitabine/carboplatin (standard arm) or bevacizumab plus 
PLD/carboplatin (experimental arm) in patients with first platinum-sensitive recurrent epitheli-
al ovarian cancer, fallopian tube carcinoma, or primary peritoneal carcinoma. The superiority 
should be demonstrated in the median PFS: 12.4 months (standard arm) versus 15.7 months 
(experimental arm).  
Patients in the present trial will receive bevacizumab 15 mg/kg on day 1 every 3 weeks with 
gemcitabine and carboplatin in the standard arm (arm 1) or bevacizumab on day 1 every 2 
weeks with pegylated liposomal doxorubicin/carboplatin (q4w) in the experimental arm (arm 
2) for 6 cycles.  
After that, patients will treated with bevacizumab 15mg/kg on day 1 every 3 weeks until pro-
tocol defined disease progression and/or unacceptable toxicity (whichever occurs first).  
1.2.1 Rationale for dose selection  
The magnitude of benefit seen with bevacizumab plus gemcitabine/carboplatin was numeri-
cally greater than gemcitabine/carboplatin with a difference in ORR of 21%.56 Therefore, the 
same regimen of bevacizumab 15 mg/kg on day 1 of each cycle prior to gemcitabine 1000 
mg/m2 on days 1 and 8 and carboplatin AUC4 on day 1 every 3 weeks will be used in this tri-
al to maximize benefit. In a phase II trial of bevacizumab 10 mg/kg on days 1 and 15 of each 
cycle plus PLD 30 mg/m2 and carboplatin AUC4 on day 1 every 4 weeks, the ORR was 72% 
and with median TTP of 13.9 months.47 In this clinical trial, bevacizumab will be distributed on 
day 1 only with the PLD/carboplatin combination, then increased to 15 mg/kg on day 1 q3w 
when given alone as maintenance therapy. 
1.2.2 Rationale for patient population  
The phase III OCEANS trial patient population was including patients who had histological 
confirmed recurrent ovarian cancer and disease progression ≥ 6 months after completion of 
frontline platinum-based chemotherapy.56 Patients with platinum-sensitive recurrent ovarian 
cancer were evaluated in the phase III CALYPSO trial comparing PLD/carboplatin with 
paclitaxel/carboplatin; PFS was statistically superior with the PLD/carboplatin combination.49 
Accordingly, for this AGO-OVAR 2.21 trial, patients with platinum-sensitive first recurrent 
ovarian cancer were selected with epithelial ovarian cancer, fallopian tube carcinoma or pri-
mary peritoneal carcinoma, regardless of FIGO stage and histological grade or type. 
2 OBJECTIVES OF THE TRIAL 
2.1 Primary Objective 
The primary efficacy outcome measure for this clinical trial is investigator-determined pro-
gression-free survival (PFS). 
2.2 Secondary Objectives 
To compare 
 Overall Survival (OS) 
 Biological progression-free survival (PFSBIO) by serum CA 125 assessed according to 
GCIG criteria 
 Quality of Life (QoL)  
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o QoL will be assessed using EORTC QLQ-C30 and QLQ-OV28 questionnaires 
 Safety and Tolerability 
3 TRIAL DESIGN 
 
3.1 Overview of Trial Design and Dosing Regimen 
This is a prospective, randomized (1:1 ratio) , two-arm, superiority, multi-national, open-label, 
phase III trial designed to evaluate optimal treatment combination of bevacizumab with 
chemotherapy consisting of gemcitabine/carboplatin or PLD/carboplatin. 
Patients with epithelial ovarian cancer (EOC), fallopian tube carcinoma (FTC) or primary peri-
toneal carcinoma (PPC) sensitive to platinum-based treatment (regardless to all FIGO stag-
es, histological grades and types) will be randomly assigned to one of the two treatment 
groups in a 1:1 ratio: 
Arm 1 (Standard Arm): Patients will receive bevacizumab 15 mg/kg on day 1 q3w until 
disease progression or occurrence of bevacizumab-related toxicities, gemcitabine 1000 
mg/m2, days 1 and 8, q3w for 6 cycles and carboplatin AUC4 on day 1 q3w for 6 cycles. 
Arm 2 (Experimental Arm): Patients will receive bevacizumab 10 mg/kg on day 1 and 15 q4w 
during combination phase with PLD and carboplatin. All patients in this arm will receive PLD 
30 mg/m2 on day 1 q4w for 6 cycles and carboplatin AUC5 on day 1 q4w for 6 cycles. 
Patients will then switch to bevacizumab 15 mg/kg on day 1 q3w when given as maintenance 
treatment until disease progression or the occurrence of unacceptable toxicity, whichever 
occurs first.  
3.2 Number of Patients / Assignment to Treatment Groups  
Patients will be randomly assigned to treatment groups. The randomization will be done by 














Gemcitabine 1000 mg/m² d1 and 8 
Carboplatin AUC 4 d1 q3w 












Pegylated Liposomal Doxorubicin 30 mg/m² d1 




N = 654 
1:1 
 
Bevacizumab 15mg/kg q3w until PD 
• Tumor assessments every 12 weeks until disease progression or the occurrence of 
unacceptable toxicity (whichever occurs first) up to 30 months. 
• For patients without disease progression: Safety follow-up visit 30 months after start 
of treatment (or if applicable 4 weeks after the last dose of Bevacizumab, whichever 
occurs later). 
• Follow-up visits: regardless of disease status every 6 months for 5 years after study 
treatment start. 
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Enter the corresponding number for allocation to the treatment groups in the appropriate 
place on each patient’s electronic Case Report Form (eCRF). The patient randomization 
numbers are to be allocated sequentially in the order in which the patients are enrolled. 
The assigned patient number of each patient has to be documented by using an Enrolment 
Log and Subject ID-List. 
3.3 Trial Duration  
The clinical trial is planned to start in Q2 2013 with respect to first patient in (FPI) including a 
recruitment period of 30 months or until 654 patients are recruited in the trial. The treatment 
will last for a maximum of 6 cycles (18 weeks) for patients in the Standard Arm and in the 
Experimental Arm. If chemotherapy treatment is finished bevacizumab 15 mg/kg will be given 
every 3 weeks until disease progression or the occurrence of an unacceptable toxicity 
(whichever occurs first). Each patient will be followed until disease progression (primary 
endpoint PFS) and for the secondary endpoint OS at a minimum for 30 months. 
3.4 End of Trial 
The clinical trial will end when all patients have been followed for up at least 30 months after 
the last patient has started study treatment. 
4 TRIAL POPULATION 
4.1 Target Population  
The target population comprises women who are  18 years old with histological confirmed 
epithelian ovarian, fallopian tube or primary peritoneal cancer, regardless of FIGO stage, his-
tological grades and types, who have their first platinum-sensitive recurrence after first-line 
treatment.  
4.2 Inclusion Criteria 
To be eligible for this clinical trial, patients must have the following documented: 
1. Signed written informed consent obtained prior to initiation of any trial-specific procedures 
and treatment as confirmation of the patients awareness and willingness to comply with 
the trial requirements. 
2. Females aged  18 years. 
3. Histological confirmed diagnosis of  
 epithelial ovarian carcinoma (including mixed Mullerian tumors) or 
 fallopian tube carcinoma or 
 primary peritoneal carcinoma. 
 All FIGO stages, histological grades and types are allowed. 
4. First disease recurrence > 6 months after first-line platinum-based chemotherapy, no pri-
or chemotherapy in the recurrent setting is allowed. Patients must have stopped any first-
line maintenance treatment with any type of anticancer treatment including bevacizumab 
at least 30 days prior to randomization. 
5. Patients with measurable or non-measurable disease (according to RECIST v1.1) or CA 
125 assessable disease (according to GCIG criteria) or histological proven diagnosis of 
relapse. 
6. In case of cytoreductive surgery for recurrence, patients must be able to commence cyto-
toxic chemotherapy within 8 weeks after cytoreductive surgery. The first dose of bevaci-
zumab can be omitted in both arms if the investigator decides to start chemotherapy with-
in 4 weeks after debulking surgery for recurrent disease. 
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7. ECOG performance status (PS) 0-2. 
8. Life expectancy > 3 months. 
9. Adequate bone marrow function (within 28 days prior to randomization)  
 Absolute Neutrophil Count (ANC)  1.5 x 109/L 
 Platelets (PLT)  100 x 109/L 
 Hemoglobin (Hb)  9.5 g/dL  
(Hemoglobin may be supported by transfusion or erythropoietin or other approved 
hematopoetic growth factors.) 
10. Adequate coagulation parameters (within 28 days prior to randomization) 
 Patients not receiving anticoagulant medication who have an International Normal-
ised Ratio (INR)  1.5 and an Activated ProThrombin Time (aPTT)  1.5 x ULN. 
(The use of full-dose oral or parenteral anticoagulants is permitted as long as the 
INR or aPTT is within therapeutic limits (according to institution medical standard) 
and the patient has been on a stable dose of anticoagulants for at least two weeks 
at the time of randomization.) 
11. Adequate liver function (within 28 days prior to randomization) 
 Serum bilirubin (BR)  2 x ULN 
 Serum transaminases  2.5 x ULN (≤ 5 x ULN in the presence of liver metastases) 
12. Adequate renal function (within 28 days prior to randomization): 
 Serum creatinine < 1.6 mg/dL or creatinine clearance ≥ 40 ml/min 
 Glomerular filtration rate (GFR) > 40 ml/min (estimates based on the Cockroft-Gault 
or Jellife formular are sufficient) 
 Urine dipstick for proteinuria < 2+. If urine dipstick is  2+, 24-hour urine must 
demonstrate < 1 g of protein in 24 hours 
13. Normal blood pressure or adequately treated and controlled hypertension (neither systol-
ic BP ≤ 140 mmHg and/nor diastolic BP ≤ 90 mmHg)  
4.3 Exclusion Criteria 
1. Non-epithelial origin of the ovary, the fallopian tube or the peritoneum (i.e. germ cell tu-
mors). 
2. Ovarian tumors of low malignant potential (e.g. borderline tumors). 
3. Malignancies other than ovarian cancer within 5 years prior to randomization, except for 
adequately treated  
- carcinoma in situ of the cervix  
- and/or basal cell skin cancer  
- and/or non-melanomatous skin cancer 
- and/or carcinoma in situ of the breast 
- and/or endometrial carcinoma (FIGO stage ≤ IA). 
Patients may have received previous adjuvant chemotherapy for other malignancies (e.g. 
breast or colorectal carcinoma) if diagnosed over 5 years ago before randomization with 
no evidence of subsequent recurrence. 
4. Administration of other simultaneous chemotherapy drugs, any other anticancer therapy 
or anti-neoplastic hormonal therapy, or simultaneous radiotherapy during the trial treat-
ment period (hormonal replacement therapy is permitted as are steroidal antiemetics). 
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5. Any previous radiotherapy to the abdomen or pelvis. 
6. Treatment with any other investigational agent, or participation in another clinical trial 
testing a drug within the past 30 days before randomization. 
7. Known hypersensitivity to used chemotherapeutic agents in this trial and bevacizumab 
and its excipients, chinese hamster ovary cell products or other recombinant human or 
humanised antibodies. 
8. Current or recent (within 10 days prior to randomization) chronic use of aspirin 
> 325 mg/day. 
9. Surgery (including open biopsy) within 4 weeks prior to anticipated first dose of bevaci-
zumab (allowing for the fact that bevacizumab can be omitted from the first cycle of 
chemotherapy). It is strongly recommended that an interval of 7 days is left between the 
insertion of any central venous access devices (CVADs) and the onset of bevacizumab 
treatment. 
10. Any planned surgery during the trial treatment period plus 4 additional weeks to allow for 
bevacizumab clearance. 
11. History of VEGF therapy related abdominal fistula or gastrointestinal perforation. 
12. Current, clinically relevant bowel obstruction, including sub-occlusive disease, related to 
underlying disease. 
13. Patients with evidence of abdominal free air not explained by paracentesis or recent sur-
gical procedure. 
14. Previous Cerebro-Vascular Accident (CVA), Transient Ischaemic Attack (TIA) or Sub-
Arachnoid Hemorrhage (SAH) within 6 months prior to randomization. 
15. Prior history of hypertensive crisis or hypertensive encephalopathy. Uncontrolled hyper-
tension (sustained elevation of neither systolic blood pressure >140 mmHg and / nor di-
astolic >90  mmHg despite antihypertensive therapy).  
16. Clinically significant (e.g. active) cardiovascular disease, including:  
 myocardial infarction or unstable angina within ≤ 6 months of randomization 
 New York Heart Association (NYHA)  grade 2 congestive heart failure (CHF)  
 poorly controlled cardiac arrhythmia despite medication (patients with rate-
controlled atrial fibrillation are eligible) 
 peripheral vascular disease grade ≥ 3 (e.g. symptomatic and interfering with 
activities of daily living [ADL] requiring repair or revision) 
17. Left ventricular ejection fraction (LVEF) defined by ECHO/MUGA below the institutional 
lower limit of normal. 
18. Significant traumatic injury during 4 weeks prior to randomization. 
19. History or clinical suspicion of brain metastases or spinal cord compression. CT/MRI of 
the brain is mandatory (within 4 weeks prior to randomization) in case of suspected brain 
metastases. Spinal MRI is mandatory (within 4 weeks prior to randomization) in case of 
suspected spinal cord compression. 
20. History or evidence upon neurological examination of central nervous system (CNS) dis-
ease, unless adequately treated with standard medical therapy (e.g. uncontrolled sei-
zures). 
21. Non-healing wound, active ulcer or bone fracture. Patients with granulating incisions 
healing by secondary intention with no evidence of facial dehiscence or infection are eli-
gible but require 3 weekly wound examinations. 
22. History or evidence of thrombotic or hemorrhagic disorders within 6 months prior to ran-
domization. 
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23. Evidence of bleeding diasthesis or significant coaugulopathy (in the absence of coagula-
tion). 
24. Fertile woman of childbearing potential not willing to use adequate contraception (oral 
contraceptives, intrauterine device or barrier method of contraception in conjunction with 
spermicidal jelly or surgically sterile) for duration of the clinical trial and at least 6 months 
afterwards. 
25. Pregnant or lactating women. 
26. Evidence of any other disease, metabolic dysfunction, physical examination finding or la-
boratory finding giving reasonable suspicion of a disease or condition that contra-
indicates the use of an investigational drug or puts the patient at high risk for treatment-
related complications. 
27. Requirement of therapeutic anticoagulation using marcumar, warfarin or PTT-prolonging 
heparin. 
4.4 Concomitant Medication and Treatment 
Only medications and therapies for treatment of cancer need to be recorded in the eCRF. 
These medications include all medications given as supportive therapy for chemotherapy, 
such as G-CSF and erythropoietin. 
All non-cancer treatments that the responsible physician feels are appropriate are allowed in 
this trial. Only non-cancer medications for treating AEs should be recorded in the eCRF. 
The gemcitabine/carboplatin and PLD/carboplatin chemotherapy regimens will be adminis-
tered according to local standard of care. 
Patients should receive full supportive care during and after the administration of bevaci-
zumab with chemotherapy. This includes transfusion of blood and blood products and/or the 
use of erythropoietin as clinically indicated, antibiotics for infective complications and anti-
hypertensives for the management of hypertension. Anaphylaxis precautions should be ob-
served during administration of bevacizumab, gemcitabine, PLD and carboplatin as per local 
practice. 
Treatment with experimental concomitant, systemic anti-tumor agents or other concurrent in-
vestigational agents of any type is not allowed in this trial before protocol defined termination 
of the clinical trial. The patient may only be entered into another therapeutic clinical trial after 
documented protocol defined disease progression or occurrence of unacceptable toxicities or 
withdrawal from this clinical trial. 
The use of full-dose oral or parenteral anticoagulants is permitted as long as the INR or 
aPTT is within therapeutic limits (according to the medical standard in the institution) and the 
patient has been on a stable dose of anticoagulants for at least two weeks at the time of ran-
domization.  
Due to a possible risk of bleeding during treatment with bevacizumab patients should not 
take more than 325 mg of aspirin daily (or more than 75 mg of clopidogrel daily) at least until 
discontinuation of bevacizumab therapy. 
In case of treatment with other inhibitors of platelet aggregation, such as prasugrel, 
ticlopidine, tirofibane or dipyridamol, patients taking these medications should not be includ-
ed into the trial. As of today, no data on bevacizumab are available regarding the simultane-
ously taking of such compounds. 
5 SCHEDULE OF ASSESSMENTS AND PROCEDURES 
For details regarding the schedule of assessments and procedures please refer to table 1A. 
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5.1 Screening / Baseline Examination  
After provision of written informed consent, potential participants will undergo the following 
screening procedures no more than 28 days prior to randomization:  
 demographics, complete medical history including ovarian cancer history (to include all 
prior surgeries), concurrent illnesses.  
 clinical laboratory testing according to local standards should include: 
o Hematology (including hemoglobin, hematocrit, platelet count, red blood cell 
count, and full white blood cell count including differential), 
o Coagulation tests (INR and aPTT), 
o Biochemistry: serum chemistry (including total protein [or albumin], alkaline phos-
phatase, AST/SGOT, ALT/SGPT, total bilirubin, creatinine, estimated creatinine 
clearance according to Cockroft-Gault or Jelliffe formula (estimated creatinine 
clearance has to be done only from cycle 1-6.) 
o Urinalysis by dipstick: In case proteinuria ≥ 2+ is detected by the dipstick method, 
a 24-hour urine collection is needed to confirm renal function is within acceptable 
limits (< 1g per day). Alternatively, proteinuria testing can be performed according 
to local standards. 
o CA 125: The same method of assessment should be used for all CA 125 meas-
urements during the trial. 
 Pregnancy test: Women of childbearing potential will have a serum pregnancy test. Not 
required for women who have undergone and have documentation of a hysterectomy. 
 Tumor evaluation: Measurable tumors are to be assessed by RECIST v1.1 criteria. The 
same method of assessment should be used at screening and for all scans during trial 
conduct. Patients will be classified as having measurable or non-measurable disease at 
screening and at each imaging assessment (according to the local standard of care) con-
ducted thereafter.  
 Chest X-Ray: A chest X-ray must be performed at screening to check for thoracic metas-
tasis in all patients. If screening chest X-ray shows any suspicion of metastatic thoracic 
lesions then a chest CT scan should be performed and disease measured according to 
RECIST v1.1 criteria. 
 Standard 12-lead electrocardiogram (ECG). 
 LVEF should be assessed via ECHO/MUGA according to local standard. 
 Adverse events (grades 1-5 according to NCI-CTCAE v 4.03). 
Within 7 days prior to randomization the following assessments should be completed. 
 Complete physical examination and measurement of vital signs (including height, weight, 
and blood pressure). 
 ECOG PS assessment. 
 QoL: Quality of life questionnaires EORTC QLQ-C30 and QLQ-OV28 will be used in this 
clinical trial. They will be assessed at baseline and every 12 weeks until investigator de-
termined progression-free survival and thereafter at every visit for the 5-year follow-up or 
death, whichever occurs first. 
 Adverse events (grades 1-5 according to NCI-CTCAE v 4.03). 
All patients undergoing screening must be listed in the Enrolment Log and Subject ID-List.  
Protocol V03F  22.03.2016 
AGO-OVAR 2.21/ENGOT-ov18 - 34 of 87 - EudraCT No. 2012-004125-24 
5.2 Trial assessments during treatment period 
All assessments will be scheduled as indicated in table 1A. Additional assessments may be 
performed as clinically indicated.  
5.2.1 Tumor response criteria  
Patients will be assessed for disease response or progressive disease throughout the clinical 
trial.  
5.2.1.1 Response Criteria 
A mandatory tumor assessment via gynecological examination including ultrasound scanning 
and only if clinically indicated, cross-sectional imaging (by CT, or MRI in case of contrast al-
lergy; evaluation according to RECIST v. 1.1 criteria) of the pelvis and abdomen (by X-ray or 
preferably by CT scan) will be performed every 12 weeks (± 7 days of the scheduled visit) 
until progressive disease or up to 30 month, starting before day 1 of cycle 1, and during fol-
low-up every 6 months (± 2 weeks) until disease progression. Patients without any tumor re-
siduals do not need CT scan or MRI, only in case of suspicion of disease progression. 
Results of tumor assessments must be available before next scheduled cycle in order to ex-
clude disease progression. 
Patients will be classified as having measurable or evaluable but non-measurable disease 
prior to day 1 of cycle 1 and at each imaging assessment (according to the local standard of 
care) conducted thereafter.  
Tumor measurements should be made by the same investigator/radiologist for each patient 
during the trial to the extent that this is feasible. All follow-up scans should be the same mo-
dality. 
5.2.1.2 Response Criteria according GCIG 
Progressive serial elevation of serum CA 125 will be used to determine CA 125 and biologi-
cal progression-free survival. CA 125 will be analyzed locally every 3 or 4 weeks during study 
treatment (starting on day 1 of cycle 1) and thereafter every 3 months until a minimum of 30 
months or disease progression or occurrence of unacceptable toxicity. The same method of 
assessment should be used for all CA 125 measurements during this clinical trial. Values will 
be assessed according GCIG criteria.  
5.2.2 Clinical efficacy assessments  
Progression-free survival (PFS) and overall survival (OS) will be assessed according to table 
1A. PFS is defined as the time from the date of randomization to investigator-determined 
disease progression. OS is defined as the time period from the date of randomization to the 
date of death. 
5.2.3 Clinical safety assessments  
Patients will undergo a complete physical examination. Measurement of vital signs (weight, 
blood pressure), and laboratory safety assessments according to local standards and record-
ing of all AEs grades 1-5 in the source notes, will be performed by the investigator. These 
assessments will be recorded at each visit until the follow-up visit. Only concomitant cancer 
therapies, all cancer treatments prior to enrollment, chemotherapy given from cycle 1 through 
cycle 6, medication for AE treatment and medications for further treatment of cancer beyond 
disease progression need to be recorded in the concomitant medication eCRF at each corre-
sponding visit.  
The National Cancer Institute’s Cancer Toxicity Criteria for Adverse Events (NCI-CTCAE) 
version 4.03 will be used to evaluate the clinical safety of the treatment in this clinical trial. 
Patients will be assessed for grades 1 to 5 adverse events, including SAEs, at each clinical 
visit and as necessary throughout the clinical trial. All AEs will be recorded in the eCRF.  
A standard 12-lead ECG will be performed during the clinical trial as clinically indicated.  
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LVEF should be assessed every 12 weeks until disease progression and during safety fol-
low-up visit for patient randomized in PLD arm. 
5.2.4 Performance Status  
Performance status (PS) will be measured using the ECOG Performance Status Scale (see 
Appendix 20.4).  
It is recommended, if possible, that a patient’s PS will be assessed by the same person 
throughout the clinical trial.  
PS will be assessed at each visit until and including the safety follow-up visit. At day 1 of cy-
cle 1 a repeat assessment is not required if it was already performed during previous 7 days 
for baseline purposes. 
5.2.5 Laboratory Assessments 
Laboratory safety assessments will be performed within 3 days prior to every treatment visit 
before study drug is administered and at safety follow-up visit. All testing will be conducted 
locally. The total volume of blood taken will be approximately 15 ml per visit.  
Regular safety assessments should be taken in accordance with local standard of care and 
may include:  
- Hematology: hemoglobin, hematocrit, platelet count, red blood cell count, white blood cell 
count with differential 
- Coagulation tests (INR and aPTT) to be performed only if clinically indicated  
- Biochemistry: serum chemistry (including total protein [or albumin only], alkaline phos-
phatase, AST/SGOT, ALT/SGPT, total bilirubin, creatinine, estimated creatinine clear-
ance according to Cockroft-Gault or Jelliffe formula (estimated creatinine clearance has 
to be done only from cycle 1-6.)  
- Urinalysis by dipstick: In case proteinuria ≥ 2+ is detected by the dipstick method, a 24-
hour urine collection is needed to confirm renal function is within acceptable limits (< 1g 
per day). Alternatively, proteinuria testing can be performed according to local standards. 
5.2.6 Health-related Quality of Life Assessments (QoL)  
Health related Quality of Life questionnaires EORTC QLQ-C30 and QLQ-OV28 will be used 
in this clinical trial. These will be assessed every 12 weeks starting on day 1 of cycle 1 until 
investigator determined progression-free survival and thereafter at every visit for the 5-year-
follow-up or death, whichever occurs first. 
QLQ-C30 incorporates 9 multi-item scales: 5 functional scales (physical, role, cognitive, emo-
tional, and social); 3 symptom scales (fatigue, pain, nausea and vomiting); and a global 
health and quality-of-life scale. 
QLQ-OV28 is a specific ovarian cancer module consisting of 28 items that assess abdominal 
symptoms, peripheral neuropathy, other chemotherapy-related side effects, hormonal symp-
toms, body image, sexual functioning and attitudes towards disease and treatment.  
5.3 Maintenance Therapy 
After completion of chemotherapy and without disease progression or occurrence of unac-
ceptable toxicity patients will be treated with bevacizumab only every 3 weeks. All assess-
ments will be scheduled as indicated in table 1A. Additional assessments may be performed 
as clinically indicated.  
 Complete physical examination and measurement of vital signs (including weight, and 
blood pressure). 
 ECOG PS assessment. 
 Clinical laboratory testing according to local standards: 
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o Hematology (including hemoglobin, hematocrit, platelet count, red blood cell 
count, and full white blood cell count including differential) 
o Biochemistry: serum chemistry (including total protein [or albumin], alkaline phos-
phatase, AST/SGOT, ALT/SGPT, total bilirubin, creatinine) 
o Urinalysis by dipstick: In case proteinuria ≥ 2+ is detected by the dipstick method, 
a 24-hour urine collection is needed to confirm renal function is within acceptable 
limits (< 1g per day). Alternatively, proteinuria testing can be performed according 
to local standards. 
o CA 125 
 QoL: Quality of life questionnaires EORTC QLQ-C30 and QLQ-OV28 will be used every 
12 weeks until investigator determined progression-free survival and thereafter at every 
visit for the 5-year-follow-up or death, whichever occurs first. 
 Adverse events (grades 1-5 according to NCI-CTCAE v 4.03). 
All assessments, except QoL, will be done until disease progression or occurrence of unac-
ceptable bevacizumab-related toxicity, whichever occurs first. 
5.4 Post-treatment follow-up  
Safety follow-up visits: regardless of reason of end of treatment patients should have a safety 
follow-up visit prior to start of new anticancer-treatment, or if applicable 4 weeks (± 7 days) 
after last dose of bevacizumab, whichever occurs first. Patients will undergo a safety follow-
up assessment, including general physical examination, measurement of vital signs, ECOG 
PS, laboratory assessments (hematology, biochemistry, urinanalysis, CA 125), QoL assess-
ment and adverse event follow-up.  
Follow-up: Follow-up visits regardless of disease status should be performed every 6 months 
during 5 years after study treatment start. Specific follow-up assessments are described in 
table 1A. 
5.5 Treatment of the Patient after End of Trial 
Upon clear evidence of disease progression, study treatment should be discontinued perma-
nently and patients will receive standard of care treatment. The investigator takes responsi-
bility for decision about the subsequent treatment. 
6 STUDY TREATMENTS 
(a) Investigational Medicinal Product (IMP) 
According to Directive 2001/20 EC of the European Parliament an investigational medicinal 
product is a pharmaceutical form of an active substance or placebo being tested or used as a 
reference in a clinical trial, including products already with a marketing authorization but used 
or assembled (formulated or packaged) in a way different from the authorized form, or when 
used for an unauthorized indication or when used to gain further information about the au-
thorized form.  
For arm 1 (standard arm (carboplatin/gemcitabine)) bevacizumab will be ‘non-investigational 
drug’ for those patients where it is standard of care in combination with gemcitabine and car-
boplatin and registered and reimbursed. Thus, bevacizumab will not be provided. 
For those patients in arm 1 where bevacizumab is not standard of care (e.g. prior anti-
angiogenetic treatment) bevacizumab will be ‘investigational drug’. Bevacizumab will be pro-
vided.  
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For those countries where bevacizumab is not registered and/or reimbursed for patients with 
platinum sensitive recurrent ovarian cancer Bevacizumab will be provided.  
For arm 2 (experimental arm (carboplatin/PLD)) bevacizumab will be provided as ‘investiga-
tional study drug'. 
PLD in combination with carboplatin is standard of care and will not be an ‘investigational 
study drug’ and will not be provided. 
(b) Standard of Care Chemotherapy 
The chemotherapy consisting of gemcitabine/carboplatin and PLD/carboplatin are consid-
ered to be the standard of care chemotherapy. 
The standard of care chemotherapy will not be supplied or reimbursed. 
If bevacizumab associated to gemcitabine/carboplatin obtains market authorization and re-
imbursement according to national authorities, this will be also standard of care; then bevaci-
zumab will not be supplied or reimbursed, too. 
6.1 Dose and Schedule of Bevacizumab  
For patients randomized in arm 1 bevacizumab will be administered intravenously with a 
dose of 15 mg/kg on day 1 every 3 weeks. The dose of 10mg/kg bevacizumab will be admin-
istered intravenously on day 1 and day 15 every 4 weeks for patients randomized in arm 2. 
Bevacizumab will be given until disease progression or the occurrence of an unacceptable 
toxicity. Bevacizumab must be administered before gemcitabine followed by car-
boplatin or before PLD followed by carboplatin.  
Bevacizumab and chemotherapy will be administered at the same visit. 
Bevacizumab will be calculated prior to every visit according to the actual weight. 
If any or all chemotherapy is discontinued prior to disease progression, including for toxicity, 
bevacizumab will be continued as maintenance therapy with a dose of 15 mg/kg every 3 
weeks until disease progression or the occurrence of an unacceptable toxicity related to 
bevacizumab. 
6.2 Preparation and Administration of Bevacizumab  
6.2.1 Formulation and Storage 
Bevacizumab (Avastin®) is supplied as a clear to slightly opalescent, colorless to pale brown, 
sterile liquid for intravenous infusion in single-use vials which are preservative-free. Bevaci-
zumab will be supplied in 5 mL glass vials with a 4 mL fill (100 mg, 25 mg/mL) and/or in 20 
mL glass vials with a 16 mL fill (400 mg, 25 mg/mL). The formulation contains sodium phos-
phate, trehalose, polysorbate 20, and Sterile Water for Injection (SWFI) in addition to bevaci-
zumab active ingredient.  
Upon receipt of the study drug, vials are to be refrigerated at 2°C - 8°C and should remain re-
frigerated until just prior to use. DO NOT FREEZE. DO NOT SHAKE. Keep vial in the outer 
carton due to light sensitivity.  
VIALS ARE FOR SINGLE USE ONLY. Vials used for one patient may not be used for any 
other patient. Vials should not be used after the re-test date shown on the pack. 
Bevacizumab does not contain any antimicrobial preservative; therefore, care must be taken 
to ensure the sterility of the prepared solution.  
Chemical and physical in-use stability has been demonstrated for 48 hours at 2°C - 30°C in 
0.9% sodium chloride solution. From a microbiological point of view, the product should be 
used immediately. If not used immediately, in-use storage times and conditions are the re-
sponsibility of the user and would normally not be longer than 24 hours at 2°C to 8°C, unless 
dilution has taken place in controlled and validated aseptic conditions. 
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6.2.2 Packaging and Labeling 
The labeling of bevacizumab will be in accordance with all local legal requirements and con-
ducted according to Good Manufacturing Practice. Labels will include the following key in-
formation: 
 Bevacizumab 400 mg or 100 mg 
 FOR CLINICAL STUDY USE ONLY 
 AGO Research GmbH 
 AGO-OVAR 2.21   
 Patient No. 
 Store at 2°C - 8°C 
 Expiry date 
6.2.3 Route of Administration 
Bevacizumab should be prepared by a healthcare professional using aseptic technique. 
Withdraw the necessary amount of bevacizumab for a dose of 15 mg/kg of body weight and 
dilute in a total volume of 100 mL of 0.9% sodium chloride injection. In case of administering 
a total dose exceeding 1000 mg, dilute the calculated dose of bevacizumab with a sufficient 
amount of 0.9% sodium chloride injection to keep final concentration between 2.3 mg/mL and 
16.5 mg/mL. Keep 100 mL as the minimal volume to administer and limit the infusion volume 
as much as possible. Discard any unused portion left in a vial, as the product contains no 
preservatives. Parenteral drug products should be inspected visually for particulate matter 
and discoloration prior to administration.  
Diluted bevacizumab should be used within 8 hours.  
Administration will be as a continuous intravenous (i.v.) infusion. Anaphylaxis precautions 
should be observed during study drug administration.  
The first dose of bevacizumab will be administered over 90 minutes. If the first infusion is well 
tolerated without infusion-related reaction (e.g. fever and/or chills) the 2nd
 
dose will be admin-
istered over 60 minutes. If the 2nd
 
dose is also well tolerated without an infusion reaction all 
subsequent doses will be administered over 30 minutes.  
 In case of an infusion-related reaction during the first cycle (during the 90-minute infusion 
or up to 24 hours later) the next infusion must be administered over at least 120 minutes. 
If the 120 minute infusion is well tolerated the next infusion and all subsequent infusions 
may be delivered over 120 minutes.  
 If any infusion-related reactions occur during the second cycle (during the 60 minute infu-
sion or up to 24 hours later) the next infusion must be administered over 90 minutes. If 
the 90 minute infusion is well tolerated, the next infusion and all subsequent infusions 
may be delivered over 90 minutes.  
 If an infusion-related reaction occurs during a 30-minute infusion or up to 24 hours later 
all subsequent infusions may be delivered over 60 minutes or longer.  
A rate-regulating device should be used for all study drug infusions. When the study drug 
bag is empty, 50 mL of 0.9% sodium chloride solution will be added to the bag or an addi-
tional bag will be hung, and the infusion will be continued for a volume equal to that of the 
tubing to ensure complete delivery of the study drug. If more saline is infused the extent of 
saline infusion does not factor into the study drug infusion time.  
Should extravasation of the study drug infusion occur the following steps should be taken:  
 Discontinue the infusion. Treat the extravasation according to institutional guidelines for 
extravasation of a non-caustic agent. If a significant volume of the study drug infusion 
remains restart the infusion at a more proximal site in the same limb or on the other side.  
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In the event of a suspected anaphylactic reaction during study drug infusion:  
 Stop the study drug infusion. Apply a tourniquet proximal to the injection site to slow sys-
temic absorption of study drug. Do not obstruct arterial flow in the limb. Maintain an ade-
quate airway. Administer antihistamines, corticosteroids, epinephrine, or other medica-
tions as required.  
 Continue to observe the patient, document observations and administer further treatment 
as required.  
The above events should be reported as AEs. 
6.3 Dose and Schedule of Chemotherapy 
Gemcitabine/carboplatin and PLD/carboplatin as standard of care chemotherapy will be ad-
ministered as followed:  
Arm 1: 
Gemcitabine  1000 mg/m2 d1 and 8, q3w; 6 cycles 
Carboplatin  AUC4 d1, q3w; 6 cycles 
Arm 2: 
PLD    30 mg/m2 d1, q4w; 6 cycles 
Carboplatin  AUC5 d1, q4w; 6 cycles 
6.3.1 Gemcitabine 
Use normally available commercial stock in keeping with the normal practice of the institution 
and following the instruction of the SPC (summary of product characteristics).  
There are no special accountability arrangements for gemcitabine.  
Reconstitute gemcitabine 1000 mg/m2
 
in 25 ml of normal saline according to the standard 
practice of the institution. Administer over 30 minutes on day 1 and day 8 of each cycle. 
Monitor closely for allergic reactions and hematological events as per local institution guide-
lines.  
If it becomes necessary to discontinue gemcitabine treatment due to toxicity patients can re-
main on carboplatin and bevacizumab. 
6.3.2 Carboplatin  
Use normally available commercial stock in keeping with the normal practice of the institution 
and following the instruction of the SPC (summary of product characteristics).   
There are no special accountability arrangements for carboplatin.  
Reconstitute carboplatin with 5% dextrose or according to the standard practice of the institu-
tion.  
Administer over 15-60 minutes (depending on local institutional practice).  
The carboplatin dose should be calculated according to the Calvert formula as follows:  
 carboplatin dose = Target AUC (GFR + 25).  
For the purpose of this protocol the GFR is considered equivalent to the creatinine clearance 
calculated according to the formula of Cockroft-Gault or Jelliffe. The exact dose of car-
boplatin therefore depends on the calculated GFR. 
Dose capping of carboplatin may be carried out according to local institutional protocols.  
If it becomes necessary to discontinue carboplatin treatment due to toxicity patients can re-
main on bevacizumab and gemcitabine or PLD.  
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6.3.3 Pegylated Liposomal Doxorubicin (PLD) 
Use normally available commercial stock in keeping with the normal practice of the institution 
and following the instruction of the SPC (summary of product characteristics).   
There are no special accountability arrangements for PLD.  
Reconstitute PLD
 
in 250 ml of 5% dextrose or according to the standard practice of the insti-
tution.  
Administer over 60-90 minutes on day 1 of each cycle. 
If it becomes necessary to discontinue PLD treatment due to toxicity, patients can remain on 
carboplatin and bevacizumab.  
6.4 Method of randomization 
Patients will be randomly assigned to one of the two treatment groups in a 1:1 ratio using 
permuted block sizes stratifying for the following prognostic factor: 
Stratum I: platinum sensitive interval 6 -12 months vs. >12 months 
Stratum II: residual tumor in case of debulking surgery for recurrence (In case of no debulk-
ing surgery for recurrence all patients will be categorized as having residual tumor.) 
Stratum III: Previous vs. no anti-angiogenetic treatment (e.g. anti-VEGF) 
Stratum IV: group language 
 
Randomization will be performed through KKS, Philipps-University of Marburg, Germany. 
Koordinierungszentrum für Klinische Studien Marburg (KKS) 
Philipps University Marburg 
Randomization FAX number +49 (0) 6421 28 66516 
Monday - Thursday between 8 a.m. and 4 p.m. 
Friday between 8 a.m. and 2 p.m.  
At randomization, the patient number is checked for uniqueness by the randomization center 
and confirmed with the treatment assignment. If the uniqueness check is not successful, the 
randomization center has to clarify this before randomization. 
Treatment assignment for each patient to one of the two groups will be given by FAX. Ran-
domization will not be possible during official company closing days.  
6.5 Compliance 
Accountability and patient compliance will be assessed by maintaining adequate “drug dis-
pensing”, “drug inventory”, and “drug destruction” records.  
Accurate records must be kept for study drug vial provided by the sponsor. These records 
must contain the following information:  
 documentation of drug shipments (date received, quantity and batch identity)  
 disposition of unused study drug not administered to a patient  
A Drug Dispensing Log must be kept current and should contain the following information:  
 the identification of the patient to whom the study drug was dispensed  
 the date(s), quantity and batch identity of the study drug administered to the patient  
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This inventory must be available for inspection by the monitor. All supplies, including partially 
used containers and copies of the dispensing & inventory logs, must be returned to the 
sponsor before the end of the trial, unless alternate destruction has been authorized by the 
sponsor, or is required by local or institutional regulations. The destruction of partially used or 
empty vials should be documented in writing. 
7 SAFETY ISSUES 
The Investigator’s Brochure of bevacizumab will be used as reference document for the 
study drug and will be provided. 
Study drug means bevacizumab only for patients randomized in arm 2 or for patients ran-
domized in arm 1 with e.g. prior anti-angiogenetic treatment (see also section 6). 
All adverse events (either related to trial specific procedures or otherwise) experienced after 
the patient has signed the informed consent form but before they have received study drug 
should be recorded as adverse events or serious adverse events.  
All adverse events occurring after signing the informed consent form up to 30 days after 
treatment discontinuation must be recorded on the AE form of the eCRF. Additionally, non-
serious, new AEs considered related to study drug which occur up to 26 weeks after the last 
dose of study drug should also be reported. SAEs considered related to study drug are to be 
reported indefinitely. 
7.1 Adverse Events 
It is the responsibility of the investigator(s) to report all adverse events in the eCRF.  
7.1.1 Adverse Events 
An adverse event is any untoward medical occurrence in a patient or clinical investigation 
subject administered a pharmaceutical product and which does not necessarily have to have 
a causal relationship with this treatment. An adverse event can therefore be any unfavorable 
and unintended sign (including an abnormal laboratory finding), symptom, or disease tempo-
rally associated with the use of a medicinal product, whether or not considered related to the 
medicinal product. Pre-existing conditions (except the underlying malignancy, see section 
7.1.1.3) which worsen during the clinical trial are to be reported as adverse events. They can 
become serious adverse events if they fulfill one of the seriousness criteria described in sec-
tion 20.2. 
All clinical adverse events (AEs) encountered during the clinical trial will be reported on the 
AE page of the eCRF.  
7.1.2.1 Intensity 
Intensity of all adverse events will be graded according to the NCI Common Terminology Cri-
teria for Adverse Events version 4.03 (CTCAE) on a five-point scale (grade 1 to 5) and re-
ported in detail on the eCRF.  
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Table 2: Grading of adverse events not listed on the CTCAE: 
CTC Grade  Equivalent To Definition  
Grade 1 Mild asymptomatic or mild symptoms; clinical or diag-
nostic observations only; intervention not indicat-
ed 
Grade 2 Moderate minimal, local or noninvasive intervention indicat-
ed; limiting age-appropriate instrumental ADL 
Grade 3 Severe severe or medical significant but not immediately 
life-threatening hospitalization or prolongation of 
hospitalization indicated; disabling; limiting self 
care ADL 
Grade 4 Life threatening Life-threatening consequences; urgent interven-
tion indicated 
Grade 5 Death death related to AE 
 
7.1.2.1 Drug – adverse event relationship 
The causality relationship of study drug to the adverse event will be assessed by the investi-
gator as either:  
Yes or No. 
If there is a reasonable suspected causal relationship to the study drug, i.e. there are facts 
(evidence) or arguments to suggest a causal relationship, drug-event relationship should be 
assessed as Yes.  
The following criteria should be considered in order to assess the relationship as Yes:  
– Reasonable temporal association with drug administration  
– It may or may not have been produced by the patient’s clinical state, environmental or tox-
ic factors, or other modes of therapy administered to the patient.  
– Known response pattern to suspected drug  
– Disappears or decreases on cessation  
– Reappears on rechallenge  
The following criteria should be considered in order to assess the relationship as No:  
– It does not follow a reasonable temporal sequence from administration of the drug.  
– It may readily have been produced by the patient’s clinical state, environmental or toxic 
factors, or other modes of therapy administered to the patient.  
– It does not follow a known pattern of response to the suspected drug.  
– It does not reappear or worsen when the drug is readministered.  
For more details please refer to section 20.1. 
7.1.2.1 Progression of underlying malignancy 
Progression of underlying malignancy is not reported as an adverse event if it is clearly con-
sistent with the suspected progression of the underlying cancer as defined by RECIST v1.1 
criteria or GCIG criteria for CA 125. Hospitalization due solely to the progression of underly-
ing malignancy should NOT be reported as a serious adverse event. Clinical symptoms of 
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disease progression may be reported as adverse events if the symptom cannot be deter-
mined as exclusively due to the progression of the underlying malignancy or does not fit the 
expected pattern of progression for the disease under trial. 
If there is any uncertainty about an adverse event being due only to the disease under the 
clinical trial it should be reported as an AE or SAE. 
7.1.2 Adverse Events of Special Interest 
Adverse Events of Special Interest for Bevacizumab which are listed in section 7.3 should be 
closely monitored as part of the study procedures. 
7.1.3 Serious Adverse Events  
Any clinical adverse event or abnormal laboratory test value that is serious occurring during 
the course of the clinical trial, irrespective of the treatment received by the patient, must be 
reported to the local Study Group within 24 hours of knowledge (expedited reporting).   
The definition and reporting requirements according to national laws and ICH Guideline for 
Clinical Safety Data Management, Definitions and Standards for Expedited Reporting will be 
adhered (for details refer to section 20.2). 
Specific exceptions to SAE reporting 
The following events, in the context of this trial should not be considered as SAEs. No SAE 
form is required and they are exempt from expedited reporting. They must be reported on the 
appropriate eCRF section: 
• disease progression or death as a result of disease progression 
• elective hospitalization and surgery for treatment of advanced epithelial ovarian fallopian 
tube cancer or peritoneal cancer or its complications 
• elective hospitalization to simplify treatment or procedures 
• elective hospitalization for pre-existing conditions that have not been exacerbated by trial 
treatment. 
7.1.4 Laboratory Test Abnormalities 
Any clinically significant laboratory result fulfilling the criteria for a serious adverse event 
(SAE) should be reported as such, in addition to being recorded as an AE in the eCRF.  
Any treatment-emergent abnormal laboratory result which is clinically significant (e.g. meet-
ing one or more of the following conditions) should be recorded as a single diagnosis on the 
adverse event page in the eCRF:  
– accompanied by clinical symptoms  
– leading to a change in study drugs (e.g. dose modification, interruption or permanent dis-
continuation)  
– requiring a change in concomitant therapy (e.g. addition of interruption of, discontinuation 
of or any other change in a concomitant medication, therapy or treatment) 
7.2 Handling of Safety Parameters 
7.2.1 Treatment and Follow-up of Adverse Events  
Adverse events, especially those for which the relationship to study drug is not "unrelated", 
should be followed up until they have returned to baseline status or stabilized. If a clear ex-
planation is established it should be recorded on the eCRF. 
7.2.2 Follow-up of Abnormal Laboratory Test Values 
In the event of unexplained abnormal laboratory test values, the tests should be repeated 
immediately and followed up until they have returned to the normal range and/or an ade-
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quate explanation of the abnormality is found. If a clear explanation is established it should 
be recorded on the eCRF. 
7.2.3 Pregnancy  
Every patient must be instructed to immediately inform the investigator if she becomes preg-
nant during the clinical trial. Pregnancies occurring up to six months after the completion of 
the study drug must also be reported to the investigator. The investigator must report all 
pregnancies within 24 hours to the local Study Group. The investigator should counsel the 
patient, discuss the risks of continuing with the pregnancy and the possible effects on the fe-
tus. Monitoring of the patient should continue until conclusion of the pregnancy.  
7.3 Dose Modifications of Bevacizumab for Toxicity 
No dose reduction of bevacizumab is foreseen for an individual patient. Skipped doses or 
termination of treatment will be based on the observed toxicities. If any weight change of 
more than 10% is observed, the treatment dosage should be modified accordingly. Other 
than in cases of significant weight change, no other dose modifications are allowed for 
bevacizumab. Missed doses will not be administered subsequently.  
In cases of toxicity, please refer to the current version of the bevacizumab Investigator’s Bro-
chure for guidance.  
As described below, bevacizumab treatment may be either temporarily or permanently sus-
pended in the case of hypertension, proteinuria, thrombosis/embolism, hemorrhage, CHF or 
wound healing complications in addition to any other serious bevacizumab-related toxicity 
(grade 3 or 4).  
Bevacizumab should be temporarily withheld in the event of grade 4 febrile neutropenia 
and/or grade 4 thrombocytopenia (regardless of the relationship to treatment), since these 
conditions are predisposing factors for an increased bleeding tendency. In general, appropri-
ate management for grade 3 or 4 bevacizumab-related events is described in sections 7.3.  
In addition, bevacizumab treatment should be permanently discontinued in patients experi-
encing any of the following events:  
 Posterior Reversible Encephalopathy Snydrome (PRES) 
 grade 3/4 hemorrhagic/bleeding events 
 grade 3/4 left ventricular dysfunction (CHF)  
 grade 4 venous thromboembolism including pulmonary embolism 
 grade 4 hypertension (hypertensive crisis) or hypertensive encephalopathy 
 grade 4 non-gastrointestinal fistula 
 grade 4 proteinuria (nephrotic syndrome) 
 any grade of CNS bleeding  
 any grade of arterial thromboembolism 
 any grade of gastrointestinal perforation 
 any grade of tracheo-esophageal fistula 
 any grade of hypersensitivity/allergic reactions related to Bevacizumab 
Table 3: Management of grade 3 or 4 bevacizumab-related adverse events 
First occurrence  Hold bevacizumab until toxicity has improved to ≤ grade 1. 
Second occurrence  Permanently discontinue bevacizumab treatment. 
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7.3.1 CNS bleeding  
Patients should be monitored for signs and symptoms of CNS bleeding, and bevacizumab 
treatment discontinued in case of intracranial bleeding of any grade. Patients with untreated 
CNS metastases were routinely excluded from clinical trials with bevacizumab, based on im-
aging procedures or signs and symptoms. Therefore, the risk of CNS hemorrhage in such 
patients has not been prospectively evaluated.  
7.3.2 Hypertension  
Patients must be closely monitored on trial for the development or worsening of hyperten-
sion. Blood pressure measurements should occur after the patient has been in a resting posi-
tion for ≥ 5 minutes. If the initial BP reading is neither ≥ 140 mmHg systolic and/nor≥ 90 
mmHg diastolic pressures the result should be verified with a repeat measurement. If hyper-
tension occurs bevacizumab treatment should be managed as described in table 4. 
Table 4: Bevacizumab treatment management for hypertension 
NCI CTCAE 
v4.03 
Hypertension Pattern Treatment Action 
Grade 1 Prehypertension 
(Systolic BP 120 – 139 mmHg or dias-
tolic BP 80 – 89 mmHg.) 
Give bevacizumab. 
Grade 2 Stage 1 hypertension 
(systolic BP 140 – 159 mmHg or dias-
tolic BP 90 - 99 mmHg); medical inter-
vention indicated; recurrent or persis-
tent  ( 24 hrs); symptomatic increase 
by  > 20 mmHg (diastolic) or to 
>140/90 mmHg if previously WNL; 
monotherapy indicated 
Withhold bevacizumab. 
Start antihypertensive therapy. 
Once BP is < 140/90 mmHg, pa-
tients may continue bevacizumab 
therapy. 
Grade 3 Stage 2 hypertension  
(systolic BP ≥ 160 mmHg or diastolic 
BP ≥ 100 mmHg); medical intervention 
indicated; more than one drug or more 
intensive therapy than previously used 
indicated 
Hold bevacizumab for persistent 
or symptomatic hypertension and 
discontinue permanently if hyper-
tension is not controlled according 
to investigator judgment. 
Grade 4 Life-threatening consequences  
(e.g. malignant hypertension, transient 
or permanent neurologic deficit, hyper-





7.3.3 Proteinuria  
Proteinuria will be assessed within 72 hours before each bevacizumab treatment by dipstick 
method unless assessed by 24-hour urine collection. Alternatively, proteinuria testing can be 
performed according to local standard. An algorithm for the appropriate management follow-
ing a positive dipstick result with corresponding bevacizumab treatment management guid-
ance is provided below (Table 5). 
Nephrotic syndrome (grade 4 proteinuria): Bevacizumab must be permanently discontinued if 
nephrotic syndrome is detected at any time. 
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Table 5: Bevacizumab treatment management for proteinuria 
NCI CTCAE 
v4.03 
Urinalysis Treatment Action 
Grade 1 1+ proteinuria  
urinary protein < 1.0 g/24 hrs 
No bevacizumab dose modification. 
Grade 2 2+ proteinuria  
urinary protein 1.0 - 3.4 g/24 hrs 
Suspend bevacizumab for urine protein 
level ≥ 2 g/24 hrs and resume when pro-
teinuria is < 2 g/24 hrs. 
For 2+ dipstick: may administer bevaci-
zumab; obtain 24-hour urine prior to 
next bevacizumab dose. 
For 3+ dipstick: obtain 24-hour urine 
prior to bevacizumab administration.  
Grade 3 Urinary protein  3.5 g/24 hrs 
 
Suspend bevacizumab. Resume when 
proteinuria is < 2 g/24 hrs, as deter-




 Permanently discontinue bevacizumab. 
 
7.3.4 Dose interruption due to infusion-associated reactions  
For administration guidelines, see section 6.2.  
• In case of an infusion-related reaction during the first cycle (during the 90-minute infusion 
or up to 24 hours later) the next infusion must be administered over at least 120 minutes. If 
the 120 minute infusion is well tolerated the next infusion and all subsequent infusions may 
be delivered over 120 minutes.  
• If any infusion-related reaction occurs during the second cycle (during the 60 minute infu-
sion or up to 24 hours later) the next infusion must be administered over 90 minutes. If the 90 
minute infusion is well tolerated the next infusion and all subsequent infusions may be deliv-
ered over 90 minutes.  
• If an infusion-related reaction occurs during a 30-minute infusion or up to 24 hours later all 
subsequent infusions may be delivered over 60 minutes or longer.  
7.3.5 Surgical procedures and wound healing complications  
Bevacizumab may adversely affect the wound healing process. Serious wound healing com-
plications with a fatal outcome have been reported. 
Bevacizumab therapy should be withheld for an interval of at least four weeks (28 days) be-
fore conducting elective surgery. In the case of unplanned surgical procedures bevacizumab 
should be stopped as soon as the indication for surgery is identified. Emergency surgery 
should be performed as appropriate without delay after a careful risk benefit assessment.  
Necrotising fasciitis including fatal cases has rarely been reported in patients treated with 
bevacizumab; usually secondary to wound healing complications, gastrointestinal perforation 
or fistula formation. Bevacizumab therapy should be discontinued in patients who develop 
necrotising fasciitis, and appropriate treatment should be promptly initiated. 
It is strongly recommended that an interval of 7 days is left between the insertion of any cen-
tral venous access devices (CVADs) and the onset of bevacizumab treatment. 
Bevacizumab therapy should be restarted ≥ 28 days and ≤ 42 days following major surgery. 
In patients who experience wound healing complications during bevacizumab treatment 
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bevacizumab should be withheld until the wound is fully healed. If the wound is not fully 
healed within 42 days bevacizumab treatment should be discontinued.  
Continuation of study treatment in patients who have had bevacizumab therapy delayed for 
more than 2 treatment cycles due to surgical procedures or wound healing must be dis-
cussed with the AGO Study Group.  
7.3.6 Thromboembolism  
Arterial thromboembolism: If a patient experiences any grade of arterial thromboembolism 
during the treatment period bevacizumab should be discontinued permanently.  
Venous thromboembolism: Patients experiencing a grade 4 venous thromboembolism (in-
cluding pulmonary embolism) must be discontinued from the clinical trial.  
If a patient experiences a grade 3 venous thromboembolism bevacizumab must be withheld 
for 3 weeks. Bevacizumab may be resumed during the period of therapeutic-dose anticoagu-
lant therapy.  
Table 6: Bevacizumab treatment management for venous thromboembolism 
NCI CTCAE 
v4.03 
Thromboembolic Event Treatment Action 
Grade 1 Venous thrombosis 
(e.g. superficial thrombosis) 
No bevacizumab dose modifications. 
Grade 2 Venous thrombosis  
(e.g. uncomplicated deep vein 
thrombosis), medical intervention 
indicated 
No bevacizumab dose modifications. 
Grade 3 Thrombosis  
(e.g. uncomplicated pulmonary 
embolism), medical intervention 
indicated 
Hold bevacizumab treatment for 3 
weeks.  
If the planned duration of full-dose anti-
coagulation is < 2 weeks bevacizumab 
should be held until the full-dose antico-
agulation period is over. If the planned 
duration of full-dose anticoagulation is > 
2 weeks, bevacizumab may be resumed 
during the period of full-dose anticoagu-
lation if all of the following criteria are 
met: 
 The patient must have an in-range 
INR (usually between 2 and 3) if on 
warfarin; heparin, coumadin or other 
anticoagulant dosing must be stable 
prior to restarting bevacizumab. 
 The patient must not have had a 
grade 3 or 4 hemorrhagic event while 
on anticoagulation. 
Grade 4 Life-threatening  
(e.g. pulmonary embolism, cere-
brovascular event); hemodynam-
ic or neurologic instability; urgent 
intervention indicated 
Permanently discontinue bevacizumab. 
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7.3.7 Hemorrhage  
If grade 3 or 4 bleeding of any kind occurs during the study treatment period bevacizumab 
should be permanently discontinued.  
If hemorrhagic complications occur in patients on full dose anticoagulation therapy perma-
nently discontinue bevacizumab treatment and follow guidelines of the institution. Standard 
procedures such as antagonisation with protamine or vitamin K, infusion of vitamin K de-
pendent factors or insertion of a vena cava filter, should be considered dependent on the se-
verity of the bleeding event and the organ affected.  
Dose modifications for the selected chemotherapy should be made according to local prac-
tice guidelines.  
7.3.8 Posterior Reversible Encephalopathy Syndrome (PRES) 
There have been reports of patients treated with bevacizumab that develop signs and symp-
toms consistent with Posterior Reversible Encephalopathy Syndrome (PRES), an occasional 
neurological disorder which can present with the following signs and symptoms among oth-
ers and which can be permanent: seizures, headache, altered mental status, visual disturb-
ance or cortical blindness, with or without associated hypertension. A diagnosis of PRES re-
quires confirmation by brain imaging, preferably magnetic resonance imaging (MRI). In pa-
tients developing PRES, treatment of specific symptoms including control of hypertension is 
recommended along with discontinuation of bevacizumab. The safety of reinitiating bevaci-
zumab therapy in patients previously experiencing PRES is not known.  
7.3.9 Gastrointestinal Perforation  
Patients with bevacizumab treatment have an increased risk of gastrointestinal perforation. 
Any cases of gastrointestinal perforation and symptomatic fistulae should be managed ag-
gressively with the involvement of the appropriate surgical team in the usual manner. 
Bevacizumab must be ceased indefinitely. The surgical team must be informed that the pa-
tient has been receiving bevacizumab and that this may potentially compromise wound heal-
ing. 
Caution should be exercised when treating patients with intra-abdominal inflammatory pro-
cesses, any clinical suspicion of frank or impending bowel obstruction or a history of any gas-
trointestinal perforation. 
7.3.10 Fistula 
An increased risk exists for the emergence of fistula. These are most often gastrointestinal in 
origin but may originate from other sites including the genitourinary system and rarely the 
trachea and/or esophagus (this specifically has not occurred in any patients with ovarian 
cancer). 
Any patient who develops any of the following must cease bevacizumab permanently: 
- a grade 4 fistula of any origin, irrespective of causality to bevacizumab 
- any grade of fistula possibly, probably or definitely related to bevacizumab 
- any grade of tracheosophageal fistula. 
Any patient who develops any other fistula deemed by the treating physician to be unrelated 
to bevacizumab and to be related to surgery must have bevacizumab ceased at least until 
the fistula resolves completely (by either conservative management or surgery). At this point, 
if it is thought to be in the patient’s best interest to continue with bevacizumab then this must 
be discussed with the AGO Study Group. Bevacizumab can not be restarted without formal 
approval. 
Any patient who develops any other fistula deemed by the treating physician to be unrelated 
to bevacizumab and to be related to the disease process itself, including for example rapid 
disease regression, must also have bevacizumab ceased at least until the fistula resolves 
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completely. At this point, if it is thought to be in the patient’s best interest to continue with 
bevacizumab, then this must be discussed on a case by case basis with the AGO Study 
Group. Bevacizumab cannot be restarted without formal approval. It is recognized that cau-
sality in these cases may be more difficult to assign with certainty, and in these cases 
bevacizumab will be ceased permanently. 
7.3.4 Congestive Heart Failure (CHF) 
No increased incidence of CHF has been seen in patients treated with bevacizumab in other 
clinical trials apart from metastatic breast cancer. 
For patients with clinically important cardiovascular disease or preceding congestive heart 
failure caution is required. 
If grade 3 or 4 of left ventricular dysfunction (CHF) occurs during the treatment period 
bevacizumab should be permanently discontinued.  
7.4 Dose Modifications and Delays of Chemotherapy 
7.4.1 Carboplatin and Gemcitabine 
7.4.1.1 Hematologic toxicity  
Treatment should be delayed if either of the following occurs within 24 hours prior to the ad-
ministration of therapy:  
 Absolute neutrophile count < 1.5 x 109/L (or < 1.0 x 109/L if the patient is planned to 
receive G-CSF)  
 Platelet count < 100 x 109/L  
Full blood count (FBC) should be repeated, at least weekly, until hematologic recovery has 
occurred (ANC ≥ 1.5 x 109/L or > 1.0 x 109/L if the patient is planned to receive G-CSF and 
PLT ≥ 100 x 109/L). If hematologic recovery occurs within 7 days, no dose modification is 
mandated and any dose modification is left to the discretion of the individual investigator. If 
hematologic recovery occurs beyond 7 days doses of gemcitabine/carboplatin should be 
modified according to the blood count. G-CSF may be used as stipulated by the ASCO 
guidelines
 
or according to local practice guidelines.  
Patients who fail to recover adequate counts after a delay of 2 weeks or more, or who have 
consecutive dose-limiting toxicities, are not likely to be able to tolerate standard chemothera-
py treatment. If it is considered in the patient’s best interest to remain within the clinical trial 
and to continue to receive treatment according to the protocol, then significant modifications 
to the chemotherapy dose may be required. Such extreme modifications are likely to be rare 
and should therefore be discussed on a case by case basis with the AGO Study Group. In 
this situation patients may continue to receive bevacizumab. 
Dose modifications for gemcitabine on day 8 will be performed according to the guidelines in 
table 7.  
Table 7: Guidelines for gemcitabine dose adjustments on day 8 for hematologic toxici-
ties 
ANC (x 109/L)  Platelets (x 109/L) Dose Level 
≥ 1.5 and ≥ 100 100 % 
≥ 1.0 to 1.4 and/or 75 – 99 50 % 
< 1.0 and/or < 75 omit dose 
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Patients may receive erythropoietin (EPO), iron supplements and/or blood transfusions as 
clinically indicated for the management of their anemia. 
Dose adjustment for gemcitabine in combination with carboplatin for subsequent cycles is 
based on toxicity observed during the preceding cycle. The dose of gemcitabine should be 
permanently reduced on day 1 and day 8 in case of any of the following hematological toxici-
ties: 
 Absolute Neutrophil Count < 500 x 106/L for more than 5 days 
 Absolute Neutrophile Count < 300 x 106/L for more than 3 days 
 Febrile Neutropenia 
 Platelets < 25 x 109/L 
 cycle delay of more than one week due to toxicity 
If any of the above toxicities recur after the initial dose reduction for the subsequent cycles, 
gemcitabine and carboplatin should be reduced according to table 8. Gemcitabine should be 
given only on day 1 (omit gemcitabine on day 8). 










1000 mg/m2  800 mg/m² - 
Carboplatin
 
AUC4 AUC3 - 
 
7.4.1.2 Non-hematologic toxicity  
Renal toxicity  
The combination of gemcitabine and carboplatin with bevacizumab is not directly ex-
pected to cause renal toxicity. Therefore, no specific dose modifications are recommend-
ed for renal toxicity. Any concerns should be discussed with the AGO Study Group.  
However, the administered dose of carboplatin must be recalculated, based on a recalcu-
lated or remeasured GFR, for  
 renal toxicity (CTC Grade 2, serum creatinine > 1.5 x ULN)  
 changes in serum creatinine of ≥ 10%  
 each dose modification of carboplatin  
 cycle 2 if there has been significant doubt about the true GFR at cycle 1 (e.g. 
due to significant ascites).  
Hepatic toxicity  
If gemcitabine will be administered to patients with liver metastases or hepatitis in their histo-
ry a deterioration of the existing liver insuffiency is possible. Transaminases should be 
checked on a regular basis. 
Hypersensitivity to carboplatin  
If there is a hypersensitivity reaction to carboplatin this should be managed as per local insti-
tutional protocols. Cisplatin can be substituted for carboplatin at the discretion of the treating 
physician. Cisplatin (75 mg/m2) would be administered i.v. over 30 minutes every 3 weeks. 
For patients who experience dose-limiting toxicity with cisplatin, the dose can be reduced to 
60 mg/m2
 
and subsequently to 50 mg/m2
 
if further dose-limiting toxicity occurs.  
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Other  
There are no dose modifications planned for alopecia, nausea, diarrhea or constipation. 
These side effects should be treated with supportive medical measures. Non-steroidal anti-
inflammatory agents can be used prophylactically or symptomatically, as per local practice.  
Any CTC grade 4 non-hematologic AE (except nausea or vomiting) will require the patient to 
be taken off treatment. For any grade 3 non-hematologic toxicity (except nausea or vomiting) 
the drugs should be withheld until symptoms resolve to ≤ grade 1. If the grade 3 event per-
sists for ≥ 3 weeks, or recurs, then discussion with the AGO Study Group is recommended.  
7.4.2 Carboplatin and Pegylated Liposomal Doxorubicin 
7.4.2.1 Hematologic toxicity  
Treatment should be delayed if either of the following occurs within 24 hours prior to the ad-
ministration of therapy:  
 Absolute Neutrophil Count < 1.5 x 109/L (or < 1.0 x 109/L if the patient is planned to 
receive G-CSF)  
 Platelet count < 100 x 109/L  
FBC should be repeated, at least weekly, until hematologic recovery has occurred (ANC ≥ 
1.5 x 109/L or > 1.0 x 109/L if the patient is planned to receive G-CSF and PLT ≥ 100 x 109/L). 
If hematologic recovery occurs within 7 days no dose modification is mandated and any dose 
modification is left to the discretion of the individual investigator. If hematologic recovery oc-
curs beyond 7 days, doses of PLD/carboplatin should be modified according to the blood 
count (or subsequent FBC if lower; according to the criteria described in table 11). G-CSF 
may be used as stipulated by the ASCO guidelines
 
or according to local practice guidelines.  
Patients who fail to recover adequate counts after a delay of 2 weeks or more, or who have 
consecutive dose-limiting toxicities, are not likely to be able to tolerate standard chemothera-
py treatment. If it is considered in the patient’s best interest to remain within the clinical trial 
and to continue to receive treatment according to the protocol, then significant modifications 
to the chemotherapy dose may be required. Such extreme modifications are likely to be rare 
and should therefore be discussed on a case by case basis with the AGO Study Group. In 
this situation patients may continue to receive bevacizumab. 
Hematologic dose-limiting toxicities and permitted dose modifications are defined in table 9 
and table 10. Patients developing any other dose-limiting toxicity require dose modification 
independently of the ANC and platelets.  
Patients may receive erythropoietin (EPO), iron supplements and/or blood transfusions as 
clinically indicated for the management of their anemia. 
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Table 9: Guidelines for PLD and carboplatin dose modification for delayed hematolog-
ical recovery 
 Delayed ANC recovery (> 7 days) 
Delayed PLT Recovery 
(> 7 days) 
ANC ≥ 1.5 x 109/l
 
ANC < 1.5 x 109/l
 






















Reduce by 1 AUC unit 
PLD: 
Either: 
Use G-CSF and continue cur-
rent dose 
OR: 
Reduce by 1 dose level 
Carboplatin: 
Reduce by 1 AUC unit 
 
Table 10: Guidelines for PLD and carboplatin dose modification for dose limiting tox-
icity  





























Reduce by 1 AUC unit 
PLD: 
Either: 
Use G-CSF  and continue 
current dose 
Or: 
Reduce by 1 dose level 
Carboplatin: 
Reduce by 1 AUC unit 
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30 mg/m2 25 mg/m² - 
Carboplatin
 
AUC5 AUC4 - 
 
7.4.2.2 Non-hematologic toxicity  
Renal toxicity  
The combination of PLD and carboplatin with bevacizumab is not directly expected to cause 
renal toxicity. Therefore, no specific dose modifications are recommended for renal toxicity. 
Any concerns should be discussed with the AGO Study Group.  
However, the administered dose of carboplatin must be recalculated, based on a recalculat-
ed or remeasured GFR, for  
 renal toxicity (CTC Grade 2, serum creatinine > 1.5 x ULN)  
 changes in serum creatinine of ≥ 10%  
 each dose modification of carboplatin  
 cycle 2 if there has been significant doubt about the true GFR at Cycle 1 (e.g. due to 
significant ascites).  
Cutaneous toxicity 
The following table (table 12) shows the dose modification for PLD and the delays recom-
mended as a function of the occurrence and severity of cutaneous toxicity (PPE). 
 







Situation at day 
28 
Situation at day 
35 
Situation at day 
42 
Grade 1 Minimal skin changes or 
dermatitis  




tional week and 
redose at full 
dose unless pa-
tient had expe-
rienced a grade 
≥ 2 toxicity in 
which case re-
duce dose by 
one level. 
Wait an addi-
tional week and 
redose at full 
dose unless pa-
tient had expe-
rienced a grade 
≥ 2 toxicity in 
which case re-




by one dose 
level; back to 4-
weekly interval. 
Grade 2 Skin changes  
(e.g. peeling, blisters, 
bleeding, edema or hy-
perkeratosis) with pain; 






by one dose 
level; back to 4-
weekly interval. 
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Situation at day 
28 
Situation at day 
35 
Situation at day 
42 
Grade 3 Severe skin changes 
(e.g. peeling, blisters, 
bleeding, edema or hy-
perkeratosis) with pain; 








Grade 4 n/a n/a n/a n/a 
 
Gastrointestinal toxicity 
Table 13 shows the dose modifications and delays for occurrence of mucositis during treat-
ment with PLD. 




Mucositis Situation at day 
28 
Situation at day 
35 
Situation at day 
42 
Grade 1 Asymptomatic 
clinical or diagnostic ob-
servations only; interven-
tion not indicated 
Wait an addi-
tional week and 
redose at full 
dose unless pa-
tient had expe-
rienced a grade 
≥ 2 toxicity in 
which case re-
duce dose by 
one level. 
Wait an addi-
tional week and 
redose at full 
dose unless pa-
tient had expe-
rienced a grade 
≥ 2 toxicity in 
which case re-
duce dose by 
one level. 
Dose reduction 
by one dose 




of PLD in inves-
tigator’s discre-
tion. 
Grade 2 Moderate pain  
not interfering with oral 







by one dose 




of PLD in inves-
tigator’s discre-
tion. 
Grade 3 Severe pain  
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Cardiac toxicity 
Prior treatment with PLD an ECG assessment should be done routinely. More specific than 
an ECG assessment for evaluation and observation of the heart function will be the meas-
urement of left ventricular ejection fraction (LVEF) by ECHO/MUGA. LVEF measurement has 
to be done for any patient treated with PLD during treatment period. 
Hypersensitivity to carboplatin  
If there is a hypersensitivity reaction to carboplatin this should be managed as per local insti-
tutional protocols. Cisplatin can be substituted for carboplatin at the discretion of the treating 
physician. Cisplatin (75 mg/m2) would be administered i.v. over 30 minutes every 3 weeks. 
For patients who experience dose-limiting toxicity with cisplatin, the dose can be reduced to 
60 mg/m2
 
and subsequently to 50 mg/m2
 
if further dose-limiting toxicity occurs.  
Other  
There are no dose modifications planned for alopecia, nausea, diarrhea or constipation. 
These side effects should be treated with supportive medical measures. Non-steroidal anti-
inflammatory agents can be used prophylactically or symptomatically, as per local practice.  
Any CTC grade 4 non-hematologic AE (except nausea or vomiting) will require the patient to 
be taken off treatment. For any grade 3 non-hematologic toxicity (except nausea or vomiting) 
the drugs should be withheld until symptoms resolve to ≤ grade 1. If the grade 3 event per-
sists for ≥ 3 weeks, or recurs, then discussion with the AGO Study Group is recommended.  
7.5 Criteria for Discontinuation or Termination of the Trial 
7.5.1 Omission during maintenance treatment  
It is permitted to omit a cycle (i.e. because of vacation) during maintenance treatment in case 
of patients wish. The omitted dose of bevacizumab will not be replaced at a later time point. 
An interruption of two consecutive cycles or more must be discussed with the AGO Study 
Group. 
7.5.1.1 Criteria for Discontinuation of the Treatment or Premature Withdrawal 
of the Patient 
In addition to the common criteria described in section 13, the criteria described in section 
7.3 concerning discontinuation of study treatment for toxicity lead to a discontinuation of the 
treatment or premature withdrawal of the patient. 
In case of a premature withdrawal the patient must return for a safety follow-up assessment. 
7.5.2 Criteria for Discontinuation or Termination of the Trial  
Criteria which could lead to discontinuation or termination of the clinical trial are described in 
section 13.  
7.6 Warnings and Precautions  
No evidence available at the time of the approval of this protocol indicated that special warn-
ings or precautions were appropriate, other than those noted in the Investigators’ Brochure 
for bevacizumab. 
8 STATISTICAL CONSIDERATIONS AND ANALYTICAL PLAN 
8.1 Sample Size calculation 
The primary outcome measure is progression-free survival (PFS). The OCEANS trial report-
ed a median PFS for the experimental arm with carboplatin/gemcitabine plus bevacizumab of 
12.4 months with a 95% CI of 11.4 to 12.7 (HR=0.484; 95% CI: 0.388; 0.605) based on the 
investigator assessments (fig. 2, p. 2042), and a median PFS of 12.3 with a 95% CI of 10.7 
to 14.6 (HR=0.451; 95% CI: 0.351; 0.580) based on the assessments of the independent re-
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view committee (fig. 4, p. 2043).23 A recently small “proof of concept” phase II trial reported 
as secondary outcome a median PFS of 13.9 months with a 95% CI of 11.2 to 16.0 for the 
combination therapy of carboplatin, PLD and bevacizumab indicating potentially effects of the 
combination therapy on PFS47 which may point to the expectation of the benefit for the exper-
imental therapy.57 
Based on the in section 1.2 detail outlined rationale for the expected clinical effect sizes with 
bevacizumab, a minimal relevant clinical difference for PFS of Hazard Ratio (HR) 0.79 
should be detectable with 80% power in favor of the experimental arm in this trial. 
With N = 654 patients randomised at a steady rate over a period of 30 months with an addi-
tional 30 months follow-up after the last patient randomised, the trial will have 80% power 
(two-sided log-rank test, significance level of 5%) to show a 26.6% change in PFS from a 
median value of 12.4 months in the control arm to 15.7 months in the experimental arm, i. e. 
a Hazard Ratio (HR) of 0.79. It is expected that 564 PFS events will have occurred at the 
time point of primary analysis in the ITT population. With respect of a patient drop-out rate of 
15% under the assumption of exponentially distributed drop-out times a total of N=654 pa-
tients has to be enrolled into the trial, 327 patients each arm. 
The number of events can be recalculated during the trial to achieve a (conditional) power of 
80% and to guarantee the experiment wise alpha error probability by means of the principle 
of Schäfer and Müller.59 This method, based on the calculation of conditional error rejection 
probability, allows by inspection the adaption of the design (i.e., sample size adjustment, du-
ration of the follow-up) on the basis of the data collected at that timepoint of inspection. A re-
jection of the nullhypothesis at timepoint of inspection is not possible for the trial. As the algo-
rithmical definition for the conditional error rejection probability functions of ε+ (τ; κ) and ε- (τ; 
κ) (τ: value obtained by the logrank statistic; κ: total number of observed events up to the 
timepoint of inspection) the p-values defined version (p=1-Φ (τ/√ κ0) will be used according 
to Schäfer and Müller. The procedure will be described in more detail in the statistical analy-
sis plan (SAP). 
The formula of Schoenfeld (Biometrika, 1981, 316-19) was used for the calculation of the 
number of events to perform the sample size estimation with the software package 
ADDPLAN. 
8.2 Definition of Population for Analysis 
8.2.1 Intent-to-Treat Population 
The Intent-to-treat (ITT) population is defined as all patients randomized in the trial, regard-
less of whether they actually received treatment. The treatment groups will be analyzed as 
randomized.. 
8.2.2 Per Protocol Population 
The Per Protocol (PP) population is a subgroup of the ITT population containing all patients 
who do not have any major protocol violation and received both study treatments (chemo-
therapy and Bevacizumab) at least once. Major protocol violations will be defined in the Sta-
tistical Analysis Plan (SAP). 
8.2.3 Safety Population 
The safety population is defined to include all patients who received at least one dose of the 
study drug and a safety follow-up, whether withdrawn prematurely or not, will be included in 
the safety analysis. 
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8.3 Outcome measures 
8.3.1 Primary outcome measure 
 Progression-free survival (PFS) 
8.3.2 Secondary outcome measure 
 Overall Survival (OS) 
 Biological progression-free survival (PFSBIO) 
 Quality of Life (QoL)  
o QoL will be assessed using EORTC QLQ-C30 and QLQ-OV28 questionnaires 
 Safety and Tolerability 
8.4 Statistical Analysis 
8.4.1 Primary Efficacy Analysis 
The primary endpoint is progression-free survival defined as the time from the date of ran-
domization to the first documented disease progression (according to RECIST v1.1/GCIG) or 
death, whichever occurs first.  
The primary hypotheses are: H0: H0: HR=1 versus H1: HR≤0.79.  
The primary analysis will be done by a stratified log-rank test (stratifying for the factors used 
for randomization) for the difference in the distribution of progression-free survival (PFS) be-
tween the groups (two-sided at an alpha-level of 5%) when 564 events have occurred. 
Kaplan-Meier estimates for median PFS with the corresponding 95% confidence intervals will 
be presented. To assess the hazard ratio a stratified cox regression analysis will be per-
formed, the point estimate for the hazard ratio and corresponding 95%CI will be presented. If 
necessary, design adaptations (i. e, recalculation of number of events) can be made accord-
ing to Schäfer and Müller59,60 (see section 8.1)  
8.4.2 Secondary Analyses 
Overall survival (OS) is defined as time from randomization to death from any cause. For OS 
the same analyses as for PFS will be performed. 
To assess the secondary outcome biological progression-free survival PFSbio according to 
GCIC criteria (see appendix 10) stratified log-rank test and cox regression analyses will be 
performed, the point estimate for the hazard ratio and corresponding 95% CI will be present-
ed. Kaplan-Meier estimates for median PFSbio with the corresponding 95% CI will also be 
presented. 
Further cox regression models will be performed to analyze the impact of significant baseline 
covariates regarding PFS and OS; different subgroups (such as status of prior anti-
angiogenetic treatment) will also be explored descriptively. 
Quality of Life (QoL) with the scores EORTC QLQ-C30 and QLQ-OV28 will analysed de-
scriptively. 
8.4.3 Safety Data Analysis 
The safety analyses will be based on the safety population. All safety parameters will be 
summarized and also listed by patient. Summary tables will be presented for incidence rates 
(number of patients with at least one incidence) of AEs, SAEs, AEs that led to premature 
withdrawal of trial treatment and interruptions/dose modifications, as well as summaries of 
severity (CTCAE v4.03 grades) and causal relationship. Tables of change from baseline will 
be presented for clinical laboratory assessments, vital signs, LVEF and ECOG performance 
status. Laboratory abnormalities will also be summarized in tables or figures showing shifts in 
grade. 
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8.4.4 Further methodological and statistical issues 
8.4.4.1 Interim Analysis 
No interim efficacy analysis and/or stopping rules are planned. The method of Schäfer and 
Müller allows by inspection necessary changes of the design (i.e., sample size adjustment, 
duration of the follow-up) on the basis of the data collected at that timepoint of inspection. A 
rejection of the the null hypothesis at the timepoint of inspection is not possible for the trial. 
There will be regular safety review of data by IDMC (Section 10). 
8.4.4.2 Multiplicity 
All significance tests not included in the primary efficacy analysis for PFS are to be consid-
ered descriptive in nature since they are secondary or exploratory analyses and therefore will 
not be adjusted for multiplicity regards. 
8.4.4.3 Statistical analysis plan 
A statistical analysis plan (SAP) for the trial to include detailed information on the analysis of 
primary and secondary outcome measures and the definitions of major protocol deviations 
will be provided by the KKS, Philipps-University of Marburg, and the AGO Study Group. 
9 DATA QUALITY ASSURANCE 
Data for this trial will be recorded via an Electronic Data Capture (EDC) system MACRO us-
ing eCRF. It will be transcribed by the site from the paper source documents onto the eCRF.  
Accurate and reliable data collection will be assured by verification and cross-checking of the 
eCRFs against the investigator’s records by the monitoring (source document verification), 
and the maintenance of a drug-dispensing log. 
Every investigator, study nurse, monitor or other person involved in the trial receives his or 
her personal login data (username and password). Access rights to the database will depend 
on the group affiliation. Users of the EDC-System MACRO will receive the training materials 
(EDC manual) by the data management of KKS, Philipps-University of Marburg. Every per-
son who gets access to the system has to fill in a registration form (User-ID request) and has 
to confirm that they have been adequately trained. 
Thus it is guaranteed that only authorised persons have access to the system to document 
patients in the trial. The data are transferred via high encryption (128-bit, SSL) across the in-
ternet 
A comprehensive validation check program utilising front-end checks in the eCRF and back-
end checks in the database will verify the data and discrepancies (queries) will be generated 
accordingly. These are transferred electronically to the eCRFs at the site for resolution by the 
investigator. 
10 CLINICAL TRIAL COMMITTEES 
An Independent Data Monitoring Committee (IDMC) will be established for the AGO-OVAR 
2.21 trial. The IDMC will meet on a regular basis and will be responsible for independently 
evaluation of the safety for the patients participating in the clinical trial. The IDMC will also 
check the integrity and the validity of the data and the conduct of the clinical trial. 
The IDMC will make recommendations concerning the conduct of the trial to the AGO Study 
Group. 
The responsibilities of the IDMC will be documented in a separate Charter. 
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11 ETHICAL ASPECTS 
Declaration of Helsinki / Good Clinical Practice 
The Declaration of Helsinki in the present version is the accepted basis for clinical trial ethics 
and must be fully followed and respected by all engaged in research on human beings. Any 
exceptions must be justified and stated in the protocol.  
Additionally, it is the responsibility of all engaged in research on human beings to ensure that 
the clinical trial is performed in accordance with the international Good Clinical Practice 
standards and according to all local laws and regulations concerning clinical trials. 
12 CONDITIONS FOR MODIFYING THE PROTOCOL 
All protocol modifications must be submitted to the appropriate Independent Ethics Commit-
tee for information and approval in accordance with local requirements, and to Regulatory 
Authorities if required. Approval must be awaited before any changes can be implemented, 
except for changes necessary to eliminate an immediate hazard to trial patients, or when the 
change(s) involves only logistical or administrative aspects of the trial (i.e. change of tele-
phone number(s)). 
13 DISCONTINUATION OR EARLY TERMINATION OF THE TRIAL 
13.1 Withdrawal from trial treatment 
A patient may withdraw, or be withdrawn, from trial treatment for the following reasons: 
- disease progression whilst on therapy 
- unacceptable toxicity 
- intercurrent illness which prevents further treatment 
- withdrawal of consent for treatment by patient 
- any alterations in the patient’s condition which justifies the discontinuation of treatment in 
the investigator’s opinion 
Patients have the right to withdraw from the trial at any time for any reasons. 
In case the patient decides to prematurely discontinue trial treatment (“refuses treatment”), 
she should be asked if she can still be contacted for further information. The outcome of that 
discussion should be documented in both, the patient clinical source documents and in the 
eCRF. 
13.2 Termination of the trial 
Both the AGO Study Group and the chief investigator, reserve the right to discontinue the tri-
al at any time for the following reasons after consultating the IDMC: 
- an accumulation of adverse events arises 
- within the study period the planned number of patients cannot be achieved 
- decision for termination by the competent authority 
- the premature termination is decided by the principal investigators. 
Should this be necessary both parties will arrange the procedures on an individual trial basis 
after review and consultation. In discontinuation of the clinical trial AGO Study Group and the 
investigator will ensure that adequate consideration is given to the protection of the patient’s 
interests. 
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14 TRIAL DOCUMENTATION, ECRFS AND RECORD KEEPING 
14.1 Trial Documentation 
The investigator must maintain adequate and accurate records to enable the conduct of the 
clinical trial to be fully documented and the trial data to be subsequently verified. These doc-
uments should be classified into two different categories (A) Investigator’s Site File and (B) 
patient clinical source documents. 
The Investigator’s Site File and patient clinical source documents (including CT/MRI scans) 
must be kept for at least 10 years or according to local laws after completion of discontinua-
tion of the clinical trial. 
14.2 Electronic Case Report Form(s) 
For each patient enrolled, an eCRF must be completed and electronically signed (authoriza-
tion of completed visits) by the principal investigator or authorized delegate from the staff. If a 
patients withdrawn from trial the reason must be noted on the eCRF. If a patient is withdrawn 
from the trial because of a treatment-limiting AE thorough efforts should be made to clearly 
document the outcome. 
15 MONITORING THE CLINICAL TRIAL 
A monitor dedicated to the study group (depending on country) will contact and visit all sites 
regularly. The monitor will verify the adherence to the protocol and the completeness, con-
sistence and accuracy of the data being entered on eCRF. 
The monitor will require access to all patient medical records including laboratory test results 
and surgery, pathology and radiology reports and supporting documents to verify the entries 
on the eCRF. The monitor should also have access to pharmacy records relating to trial 
medication (including receipt, dispensing and inventory documentation). The investigator (or 
his/her designee) should work with the monitor to ensure that any problems detected during 
these visits are resolved. 
16 AUDITS AND INSPECTIONS 
The investigator should understand that source documents for this trial should be made 
available to authorized representatives of the sponsor and the regulatory agency(ies) after 
appropriate notification. The verification of the eCRF data must be done by direct inspection 
of source documents. This includes examining, analyzing, verifying, and reproducing any 
records and reports that are important to the evaluation of the clinical trial. The investigator is 
responsible for giving any requested support for any inspection or audit visit and has to be 
available during these visits.  
In case of audits or inspections a direct access to the eCRF will be provided. 
17 CONFIDENTIALITY OF TRIAL DOCUMENTS AND SUBJECT RECORDS 
The investigator must ensure that patient’s anonymity will be maintained and that their identi-
ties are protected form unauthorized parties. On eCRFs or other documents patients should 
not be identified by their names but by an identification code. The investigator should keep a 
Patient Enrolment Log showing codes, names and addresses. The investigator should main-
tain documents not for submission to the sponsor (i.e. patients written consent form in strict 
confidence at the site). 
18 PUBLICATION OF DATA  
The data from the whole trial will be analyzed and reported together. Positive and inconclu-
sive as well as negative results will be published or otherwise made publicly available. 
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The results of this trial may be published or presented at scientific meetings. If this is fore-
seen, the investigator agrees to submit all manuscripts or abstracts to AGO Study Group pri-
or submission. 
The rights of the investigator and of the AGO Study Group with regard to publication of the 
results of this trial are described in the investigator contract. As general rule, no trial results 
should be published prior to finalization of the primary publication. 
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20.1 Appendix 1 - Adverse Events Categories for Determining Rela-
tionship to Study Drug 
(a) Probable (must have first three) 
This category applies to those adverse events which are considered, with a high degree of cer-
tainty, to be related to the study drug. An adverse event may be considered probable, if: 
1. It follows a reasonable temporal sequence from administration of the drug. 
2. It cannot be reasonably explained by the known characteristics of the subject’s clinical 
state, environmental or toxic factors or other modes of therapy administered to the sub-
ject. 
3. It disappears or decreases on cessation or reduction in dose. (There are important ex-
ceptions when an adverse event does not disappear upon discontinuation of the drug, yet 
drug-relatedness clearly exists: i.e. (1) bone marrow depression, (2) tardive dyskinesias.) 
4. It follows a known pattern of response to the suspected drug. 
5. It reappears upon rechallenge. 
(b) Possible (must have first two) 
This category applies to those adverse events in which the connection with the study drug 
administration appears unlikely but cannot be ruled out with certainty. An adverse event may 
be considered possible if, or when: 
1. It follows a reasonable temporal sequence from administration of the drug. 
2. It may have been produced by the subject’s clinical state, environmental or toxic factors, 
or other modes of therapy administered to the subject. 
3. It follows a known pattern of response to the suspected drug. 
(c) Remote (must have first two) 
In general, this category is applicable to an adverse event which meets the following criteria: 
1. It does not follow a reasonable temporal sequence from administration of the drug. 
2. It may readily have been produced by the subject’s clinical state, environmental or toxic 
factors, or other modes of therapy administered to the subject. 
3. It does not follow a known pattern of response to the suspected drug. 
4. It does not reappear or worsen when the drug is readministered. 
(d) Unrelated 
This category is applicable to those adverse events which are judged to be clearly and incon-
trovertibly due only to extraneous causes (disease, environment, etc.) and do not meet the 
criteria for drug relationship listed under remote, possible, or probable. 
 Probable Possible Remote Unrelated 
Clearly due to extraneous causes – – – + 
Reasonable temporal association with drug 
administration 
+ + – – 
May be produced by subject clinical state, 
etc. 
– + + + 
Known response pattern to suspected drug + + – – 
Disappears or decreases on cessation or 
reduction in dose 
+ – – – 
Reappears on rechallenge + – – – 
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20.2 Appendix 2 - Definitions according to national laws and ICH 
Guidelines for Clinical Safety Data Management, Definitions and 
Standards for Expedited Reporting 
An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical investiga-
tion subject, administered a pharmaceutical product and which does not necessarily have to 
have a causal relationship with this treatment. 
An AE can therefore be any unfavorable and unintended sign (including an abnormal labora-
tory finding, for example), symptom, or disease temporally associated with the use of a me-
dicinal product, whether or not considered related to the medicinal product. 
Adverse Drug Reaction (ADR) is any noxious and unintended response to a medicinal prod-
uct related to any dose. This means that a causal relationship between a medicinal product 
and an AE is at least a reasonable possibility, (i.e. the relationship cannot be ruled out). 
A Serious Adverse Event (SAE) or Serious Adverse Drug Reaction is any untoward medical 
occurrence or effect that at any dose: 
 Results in death (NOTE: death is an outcome, not an event) 
 Is life-threatening (NOTE: the term "life-threatening" refers to an event in which the pa-
tient was at risk of death at the time of the event; it does not refer to an event that hypo-
thetically might have caused death if it were more severe.) 
 Requires in-patient hospitalization or prolongation of existing hospitalization 
 Results in persistent or significant disability/incapacity, or 
 Is a congenital anomaly/birth defect 
 Is an important medical event (an event that jeopardizes the patient or may require inter-
vention to prevent one of the other outcomes listed above 
Examples of such events are intensive treatment in an emergency room or at home for  aller-
gic bronchospasm; blood dyscrasias or convulsions that do not result in hospitalization; or de-
velopment of drug dependency or drug abuse. 
An unexpected Adverse Drug Reaction is one, the nature or severity of which is not consistent 
with the applicable product information. 
Causality is initially assessed by the investigator. With respect to report and documentation ob-
ligation (regulatory authorities, ethics committees and other investigators) for Serious Adverse 
Events, causality can be one of 2 possibilities: 
 No (unrelated; equals not drug related).  
 Yes (remotely, possibly, probably or definitely drug related). 
All adverse events not assessed as definitive "not drug related" by either the investigator or 
the sponsor will be considered as adverse drug reaction. 
A Suspected Unexpected Serious Adverse Reaction (SUSAR) is a serious adverse reaction, 
the nature, or severity of which is not consistent with the applicable product information. 
According to ICH Topic E2A Step 5 Clinical Safety DM, Definitions and Standards for Expe-
dited Reporting the sponsor ensures that all relevant information about suspected unex-
pected serious adverse reactions, which are fatal of life threatening, is recorded and reported 
to the competent authority as soon as possible and no later than 7 days after the sponsor is 
informed of such a suspected adverse reaction. No later than 8 days after the reporting, the 
sponsor must inform the competent authority of relevant follow-up information on the spon-
sor’s and the investigator’s follow-up action to the reporting.  
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Any other suspected unexpected serious adverse reactions must be reported to the compe-
tent authority no later than 15 days from the time when the sponsor is informed about them. 
It is important that the severity of an adverse event is not confounded with the seriousness of 
the event. For example, vomiting which persists for many hours may be severe, but is not 
necessarily a serious adverse event. On the other hand, stroke which results in only a limited 
degree of disability may be considered a mild stroke, but would be a serious adverse event. 
All serious adverse events occurring during the clinical trial or within 30 days after treatment 
discontinuation whether considered treatment-related or not, must be reported. In addition, a 
serious adverse event occurring after this time should also be reported, if it is be considered 
related to study drug.  
Such preliminary reports will be followed by detailed descriptions later which will include cop-
ies of hospital case reports, autopsy reports and other documents. 
For serious adverse events, the following must be assessed and recorded on the adverse 
events page of the eCRF: intensity, relationship to study drug, action taken, and outcome to 
date. 
Document and report obligations have to be adhered according to the national and interna-
tional laws and regulations.  
Contact details and Fax No. for SAE and pregnancy reporting are: 
For sites assigned to AGO Study Group: 
 





Fax No.: +49 (0) 201 959812 21 
 
For sites assigned to other participating Study Groups should report to their local 
Study Group (Fax No. is provided on the SAE form). 
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20.3 Appendix 3 - FIGO Staging 
Appendix 3.1: Ovarian Cancer Stages 
Stage I Growth limited to the ovaries 
Stage IA Growth limited to one ovary; no ascites, no tumor on the external surface of the 
ovary, capsule intact 
Stage IB Growth limited to both ovaries: no ascites, no tumor on the external surface of the 
ovaries, capsule intact 
Stage IC* Tumor either stage IA or IB, but with tumor on surface or one or both ovaries; or 
with capsule(s) ruptured; or with ascites present containing malignant cells or with 
positive peritoneal washings 
Stage II Growth involving one or both ovaries with pelvic extension 
Stage IIA Extension and/or metastases to the uterus and/or tubes 
Stage IIB Extensor to other pelvic tissues 
Stage IIC Tumor either Stage IIA or IIB, but with tumor on surface of one or both ovaries; or 
with capsule(s) ruptured; or with ascites present containing malignant cells or with 
positive peritoneal washings 
Stage III Tumor involving one or both ovaries with histological confirmed peritoneal implants 
outside the pelvis and/or positive retroperitoneal or inguinal nodes. Superficial liver 
metastasis equals stage III. Tumor limited to the true pelvis, but with histological 
proven malignant extension to small bowel or omentum 
Stage IIIA Tumor grossly limited to the true pelvis, with negative nodes, but with histological 
conformed microscopic seeding of abdominal peritoneal surface, or histological 
proven extension to small bowel or mesentery 
Stage IIIB Tumor of one or both ovaries with histological confirmed implants, peritoneal me-
tastasis of abdominal peritoneal surfaces, none exceeding 2 cm in diameter, 
nodes are negative 
Stage IIIC Peritoneal metastasis beyond the pelvis greater than 2 cm in diameter and/or posi-
tive retroperitoneal or inguinal nodes 
Stage IV Growth involving one or both ovaries with distant metastases. If pleural effusion is 
present, there must be positive cytology to allot a case to stage IV. Parenchymal 
liver metastases equals stage IV 
 
*: in order to evaluate the impact on prognosis of the different criteria for allotting a case to Stage IC or IIC it 
would be of value to know if the source of malignant cells detected was 1) peritoneal washings or 2) ascites; if 









Petru E et al. Gynecologic Cancer Intergroup (GCIG) proposal for changes of the current FIGO stag-
ing system. EJOG 2009; 143:69-74. 
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Appendix 3.2: Fallopian Tube Cancer Stages 
Stage I Growth limited to the fallopian tubes  
Stage IA Growth is limited to one tube with extension into the submucosa and/or muscularis 
but not penetrating the serosal surface; no ascites 
Stage IB Growth is limited to both tubes with extension into the submucosa and/or muscu-
laris but not penetrating the serosal surface; no ascites.  
Stage IC* Tumor either Stage IA or IB but with tumor extension through or onto the tubal se-
rosa; or with ascites present containing malignant cells or with positive peritoneal 
washings.  
Stage II Growth involving one or both fallopian tubes with pelvic extension.  
Stage IIA Extension and/or metastasis to the uterus and/or ovaries.  
Stage IIB Extension to other pelvic tissues.  
Stage IIC Tumor either Stage IIA or IIB and with ascites present containing malignant cells or 
with positive peritoneal washings.  
Stage III Tumor involves one or both fallopian tubes with histological confirmed peritoneal 
implants outside of the pelvis and/or positive retroperitoneal or inguinal nodes. Su-
perficial liver metastasis equals Stage III. Tumor appears limited to the true pelvis 
but with histological proven malignant extension to the small bowel or omentum.  
Stage IIIA Tumor is grossly limited to the true pelvis, with negative nodes, but with histologi-
cal confirmed microscopic seeding of abdominal peritoneal surfaces, or histologi-
cal proven extension to small bowel or mesentery.  
Stage IIIB Tumor of one or both tubes with histological confirmed implants, peritoneal metas-
tasis of abdominal peritoneal surfaces, none exceeding 2 cm in diameter, nodes 
are negative.  
Stage IIIC Peritoneal metastasis beyond the pelvis greater than 2 cm in diameter and/or posi-
tive retroperitoneal or inguinal nodes.  
Stage IV Growth involving one or both fallopian tubes with distant metastases. If pleural ef-
fusion is present, there must be positive cytology to be stage IV. Parenchymal liver 
metastases equals stage IV.  
 
*: in order to evaluate the impact on prognosis of the different criteria for allotting a case to Stage IC or IIC it 
would be of value to know if the source of malignant cells detected was 1) peritoneal washings or 2) ascites; if 










Petru Eet al. Gynecologic Cancer Intergroup (GCIG) proposal for changes of the current FIGO staging 
system. EJOG 2009; 143:69-74  
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Appendix 3.3: Primary Peritoneal Cancer  
There is no recognised formal staging system for primary peritoneal carcinoma and the FIGO 
staging for epithelial ovarian carcinoma has been adopted. Surface involvement of the ova-
ries in the absence of more widespread peritoneal disease would be classified as FIGO 
stage IC. Patients with extension of disease beyond the ovaries would be classified as hav-
ing stage IIC disease if confined to the pelvis, and stage III or IV disease for disease beyond 
the pelvis (defined according to the FIGO ovarian system). 
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20.4 Appendix 4 - ECOG Performance Status 
 
Description Scale 
Fully active, able to carry on all pre-disease performance 
without restriction 
0 
Restricted in physically strenuous activity but ambulatory 
and able to carry out work of a light or sedentary nature, 
e.g., light house work, office work 
1 
Ambulatory and capable of all selfcare but unable to carry 
out any work activities. Up and about more than 50% of 
waking hours 
2 
Capable of only limited selfcare, confined to bed or chair 
more than 50% of waking hours 
3 
Completely disabled. Cannot carry on any selfcare. Totally 


























Oken MM et al. Toxicity And Response Criteria Of The Eastern Cooperative Oncology Group. Am J 
Clin Oncol 1982; 5):649-55. 
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20.5 Appendix 5 - Estimation and Measurement of Glomerular Filtra-
tion Rate and Recommendations for Calculation of Carboplatin 
Dose 
Estimation and Measurement of Glomerular Filtration Rate (GFR) 
 
For the purposes of this protocol, the GFR can be considered equivalent to the creat-
inine clearance (CrCl). The following methods are suggested; however it is advised 
that the centre calculates the GFR according to local guidelines:  
 
 Estimation of GFR using the Jelliffe formula 
  GFR =  0.9 x [98-{0.8(age-20)}] x [BSA/1.73] 
      SCr x 0.0113 
 
 Estimation of GFR using the Cockcroft-Gault formula 
   GFR = 1.05 x (140-age) x Wt 
                 SCr 
 
Where CrCl  = Creatinine Clearance (ml/min) 
  GFR  = Glomerular Filtration Rate (ml/min) 
  BSA  = DuBois Body Surface Area (m2) 
  SCr  = Serum Creatinine (μmol/l) 
  Wt  = Weight (kg) 
  Age  = Age in years (20 to 80) 
 
To convert serum creatinine in mg/dl to µmol/l use the following formula: 
    Cr (μmol/l)  =  Cr (mg/dl) x 88.4 
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20.6 Appendix 6 - NYHA Classification of Cardiac Disease 
 
Class I Patients with cardiac disease but without resulting limitation of physical 
activity. Ordinary physical activity does not cause undue fatigue, palpita-
tion, dyspnoea or angina pectoris. 
Class II Patients with cardiac disease resulting in slight limitations of physical ac-
tivity. They are comfortable at rest. Ordinary physical activity results in fa-
tigue, palpitation, dyspnoea or anginal pain. 
Class III Patients with cardiac disease resulting in marked limitations of physical 
activity. They are comfortable at rest. Less than ordinary physical activity 
causes fatigue, palpitation, dyspnea or anginal pain. 
Class IV Patients with cardiac disease resulting in inability to carry on any physical 
activity without discomfort. Symptoms of cardiac insufficiency or the angi-
na syndrome may be present even at rest. If any physical activity is un-






















Oxford Textbook of Internal Medicine: Vol 2; 1997 
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20.8 Appendix 8 - NCI Common Terminology Criteria for Adverse 
Events (v4.03) 
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20.9 Appendix 9 - Evaluation and Definitions of Response and Pro-
gression 
MEASURABLE DISEASE 
Patients will be classified as having measurable or non-measurable disease at screening.  
Method of assessment  
Patients will be assessed for disease response or progression throughout the clinical trial ac-
cording to RECIST v1.1 criteria. A mandatory tumor assessment via gynecological examina-
tion including ultrasound scanning and only if clinically indicated, CT scanning, or MRI in 
case of contrast allergy, will be performed every 12 weeks (± 7 days of the scheduled visit) 
until disease progression or up to 30 months, starting before day 1 of cycle 1 and during fol-
low-up every 6 months (± 2 weeks) until disease progression. Patient without any tumor re-
siduals do not need CT scan or MRI, only in case of suspicion of disease progression. 
Definition of measurable disease lesions 
Measurable disease is defined as accurately measured in at least one dimension (longest di-
ameter [LD] in the plane of measurement is to be recorded with a minimum size of: 
- 10 mm by CT scan (CT scan slice thickness no greater than 5 mm) 
- 10 mm caliper measurement by clinical exam (lesions which cannot be accurately meas-
ured with calipers should be recorded as non-measurable) 
- 20 mm by chest X-ray 
Malignant lymph nodes: To be considered pathologically enlarged and measurable, a lymph 
node must be  15 mm in short axis when assessed by CT scan (CT scan slice thickness 
recommended to be no greater than 5 mm). At screening and in follow-up, only the short axis 
will be measured and followed. See also notes below on ‘Screening documentation of target 
and non-target lesions’ for information on lymph node measurement. 
Definition of Non-measurable lesions  
These are all other lesions, including small lesions (longest diameter < 10 mm or pathological 
lymph nodes with 10 to <15 mm short axis), as well as truly non-measurable lesions. Le-
sions considered truly non-measurable include: leptomeningeal disease, ascites, pleural or 
pericardial effusion, inflammatory breast disease, lymphangitic involvement of skin or lung, 
abdominal masses/abdominal organomegaly identified by physical examination that is not 
measurable by reproducible imaging techniques. 
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Special considerations regarding lesion measurability 
Bone lesions, cystic lesions and lesions previously treated with local therapy require particu-
lar comment: 
Bone Lesions: 
 Bone scan, PET scan or plain films are not considered adequate imaging techniques 
to measure bone lesions. However, these techniques can be used to confirm the 
presence or disappearance of bone lesions. 
 Lytic bone lesions or mixed lytic-blastic lesions, with identifiable soft tissue compo-
nents, that can be evaluated by cross sectional imaging techniques such as CT or 
MRI can be considered as measurable lesions if the soft tissue component meets the 
definition of measurability described above. 
 Blastic bone lesions are non-measurable. 
Cystic Lesions: 
 Lesions that meet the criteria for radiographically defined simple cysts should not be 
considered as malignant lesions (neither measurable nor non-measurable) since they 
are, by definition, simple cysts. 
 ‘Cystic lesions’ thought to represent cystic metastases can be considered as measur-
able lesions, if they meet the definition of measurability described above. However, if 
non-cystic lesions are present in the same patient, these are preferred for selection 
as target lesions. 
Lesions with prior local treatment: 
 Tumor lesions situated in a previously irradiated area, or in an area subjected to other 
loco-regional therapy, are usually not considered measurable unless there has been 
demonstrated progression in the lesion. Trial protocols should detail the conditions 
under which such lesions would be considered measurable. 
Screening / Baseline documentation of “Target” and “Non-Target” lesions 
 All measurable lesions up to a maximum of five lesions total (and a maximum of two 
lesions per organ) representative of all involved organs should be identified as target 
lesions and will be recorded and measured at screening / baseline.  
 Target lesions should be selected on the basis of their size (lesions with the longest 
diameter), be representative of all involved organs, but in addition should be those 
that lend themselves to reproducible repeated measurements. It may be the case 
that, on occasion, the largest lesion does not lend itself to reproducible measurement 
in which circumstance the next largest lesion which can be measured reproducibly 
should be selected. 
Lymph nodes merit special mention since they are normal anatomical structures which may 
be visible by imaging even if not involved by tumor. Pathological nodes which are defined as 
measurable and may be identified as target lesions must meet the criterion of a short axis of 
15 mm by CT scan. Only the short axis of these nodes will contribute to the baseline sum. 
The short axis of the node is the diameter normally used by radiologists to judge if a node is 
involved by solid tumor. Nodal size is normally reported as two dimensions in the plane in 
which the image is obtained (for CT scan this is almost always the axial plane; for MRI the 
plane of acquisition may be axial, saggital or coronal). The smaller of these measures is the 
short axis. All other pathological nodes (those with short axis 10 mm but <15 mm) should be 
considered non-target lesions. Nodes that have a short axis <10 mm are considered non-
pathological and should not be recorded or followed. 
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All other lesions (or sites of disease) including pathological lymph nodes should be identified 
as non-target lesions and should also be recorded at baseline. Measurements are not re-
quired and these lesions should be followed as ‘present’, ‘absent’, or in rare cases ‘unequiv-
ocal progression’ (more details to follow). In addition, it is possible to record multiple non-
target lesions involving the same organ as a single item on the eCRF (e.g. ‘multiple enlarged 
pelvic lymph nodes’ or ‘multiple liver metastases’). 
 
DEFINITION OF RESPONSE 
Response Criteria based on RECIST v1.1 criteria 
  Evaluation of target lesions 
* Complete Response (CR): Disappearance of all target lesions. 
Any pathological lymph nodes (whether target or non-
target) must have reduction in short axis to < 10 mm. 
* Partial Response (PR): At least a 30% decrease in the sum of the diameters of 
target lesions, taking as reference the baseline sum di-
ameters 
* Progressive Disease (PD): At least a 20% increase in the sum of the diameters of 
target lesions, taking as reference the smallest sum on 
trial (this includes the baseline sum if that is the smallest 
on trial). 
In addition to the relative increase of 20%, the sum must 
also demonstrate an absolute increase of at least 5 mm. 
(Note: the appearance of one or more new lesions is also 
considered progression). 
* Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient 
increase to qualify for PD, taking as reference the small-
est sum diameter while on trial 
  Evaluation of non-target lesions 
* Complete Response (CR): Disappearance of all non-target lesions and normalisation 
of tumor marker level. All lymph nodes must be non-
pathological in size (< 10 mm short axis). 
* Non-CR/Non-PD  Persistence of one or more non-target lesion(s) and/or 
maintenance of tumor marker level above the normal lim-
its 
* Progressive Disease (PD): Unequivocal progression of existing non-target lesions. 
(Note: the appearance of one or more new lesions is also 
considered progression).  
 
Evaluation of best overall response 
The best overall response is the best response recorded from the start of the treatment until 
disease progression/recurrence (taking as reference for PD the smallest measurements rec-
orded since the treatment started). In general, the patient's best response assignment will 
depend on the achievement of both measurement and confirmation criteria 
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Patients with measurable disease at screening / baseline 
Target lesions Non-target lesions New lesions  Overall response 
CR CR No CR 
CR Non-CR/Non-PD No PR 
CR Not evaluated No PR 
PR Non-PD or not all evalu-
ated 
No PR 
SD Non-PD or not all evalu-
ated 
No SD 
Not all evaluated Non-PD No NE 
PD Any Yes or No PD 
Any PD Yes or No PD 
Any Any Yes PD 
CR = Complete Response, PR = Partial Response, SD = Stable Disease,  
PD = Progressive Disease, NE = inevaluable 
 
Patients with non-target disease only 
Non-target lesions New lesions  Overall response 
CR No CR 
Non-CR/Non-PD No Non-CR/Non-PD* 
Not all evaluated No NE 
Unequivocal PD Yes or No PD 
Any Yes PD 
CR = Complete Response, PD = Progressive Disease, NE = inevaluable 
* Non-CR/Non-PD is preferred over ‘stable disease’ for non-target disease since SD is in-
creasingly used as endpoint for assessment of efficacy in some trials so to assign this 
category when no lesions can be measured is not advised. 
 
Patients with a global deterioration of health status requiring discontinuation of treatment 
without objective evidence of disease progression at that time should be classified as having 
“symptomatic deterioration”. Every effort should be made to document the objective progres-
sion even after discontinuation of treatment.  
In some circumstances it may be difficult to distinguish residual disease from normal tissue. 
When the evaluation of complete response depends on this determination, it is recommend-
ed that the residual lesion be investigated (fine needle aspirate/biopsy) to confirm the com-
plete response status.  
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Confirmation 
The main goal of confirmation of objective response is to avoid overestimating the response 
rate observed. In cases where confirmation of response is not feasible, it should be made 
clear when reporting the outcome of such studies that the responses are not confirmed.  
Duration of Overall Response 
The duration of overall response is measured from the time measurement criteria are met for 
CR or PR (whichever status is recorded first) until the first date that recurrence or PD is ob-
jectively documented (taking as reference for PD the smallest measurements recorded on 
trial).  
Duration of Stable Disease 
SD is measured from the date of randomization until the criteria for disease progression are 
met, taking as reference the smallest sum on trial (if the baseline sum is the smallest, this is 
the reference for calculation of PD). 
DEFINITION OF PROGRESSION   
Determination of the time point of progression will be based first but not exclusively on imag-
ing assessment of tumor manifestations according to modified RECIST v1.1 criteria. Due to 
the intrapelvic location of the primary tumor and the frequent occurrence of diffuse peritoneal 
disease at recurrence, both CT and MRI may not always be reliable for documentation of 
progressive disease. Therefore, criteria other than imaging may be applicable to define pro-
gressive disease. 
For patients with measurable disease at randomization 
Progression is defined as ANY of the following: 
 At least a 20% increase in the sum of the diameters of target lesions, taking as reference 
the smallest sum on trial recorded since trial entry (this includes the baseline sum if that 
is the smallest on trail). In addition to the relative increase of 20%, the sum must also 
demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or 
more new lesions is also considered progression).  
 In the case where the ONLY target lesion is a solitary pelvic mass measured by physical 
exam which is not radiographically measurable, a 50% increase in the LD is required tak-
ing as reference the smallest LD recorded since trial entry 
 The appearance of one or more new lesions  
 Death due to disease without prior objective documentation of progression 
 Global deterioration in health status attributable to the disease requiring a change in 
therapy without objective evidence of progression  
 Unequivocal progression of existing non-target lesions, other than pleural effusions with-
out cytological proof of neoplastic origin, in the opinion of the treating physician (in this 
circumstance an explanation must be provided) 
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For patients with only non-measurable disease at randomization 
Progression, for patients with non-measurable disease at randomization, is defined as in-
creasing clinical, radiological or histological evidence of disease since trial entry. 
Unequivocal progression of existing non-target lesions means an overall level of substantial 
worsening in non-target disease such that the overall tumor burden has increased sufficiently 
to merit discontinuation of therapy. A modest ‘increase’ in the size of one or more non-target 
lesions is usually not sufficient to quality for unequivocal progression status. 
Because worsening in non-target disease cannot be easily quantified (by definition: if all le-
sions are truly non-measurable) a useful test that can be applied when assessing patients for 
unequivocal progression is to consider if the increase in overall disease burden based on the 
change in non-measurable disease is comparable in magnitude to the increase that would be 
required to declare PD for measurable disease: i.e. an increase in tumor burden representing 
an addition 73% increase in ‘volume’ (which is equivalent to a 20% increase diameter in a 
measurable lesion). Examples include an increase in a pleural effusion from ‘trace’ to ‘large’, 
an increase in lymphangitic disease from localized to widespread, or may be described in 
protocols as ‘sufficient to require a change in therapy’. If ‘unequivocal progression’ is seen, 
the patient should be considered to have had overall PD at that point. While it would be ideal 
to have objective criteria to apply to non-measurable disease, the very nature of that disease 
makes it impossible to do so, therefore the increase must be substantial.  
 
Eisenhauer EA et al. New response evaluation criteria in solid tumors: Revised RECIST guideline 
(version 1.1). Eur J Cancer 2009;45:228-47. 
Schwartz LH et al. Evaluation of lymph nodes with RECIST 1.1. Eur J Cancer 2009; 45:261–67. 
Ferrandina G et al.. Impact of pattern of reccurrence on clinical outcome ovarian cancer patients: clini-
cal considerations. Eur J Cancer 2006; 42:2296-302. 
  
Protocol V03F  22.03.2016 
AGO-OVAR 2.21/ENGOT-ov18 - 83 of 87 - EudraCT No. 2012-004125-24 
20.10 Appendix 10 – CA 125 Definitions agreed by GCIG November 
2005 
 
The GCIG has agreed criteria for defining response and progression of ovarian carcinoma 
which use the serum marker CA 125, and the situations where these criteria should be used.  
 
Evaluation of response according to CA 125 
 
Definition of response: A response according to CA 125 has occurred if there is at least a 
50% reduction in CA 125 levels from a pretreatment sample. The response must be con-
firmed and maintained for at least 28 days. Patients can be evaluated according to CA 125 
only if they have a pretreatment sample that is at least twice the upper limit of normal within 2 
weeks prior to starting treatment. 
 
To calculate CA 125 responses accurately, the following rules apply. 
 Intervening samples and the 28-day confirmatory sample must be less than or equal 
to (within an assay variability of 10%) the previous sample. 
 Variations within normal range of CA 125 levels will not interfere with the response 
definition. 
 For each patient, the same assay method must be used and the assay must be test-
ed in a quality-control scheme. 
 Patients are not evaluable by CA 125 if they have received mouse antibodies (unless 
the assay used has been shown not to be influenced by HAMA) or if there has been 
medical and/or surgical interference with their peritoneum or pleura during the previ-
ous 28 days. If assessing therapy that includes two treatment modalities for relapse 
(e.g., surgery and chemotherapy), any CA 125 response results from both treatment 
modalities. CA 125 cannot distinguish between the effects of the two treatments. 
 
The date when CA 125 level is first reduced by 50% is the date of the CA 125 response. To 
calculate response rates, an intent-to-treat analysis should be used that includes all patients 
with an initial CA 125 level of at least twice upper limit of normal as eligible and evaluable. In 
addition, as a separate analysis, those patients who have both a CA 125 response and 
whose CA 125 level falls within the normal range, can be classified as CA 125 complete re-
sponders. Patients who have fall of CA 125 to within the normal range but whose initial CA 
125 was less than twice the upper limit of normal, have not had a CA 125 response and can-
not therefor be classified as a CA 125 complete responder. 
 
Evaluation of response according to CA 125 in patients receiving maintenance or con-
solidation therapy 
 
Patients whose CA 125 is greater than twice the upper limit of normal when they start 
maintenance or consolidation therapy can be evaluated according to the GCIG CA 125 re-
sponse definition. It should be noted that there is no data to validate response evaluation in 
this situation. To prevent the prior therapy interfering with the response assessment the fol-
lowing requirement is recommended. Two pre-treatment samples no more than 8 weeks 
apart are required if test treatment is given as part of maintenance or consolidation therapy. 
For the test treatment to be evaluable according to CA 125 there must be no more than a 
10% fall in CA 125 between the two pre-treatment samples. The sample closest in time to 
the test therapy should be considered the pre-treatment sample. 
 
  
Protocol V03F  22.03.2016 
AGO-OVAR 2.21/ENGOT-ov18 - 84 of 87 - EudraCT No. 2012-004125-24 
Evaluation of response according to CA 125 in patients receiving first line therapy 
 
The CA 125 response definition was produced to evaluate relapse therapy. If assessing 
therapy that includes two treatment modalities (e.g., surgery and chemotherapy), any CA 125 
response is a result of both treatments, and it should be clearly stated that CA 125 cannot 
distinguish between the effects of the two treatments. It should be remembered that for a pa-
tient to be classified as a complete responder according to RECIST, tumor marker levels 
such as CA 125 must be within the normal range. 
 
Evaluation of best overall response in patients without initial measurable disease and 
evaluable by CA 125 
 
CA 125 may be used to evaluate response in patients without initial measurable disease, ei-
ther because no measurable disease can be detected or because appropriate scans have 















CR No CR 
Confirmed and 
maintained for at 
least 28 days. 
Response Non PD No PR 
Normalized but 
not Response 
Non CR / Non PD No SD 
Non PR / Non PD Non PD No SD  
PD Any Yes or No PD  
Any PD* Yes or No PD  
Any Any Yes PD  
#
Non-Target lesions include ascites and peritoneal thickening, which are not measurable according to 
RECIST 
*Unequivocal progression in non-target lesions may be accepted as disease progression. 
 
Evaluation of best overall response in patients with initial measurable disease and 
evaluable by CA 125 
 
A report that combines both CA 125 and RECIST criteria, is likely to include patients that are 
measurable by one or both of the criteria, who may have events at different time points. In 
patients that are measurable by both criteria the date of response will be the date of the ear-
lier of the two events. The following rules apply when determining the best overall response. 
If patients have PD according to RECIST within 28 days of CA 125 response they are classi-
fied as PD. If PD according to RECIST is > 28 days before or after the CA 125 response they 
are classified as PR. Patients whose best response according to RECIST is SD but who 
have a CA 125 response are classified as CA 125 responders. 
 
Best overall response in patients with initial measurable disease and evaluable by CA 125, 










this category CR CR No Normal CR 
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CR 
Non CR / Non 
PD 
No Not PD PR 
also requires 
it to be con-
firmed and 
maintained 
for at least 28 
days. 
CR CR No PR not normal PR 
PR Non PD No Not PD PR 
NE Non PD No PR PR 
PD or New > 28 days from CA 125 PR* PR PR 
SD Non PD No PR PR 
SD Non PD No Not PR or PD SD 
PD or New ≤ 28 days from CA 125 PR* PR PD 
PD Any Yes or No Any PD 
NE PD Yes or No Any PD 
NE Any Yes Any PD 
NE Any Yes or No PD PD 
~
target lesions include up to 10 measurable lesions as defined by RECIST 
#
non-target lesions includes ascites and peritoneal thickening which are not measurable according to 
RECIST 
*
patients who have a CA 125 response that occurs more than 28 days from PD according to RECIST 
are considered a PR according to best response, but PD if the RECIST PD is within 28 days of CA 
125 response 
 
Definition of progression on first line therapy and recurrence after first line therapy 
according to CA 125 
 
Progression is defined according to RECIST but can also be based upon serum CA 125 (de-
fined below) but tumor measurements should take precedence over CA 125. If measurable 
disease is shrinking during treatment, but the CA 125 indicates progression (as defined be-
low) the patient should continue to receive protocol treatment. If measurable disease shows 
stable disease but CA 125 indicates progression after a minimum of 3 courses of chemo-
therapy, protocol treatment should be changed. If the GCIG definition based on CA 125 is 
used to define progression after relapse therapy it should be noted that it has not been vali-
dated. 
 
Evaluation of progression according to CA 125 
 
Progression or recurrence based on serum CA 125 levels will be defined on the basis of a 
progressive serial elevation of serum CA 125, according to the following criteria: 
 A: Patients with elevated CA 125 pre-treatment and normalization of CA 125 must 
show evidence of CA 125 greater than, or equal to, two times the upper normal limit 
on two occasions at least one week apart or 
 B: Patients with elevated CA 125 pre-treatment, which never normalizes must show 
evidence of CA 125 greater than, or equal to, two times the nadir value on two occa-
sions at least one week apart or 
 C: Patients with CA 125 in the normal range pre-treatment must show evidence of CA 
125 greater than, or equal to, two times the upper normal limit on two occasions at 
least one week apart. 
 
Elevated values must be confirmed by two separate measurements obtained at least one 
week apart. CA 125 progression will be assigned the date of the first measurement that 
meets the criteria as noted. Patients are not evaluable by CA 125 if they have received 
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mouse antibodies (unless the assay used has been showed not to be influenced by HAMA) 
or if there has been medical and/or surgical interference with their peritoneum or pleura dur-
ing the previous 28 days. 
 
A patient may be declared to have progressive disease on the basis of either the objective 
RECIST criteria or the CA 125 criteria. The date of progression will be the date of the earlier 
of the two events if both are documented. 
 















A Compared to baseline (or low-
est sum while on study if less 
than baseline), a 20% increase 
in sum of longest diameters 
(RECIST definition) 
or 
Any new lesions (measurable 
or non-measurable) 
 
Date PD: date of documentation of 
increase or new lesions 




Date of PD: first date of the CA 125 
elevation to ≥ 2 x ULN 
 




Date of PD: first date of the CA 
125 elevation to ≥ 2 x nadir value 
C As for A As for A 
GCIG groups A, B & C defined above. 
#
Repeat CA 125 any time, but normally not less than 1 week after the first elevated CA 125 level. CA 
125 levels sampled after patients received mouse antibodies (unless the assay used has been shown 
not to influenced by HAMA) or if there has been medical and/or surgical interference with their perito-
neum or pleura during previous 28 days, should not be taken into account. 
 
http://www.gcig.igcs.org/CA-125.html (last access 21-Nov-2012) 
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20.11 Appendix 11 – Definition of Responsibilities in Trial Sites 
 
Only valid for German sites. 
 
Am 26. Oktober 2012 trat das Zweite Arzneimittelrechtsänderungsgesetz in Kraft. Infolge 
dessen gelten neue Anforderungen hinsichtlich Prüfer, Stellvertreter, Prüfstelle und Prüf-
gruppe. 
 
§ 4 (25) AMG (Prüfer) 
 Prüfer ist in der Regel ein für die Durchführung der klinischen Prüfung bei Menschen in 
einer Prüfstelle verantwortlicher Arzt oder in begründeten Ausnahmefällen eine andere 
Person, deren Beruf auf Grund seiner wissenschaftlichen Anforderungen und der seine 
Ausübung voraussetzenden Erfahrungen in der Patientenbetreuung für die Durchführung 
von Forschungen am Menschen qualifiziert. 
 Wird eine klinische Prüfung in einer Prüfstelle von einer Gruppe von Personen 
durchgeführt, so ist der Prüfer der für die Durchführung verantwortliche Leiter dieser 
Gruppe. 
 Wird eine Prüfung in mehreren Prüfstellen durchgeführt, wird vom Sponsor ein Prüfer 
als Leiter der klinischen Prüfung benannt. 
 
§ 40 (1a) AMG (Stellvertreter, Prüfgruppe) 
 Der Prüfer bestimmt angemessen qualifizierte Mitglieder der Prüfgruppe. 
 Er hat sie anzuleiten und zu überwachen sowie ihnen die für ihre Tätigkeit im Rah-
men der Durchführung der klinischen Prüfung erforderlichen Informationen, insbe-
sondere den Prüfplan und die Prüferinformation, zur Verfügung zu stellen. 
 Der Prüfer hat mindestens einen Stellvertreter mit vergleichbarer Qualifikation zu 
benennen. 
 
§ 40(2) AMG (Aufklärung der Patienten) 
 Die betroffene Person ist durch einen Prüfer, der Arzt oder bei zahnmedizinischer 
Prüfung Zahnarzt ist, oder durch ein Mitglied der Prüfgruppe, das Arzt, oder, bei 
zahnmedizinischer Prüfung, Zahnarzt ist, über Wesen, Bedeutung, Risiken und Tragweite 
der klinischen Prüfung sowie über ihr Recht aufzuklären, […] 
 Der betroffenen Person ist ferner Gelegenheit zu einem Beratungsgespräch mit Prüfer 
oder Mitglied der Prüfgruppe, das Arzt oder Zahnarzt ist, über sonstige Bedingungen 
der klinische Prüfung […] 
 
§ 67 (1) AMG (Anzeigepflicht) 
 Ist […] eine klinische Prüfung bei Menschen anzuzeigen, so sind der zuständigen Be-
hörde auch deren Sponsor, […] sowie der Prüfer und sein Stellvertreter, soweit erfor-
derlich auch mit Angabe der Stellung Leiter der klinischen Prüfung, namentlich zu be-
nennen. 
 
 
 
